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ZUSAMMENFASSUNG 
 
Das Gram-positive Pathogen Staphylococcus aureus ist zwingend auf die korrekte Synthese 
des Peptidoglykanvorläufers Lipid II-Pentaglycin (LII-Gly5) angewiesen. Eine komplette 
Blockierung der Produktion der Pentaglycinseitenkette ist letal, eine partielle Hemmung führt 
auch in Methicillin-resistenten S. aureus (MRSA) zu einer generellen Antibiotika-
Überempfindlichkeit. Genetische Analysen haben ergeben, dass die Gly5 Synthese 
sequentiell durch die Faktoren FemABX, nicht-ribosomalen Peptidyl-Transferasen, 
katalysiert wird. Um die molekulare Peptidoglykan-Biosynthese aufzuklären, wurde ein in 
vitro System entwickelt, welches die Testung verschiedener Kombinationen von Fem-
Faktoren mit potentiellen Substraten erlaubte. Es zeigte sich, dass FemX, welches das erste 
Glycin anhängt, nur LII, FemA nur LII-Gly, und FemB nur LII-Gly3 erkennt. Die Fem-Faktoren 
waren individuell aktiv und benötigten keine weiteren Proteine. Dieser Assay wird 
weiterentwickelt werden um potentielle FemABX-Inhibitoren zu identifizieren. Multiresistente 
MRSA, sowie weitere Humanpathogene wie Pneumokokken und Enterokokken, die ein 
verzweigtes Peptidoglykan haben, könnten mit Substanzen dieser neuen Antibiotika-Klasse 
kontrolliert und therapiert werden. 
 
Abwehrmechanismen des Wirts und die Wirkung von Antibiotika können in S. aureus durch 
die Bildung so genannter small colony variants (SCVs) umgangen werden, deren Physiologie 
und Phänotyp atypisch sind. Durch Inaktivierung von hemB wurde eine stabile SCV 
konstruiert. Der Vergleich von Wildtyp und hemB Mutante zeigte signifikante Unterschiede in 
Bezug auf die Expression von Regulatoren und Virulenzfaktoren. In der hemB Mutante war 
die Transkription nach der exponentiellen Wachstumsphase allgemein drastisch reduziert. 
Überraschenderweise wurden aber SigB kontrollierte Gene, insbesondere sarC und clfA, 
während des gesamten Wachstums transkribiert. In einer hemB sigB Doppelmutante fehlten 
diese Transkripte, was auf deren Abhängigkeit von SigB und eine durchgehende SigB 
Aktivität in der hemB Mutante hindeutet. SigB ist somit einer der Regulatoren, die in der 
hemB Mutante die Expression von Virulenzfaktoren kontrollieren. Weil diese Studie in 
isogenen Stämmen und unter konstanten experimentellen Bedingungen durchgeführt wurde, 
stellen die generierten Daten eine bisher einzigartige Übersicht über die Transkriptionsprofile 
der verschiedenen Regulatoren dar. 
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SUMMARY 
 
Accurate synthesis of the peptidoglycan precursor lipid II-pentaglycine (LII-Gly5) is crucial for 
the Gram-positive pathogen Staphylococcus aureus. The absence of the pentaglycine chain 
is lethal; a partial inhibition of its synthesis conveys general antibiotic hyper-susceptibility, 
even to methicillin-resistant S. aureus (MRSA). Genetic analysis had revealed the sequential 
elongation of the Gly5 chain to be catalysed by the non-ribosomal peptidyl-transferases 
FemABX. To elucidate the molecular basis of peptidoglycan biosynthesis, an in vitro system 
was developed for testing different combinations of Fem factors with their potential 
substrates.  FemX, responsible for the addition of the first glycine, was found to recognize 
only LII, FemA only LII-Gly, and FemB only LII-Gly3. None of them required the presence of 
any of the other Fem factors, or additional proteins. This assay will be further developed to 
possibly identify potential FemABX inhibitors. Multi-resistant MRSA and other human 
pathogens with a branched peptidoglycan, like pneumococci or enterococci, could be 
controlled and eradicated with substances belonging to this new class of antibiotics. 
 
S. aureus can escape host defence as well as antibiotic-treatment by formation of so-called 
small colony variants (SCVs) among other strategies. SCVs display an atypical physiology 
and phenotype. A stable SCV was created by inactivating hemB. Comparison of the 
transcription profile of global regulators and virulence factors revealed significant differences 
between the parental strain and its hemB mutant. A general transcription stop was observed 
after the exponential phase in the hemB mutant. However, the reported target genes of SigB, 
sarC and clfA, were transcribed throughout growth. In a hemB sigB double mutant these 
transcripts were absent, indicating (i) their dependence on SigB and (ii) confirming the 
permanent presence of active SigB in the hemB mutant. While a potential influence of 
additional regulators can not be excluded, it was shown that SigB is involved in the control of 
the hemB transcriptome. Moreover, since this study was performed in one defined genetic 
background it provided a unique opportunity to interrelate transcriptional patterns of different 
regulators over the entire growth cycle.  
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1  INTRODUCTION 
 
1.1.   The pathogen Staphylococcus aureus 
 
Staphylococcus aureus is a Gram-positive bacterium with low G+C content and high 
genetic plasticity.  Its circular chromosome, of approximately 2.8 Mb, and plasmids, ranging 
from 1 – 60 kb, can harbour several pathogenicity islands, prophages, transposons and 
insertion elements, each conferring additional properties to the organism, especially in 
respect to resistance and virulence. Up to 20 % of the S. aureus genome can be constituted 
of such otherwise dispensable and accessory genes (13, 167, 216). The remarkable ability of 
S. aureus to rapidly adapt under selective pressure is in part explainable by the transfer of 
mobile elements between staphylococcal strains, species, and other Gram-positive bacteria 
(344).  
 
S. aureus can be encountered in the environment as well as on its hosts; man and 
livestock. Human ecological niches of S. aureus are the skin and mucous membranes, where 
this opportunistic pathogen usually grows asymptomatically. Several studies reported 30 to 
60 % of healthy adults to be transiently colonised by S. aureus, with 10 to 20 % persistently 
colonised (58, 202, 281). Carriers not only contribute to the distribution of S. aureus (203), 
they are also at increased risk for subsequent infections. Especially for immunocompromised 
individuals, intravenous drug addicts, patients undergoing surgery or on dialysis and those 
with implanted medical devices, carriage has been identified as an important risk factor for 
infection (202, 357, 395). Apart from rather harmless superficial skin infections and food 
poisoning, S. aureus can cause a wide range of severe illnesses, such as endocarditis, 
sepsis, osteomyelitis and pneumonia. S. aureus-induced disease is often suppurate and 
associated with extensive tissue destruction and necrosis.  
 
The ability of S. aureus to survive harsh conditions and adopt several resistances has 
made its cure difficult. Recent reports indicate that the rates for methicillin-resistant  
S. aureus (MRSA) related infections are increasing (87, 147) and endogenous intermediate 
resistance against glycopeptides, which are often the antibiotics of last resort, has begun to 
develop (165, 329). In addition, the acquisition of the vanA gene from Enterococcus faecalis 
by S. aureus, mediating high-level vancomycin resistance, has been reported (405).  
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In the past, S. aureus reacted to the introduction of new antibiotics by developing 
resistance within one year (179, 314) and remains one of the leading causes of hospital- and 
community acquired infections. The consecutive spread of the resistant strains from the 
hospital to the community was a predictable event. Less expected was the emergence of 
novel strains of MRSA in the community, that are genetically distinct from MRSA strains 
originating in the hospital, as observed in the past decade (59, 81, 167, 271). These 
community-acquired MRSA (CA-MRSA opposed to HA-MRSA, for hospital-acquired) are 
often resistant against fewer antibiotics than HA-MRSA, and fitter, due to the lower genetic 
burden (83, 98). When entering hospitals, CA-MRSA can therefore replace HA-MRSA, 
contributing to an increased turn-over of MRSAs (287, 337). Proper susceptibility profiling 
and moderate use of antibiotics is strongly recommended to reduce fatal outcomes and the 
development of new (multi-drug) resistant strains (8, 89, 300).  
 
1.2.   Regulation of virulence 
 
The controlled, appropriate and coordinate expression of virulence factors during 
infection is a prerequisite for a successful establishment in the host (Fig. 1). Overlapping and 
interacting regulatory networks consisting of a multitude of global regulators allow S. aureus 
to react to changing environments and to adapt to the specific niches encountered. A vast 
array of virulence factors assures survival in a cooperative way; many are redundant and 
none is essential.  
Due to the elicited regulatory response imposed by a specific infection model and 
difficulties in standardising cultivation conditions in the host organism, in vivo expression 
analyses reveal often only part of the regulatory network and are prone to greater deviations. 
When considering ex vivo expression analyses of clinical isolates, one has to take into 
account that these strains likely harbour mutations and might not represent standard 
S. aureus. However, contrary to in vitro data, careful study of such adapted organisms gives 
valuable information about host-pathogen interaction, minimal required elements for a 
defined infection and possible bypass pathways in the case of mutations.  
For standardising growth conditions and in order to reliably reproduce fluctuating 
changes, in vitro cultivation is recommended. Thereby, the growth phase dependent 
expression of first surface-associated and then excreted proteins is observed, representing 
the change from a colonizing to an invasive behaviour (312).  
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Fig. 1. Pathogenesis of staphylococcal invasion of tissue. The sequence of events progresses from left to right. 
Circulating staphylococci bind to sites of endovascular damage where platelet-fibrin thrombi (PFT) have formed. 
The bacteria may attach through MSCRAMM-mediated mechanisms. Alternatively, they may adhere to 
endothelial cells directly through adhesin-receptor interactions or by means of bridging ligands that include serum 
constituents such as fibrinogen. Modifications of the endothelium resulting from microenvironmental changes 
(such as alterations in the extracellular matrix (ECM)) can signal changes in cellular susceptibility to infection. 
After phagocytosis by endothelial cells, the bacteria elaborate proteolytic enzymes that facilitate the spread to 
adjoining tissues and the release of staphylococci into the bloodstream. Tissue factor is expressed by infected 
endothelial cells, facilitating the deposition of fibrin and the formation of vegetations. Once in the adjoining 
subepithelial tissues, the bacteria elicit an inflammatory response that results in abscess formation. This 
sequence of events contributes to the establishment of metastatic foci of infection, as well as the pathogenesis of 
endocarditis when cardiac endothelium is involved. After phagocytosis, endothelial cells express Fc receptors and 
adhesion molecules (vascular-cell adhesion molecules; VCAM, and intercellular adhesion molecules; ICAM) and 
release interleukin-1, interleukin-6, and interleukin-8. As a result, leukocytes adhere to endothelial cells, with 
diapedesis to the site of infection. Changes in the conformation of endothelial cells result in increased vascular 
permeability, with transudation of plasma proteins. Both tissue-based macrophages and circulating monocytes 
release interleukin-1, interleukin-6, interleukin-8, and tumor necrosis factor (TNF-α) after exposure to 
staphylococci. Macrophage activation occurs after the release of interferon-γ by T cells. Cytokines released into 
the bloodstream from monocytes or macrophages, as well as endothelial cells, contribute to the manifestations of 
the sepsis syndrome and vasculitis associated with systemic staphylococcal disease. Expression of Fc receptors 
may contribute to the vasculitis occasionally encountered during bacteremia by acting as a binding site for 
immunoglobulin (Ig) or immune complexes. PMN denotes polymorphonuclear leukocyte.  Reproduced from (228). 
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A description of the interplay of regulators and their effect on selected virulence 
determinants follows and is schematically summarised in Fig. 2. 
 
 
 
Fig. 2. State of the knowledge of the interplay of global regulators and regulation of virulence determinants in 
S. aureus. A Regulatory network. Designated effects might be indirect and may occur at different levels of gene 
expression. B Target genes and factors influencing their expression. 
 
1.2.1.  Virulence determinants 
 
Cell-associated products, including adhesins of the MSCRAMM (microbial surface 
components recognizing adhesive matrix molecules) family and capsular polysaccharide, 
facilitate binding to host tissue and help resist host immune responses. Most MSCRAMMs 
are covalently anchored to the cell wall peptidoglycan (described in section “Cell wall 
composition” and exemplified in Fig. 3 by a clumping factor). Secreted exoproteins, such as 
cytolysins or extracellular proteases, lipases and hyaluronidases, are thought to combat host 
defences and to facilitate tissue invasion, as well as to assure nutrient acquisition. 
Staphylococci have typically been regarded as non-invasive extracellular pathogens that 
damage host cells after adhering to the extracellular matrix; however, there is growing 
evidence that S. aureus has the ability to invade and persist within eukaryotic cells (4, 96, 
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178, 270, 316, 385). Following invasion of host cells, the release of cytokines is induced, 
exacerbating disease and triggering apoptosis (3, 46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Structure of S. aureus. Panel A shows the surface and secreted proteins. The synthesis of many of these 
proteins is dependent on the growth phase, as shown by the graph, and is controlled by regulatory genes such as 
agr. Panels B and C show cross sections of the cell envelope. Many of the surface proteins have a structural 
organization similar to that of clumping factor, including repeated segments of amino acids (Panel C). TSST-1 
denotes toxic shock syndrome toxin 1. Reproduced from (228). 
 
1.2.1.1. Adhesion factors (adapted from (3)) 
 
The ability to adhere to the extracellular host matrix and to interact with blood proteins 
is thought to be essential for colonisation and the establishment of infection (113, 227, 228). 
Moreover, the first step of host cell invasion is adhesion. Some host components targeted by 
S. aureus include fibrin(ogen), fibronectin, thrombospondin, von Willebrand factor, collagen, 
bone sialoprotein, and elastin (297). The first four proteins are found in the blood and adhere 
to indwelling catheters, based on studies in animals and human subjects. Implanted devices 
are generally quickly covered with bacteria if host cells and proteins are not fast enough in 
wrapping them up. Specific MSCRAMMs include fibronectin-binding proteins (FnBPs) (185), 
fibrinogen-binding proteins (44, 62, 254), elastin-binding adhesin (295), collagen-binding 
adhesin (296), and a broad specificity adhesin (MAP) that facilitates low-affinity binding of 
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S. aureus to several proteins, including osteopontin, collagen, bone sialoprotein, fibronectin, 
fibrinogen, and vitronectin (256). S. aureus can utilise MSCRAMMs to adhere directly to cells 
or via bridging ligands, cellular proteins with affinity for host receptors and MSCRAMMs (94, 
351).  
 
Fibronectin-binding proteins  
FnBPs are likely the most-important MSCRAMMs in S. aureus colonisation, invasion 
of eukaryotic cells and establishment of human infections, including endocarditis (217, 356, 
409). They are encoded by the two related and neighbouring genes fnbA and fnbB, which 
likely arose by gene duplication. Most clinical isolates contain at least one of them (264, 
299). The interaction between S. aureus and host cells has been proposed to occur through 
a bridging model where fibronectin is bound by the FnBPs as well as by host cell integrins. 
Integrins mediate communication and adhesion between cells and are components of the 
extracellular matrix. A clustering of integrins, induced by ligand-binding, possibly causes 
activation of a signal transduction cascade leading to the expression of proinflammatory 
cytokines (46, 70, 73, 75). Interestingly, integrins have been proposed to be involved in 
receptor- mediated endocytosis of S. aureus. Apart from integrin, a mammalian heat shock 
protein has been shown to contribute to internalisation by interaction with FnBPs as well (94). 
Intracellular bacteria seem to trigger sooner or later apoptosis, whereby agr and sar 
regulators play a role. An exception of this rule are the small colony variants, described later. 
 
Protein A 
spa encodes the cell-wall associated protein A, which has a hypervariable repeat 
region binding immunoglobulin G (IgG) and C-reactive protein (76). Both host proteins are 
involved in opsonisation, phagocytosis and complement activation. Binding of the Fc domain 
of IgGs protects S. aureus against opsonophagocytosis (384). In addition, protein A binds to 
innate-like B-cells in the spleen, induces apoptosis and provokes B-cell depletion (144). 
Protein A displays high size heterogeneity among strains (53), but the number of repeats can 
also vary in one strain during prolonged infection (191). This is thought to be mainly caused 
by slipped-strand mispairing (SSM), which seems to occur in combination with inadequate 
DNA mismatch repair systems and is an important prerequisite for bacterial phase variation 
and adaptation (386). 
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Clumping factors 
It is speculated that bacteria could protect themselves from phagocytic and immune 
defences by causing localized clotting. So far, S. aureus is known to encode three clumping 
agents, which in part also function as adhesins. 
 
clfAB 
Contrary to the FnbPs, the two fibrinogen-binding adhesins and clumping factors ClfA 
and ClfB are not encoded by allelic variants but distinct, unlinked genes. ClfB seems to be 
expressed only under aerobic conditions early in growth (278), while ClfA is predominantly 
present after the exponential phase (409). The interaction site of their products with 
fibrinogen differs too; ClfA binds to the γ chain of fibrinogen, while ClfB appears to bind rather 
to the α and β chains of fibrinogen. However, both proteins contain a Ser-Asp dipeptide 
repeat domain, serving as a stalk crossing the cell wall and presenting the A domain (Fig. 3), 
which binds the ligand in a Ca2+-dependent way. The fact that the two Clf proteins recognise 
different parts of the host ligand, and might act synergistically to allow bacteria to attach 
more firmly to thrombi under flow conditions in the bloodstream, could explain why S. aureus 
possesses two fibrinogen-binding adhesins. Since ClfB also binds to keratin, thereby 
mediating adhesion to epithelial cells, it has been proposed to be required for nasal 
colonisation (402). ClfA has been shown to play an important role in the establishment of 
endocarditis. Recently, protection against phagocytosis by macrophages has been reported 
to be conferred by ClfA (293). 
 
Coagulase 
The secreted protein coagulase binds to and activates prothrombin, thereby causing 
clotting of platelets in a different way compared to the Clfs (410). The protease activity 
characteristic of thrombin is activated in the complex, resulting in the conversion of fibrinogen 
to fibrin. Coagulase is a traditional marker for identifying S. aureus in the clinical microbiology 
laboratory (9).  
 
Toxins 
Cytotoxins or -lysins, such as alpha-toxin (encoded by hla), form pores and induce 
proinflammatory changes in mammalian cells. The consequent cellular damage may 
contribute to manifestations of the sepsis syndrome (32, 401). 
Superantigens are pyrogenic toxins which function by binding to major 
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histocompatibility complex class II proteins, thereby activating 10-50 % of the T-cell 
population (as compared to 0.01 % by processed antigens) and causing extensive T-cell 
proliferation as well as cytokine release (242). This overwhelming immune response leads to 
the toxic shock syndrome (TSS) characterised by fever, chills and vomiting, progressing to 
low blood pressure and multiorgan dysfunction (7, 97). Known proteins causing TSS are the 
enterotoxins and the structurally similar toxic shock syndrome toxin 1 (TSST-1), which is 
associated with most menstrual TSS cases and found in 20 % of S. aureus isolates. 
Enterotoxins are mainly responsible for food poisoning (154). 
Exfoliative toxins, such as epidermolytic toxins A and B, cause skin erythema and 
separation, as seen in the staphylococcal scalded skin syndrome (SSSS). Both toxins 
produce blistering by disruption of the epidermal granular cell layer, apparently from direct 
effects on desmosomes. This disruption leads to interdesmosomal splitting. The toxins most 
likely bind directly to the desmosomal protein desmoglein-1, but the mechanism of action of 
the toxin is not fully understood.  
Panton-Valentine leukocidin, a pore-forming toxin, has been epidemiologically 
associated with severe cutaneous infections, as well as pneumonia, and acts as a 
leukocytolytic toxin (74, 89, 194). 
 
1.2.2.  Global regulators 
 
1.2.2.1. Two component regulatory systems 
 
Two component regulatory systems are found in all prokaryotes, except 
mycoplasmas (118, 163), playing a critical role in sensing and responding to environmental 
conditions and in bacterial pathogenesis (166, 365). Generally, they consist of a sensor 
histidine kinase protein, which is usually bound to the bacterial membrane, and a cognate 
response regulator protein, which often acts as a DNA-binding transcription regulator. 
Autophosphorylation of the histidine kinase component in response to an environmental 
signal is followed by phosphoryl transfer to the response regulator, which alters the 
expression of regulon genes needed to respond to the environmental condition. 16 two 
component systems have been identified so far in S. aureus; only a subset is described here.  
 
agr  
The accessory gene regulator locus agr represses in post-exponential phase cell-
surface associated proteins, such as spa or fnbA, and activates exotoxin production, e.g. hla 
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(175, 266, 286, 342). agr encodes two divergently transcribed mRNAs. RNAII transcription is 
initiated at the promoter P2, covering agrBDCA and coding for a quorum-sensing two-
component system consisting of four elements (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Model of the agr system. The pro-AIP peptide is constantly processed and secreted by AgrB. The AIP 
binds to the receptor histidine kinase AgrC, activating auto-phosphorylation. In consequence, the response 
regulator AgrA is phosphorylated, up-regulating predominantly transcription from the P2 promoter of the agr locus 
(as symbolised by the thickness of the arrows). When reaching a certain threshold concentration of AIPs, RNAIII 
transcription is efficiently triggered as well. Besides encoding δ-hemolysin, RNAIII itself controls directly or 
indirectly, positively (arrow) or negatively (cross-bar) transcription of target genes. Below, a schematic 
organisation of the agr operon is given. Transcripts (wave lines), promoters (arrows) and open reading frames 
(boxes) are indicated. Proteins are represented by ellipses, peptides by bead-strings. The secondary structure of 
the regulatory RNAIII molecule (violet) is emblematic (adapted from (23)).  
 
The propeptide AgrD is constantly N- and C-terminally processed and secreted to the 
medium with the aid of AgrB (180, 334, 422). Modified AgrD operates as an auto-inducing 
peptide (AIP) by binding to the receptor histidine kinase AgrC, thereby enhancing auto-
phosphorylation and activation of AgrC (223). AgrC phosphorylates the LytTR family 
response regulator AgrA (280), which binds to paired heptad repeats in the P2 and P3 
promoter regions of the agr locus. Phosphorylated AgrA has an increased affinity for P2, but 
not for P3, whose downstream direct repeat differs by 1 bp from the LytTR family consensus 
sequence (204). It is not yet clear whether AgrA binds the agr promoters as a mono- or as a 
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dimer. Known binding sites of SarA (280), positively regulating the expression of the agr 
locus (64, 68), partially overlap with AgrA protected areas (Fig. 5) (267, 315). Apparently, 
either physical displacement or interaction is necessary for agr regulation by both of these 
factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Sequence of the RNAIII-agr intergenic region. The locations of the P2 and P3 promoter regions are 
indicated by the solid bars above the sequence. SarA-protected areas determined by Rechtin et al.1999 are 
shown by the dotted-line boxes (315). The direct repeats conforming to the consensus LytTR recognition sites are 
indicated in bold type. Protected areas of the P2-P3 promoter region are represented by solid boxes. The 
approximate locations of residues showing increased sensitivity to DNase I cleavage upon AgrA binding are 
indicated by vertical arrows. Adapted from (204). 
 
Increasing cell density, and consequently AIP concentration, causes first RNAII 
amplification, leading to growing quantities of (phosphorylated) AgrA. After reaching high 
enough amounts, AgrA is able to trigger RNAIII transcription despite its lower affinity for P3. 
The threshold cell density for initiation of RNAIII transcription has been estimated to be 
109 cfu/ml (15). Since a pattern search of the S. aureus genome using the AgrA consensus 
binding site revealed no other promoter sites, RNAIII has been proposed to exert the main 
effect of the agr locus as a regulatory molecule (286, 413). Its complex secondary structure 
(23) is well conserved among several staphylococci, although the sequence is not (24, 373).  
RNAIII has been shown to influence gene expression at the transcriptional and the 
translational level. While it has not yet been determined whether and how regulation of 
transcription occurs directly (23), translation of hla is favoured by pairing of the 5’ RNAIII 
region with the hla leader sequence, which otherwise folds into an untranslatable 
configuration (266, 286). Another mechanism seems to be employed in the case of spa, 
where the translation initiation site has been proposed to be blocked by hybridisation to the 
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complementary 3’ end of RNAIII (283). 
The agr locus is conserved among staphylococci (90, 176, 180, 290). Based upon co-
evolutionary variations in the hypervariable BDC region (Fig. 4), four agr specificity groups 
exist in S. aureus, which are defined by mutually inhibitory cross-group AIP-AgrC 
interactions. The resulting interference rather blocks the agr regulon than bacterial growth. 
Activation of the cognate receptor by the AIPs is highly sequence specific, e.g. type I and IV 
differ in but one amino acid (for a review see ref. (283)). Post-translational processing of 
AgrD leads to a 7-9 aa peptide, forming a characteristic, 5 aa thiolacton ring (also called 
macrocycle), with the N-terminal tail emerging at a conserved cystein (Fig. 6). This thiolacton 
ring is essential for AIPs, whether for inhibition or activation (230, 251, 255). Apparently, at 
the two C-terminal positions, bulky amino acids form a highly conserved hydrophobic patch, 
which has been proposed to be placed in a hydrophobic pocket of the receptor domain and 
to confer a general binding ability of AIPs to any receptor. The recognition of cognate AIPs 
by the polytopic receptor AgrC would then occur at specific contact sites of the proximal 
receptor end, influencing receptor responsiveness (413).  
 
 
 
 
 
 
 
 
 
 
Fig. 6. Structure of the agr group I specificity 
autoinducing-peptide AIP. Amino acid residues are 
in yellow, those belonging to the macrocycle are 
encircled. The conserved, essential cysteine residue 
and the thiolactone bond are indicated in red. The 
C-terminal amino acids forming a bulky, 
hydrophobic patch are encircled by thick, black 
lines. 
The interference between different agr groups might serve to isolate populations and 
may represent a major determinant of strain and species divergence. In S. aureus, agr 
groupings are broadly correlated with strain genotypes, resulting in general congruence 
between phylogenetic trees and agr groups. Thus, most menstrual toxic shock syndrome 
strains, and strains found to cause leucocidin-induced necrotizing pneumonia, belong to agr 
group III (132, 180). Most of the recently encountered glycopeptide intermediate resistant 
S. aureus (GISA) strains belong to agr group II (339, 392), and most exfoliatin-producing 
strains belong to agr group IV (176, 255). The cross-inhibitory activity of AIPs on a non-
cognate agr regulon may bury a therapeutical potential; in a murine abscess model, 
administration of a synthetic group II AIP along with a group I strain strongly attenuated 
infection (251). 
Although the importance of agr in virulence has been shown in disease models of 
skin abscess (251), endophthalmitis (45), septic arthritis (1, 42), endocarditis (66) and 
osteomyelitis (42, 131), where agr mutants displayed attenuated virulence, under certain 
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conditions S. aureus seems to use other regulatory circuits than agr to establish infection 
(137, 138). While an agr mutant can still cause pneumonia, invasive infection of the lung was 
no longer possible (161). In a peritoneal sepsis model, agr was not expressed and did not 
affect virulence (22). Similarly, in a device related subcutaneous infection model of guinea 
pigs and rabbits, agr expression was reduced compared to in vitro growth (138, 417). Ex vivo 
data from patients with cystic fibrosis revealed that agr expression was reduced in lung 
infection as well. Co-colonisation with strains belonging to different agr groups was 
consequently possible, which otherwise is rarely the case (139, 189). Possibly because it 
represents a metabolic burden (283), spontaneous agr mutants appear frequently in the 
laboratory (40, 358), biofilm or chronic infections  (140, 416). 
 
arl 
The autolysis-related locus regulator/sensor protein (arlRS) plays a role in biofilm 
formation by influencing adhesion and autolysis. In addition, arl was found to be required for 
growth-phase dependent relaxation of DNA supercoiling, which positively influences spa 
transcription. Moreover, arl interacts with sar and with agr to modulate virulence factors like 
spa and hla (114-116). In strain Newman, but not in strain COL or in an RsbU+ 8325 
background, arl was found to be up-regulated by SigB (38). 
 
sae 
The S. aureus exoprotein expression locus sae has been shown to influence the 
production of several virulence factors with major consequences for infection, probably in 
response to various environmental stimuli (134, 136, 284, 363, 406). sae strongly depends 
on RNAIII in post-exponential phase (135, 284). While SarA has been reported to be a 
positive regulator, the effect of SigB on sae is not yet clear (363). In one case an attenuating 
effect had been observed in an 8325 background (284), whereas in a microarray study 
performed by our group in strain Newman, no such influence could be shown (38). sae is 
known to be required for fnbA and hla transcription (138). While in vitro, also agr and sar 
influence hla, in vivo sae is the predominant factor (138). For fnbA activation in vitro, sae, 
sigB and sar seem to be similarly important, since mutants of any of these regulators 
displayed reduced fnbA transcription (38, 272, 363, 411, 415).  
 
srr 
The auto-inducing srr locus (for staphylococcal respiratory response, srrAB; synonym 
staphylococcal resDE homologues, srhSR) reacts to environmental oxygen changes by 
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controlling expression of respiratory and fermentative enzymes as well as virulence factors, 
among which agr, TSST-1 and spa seem to be directly down-regulated (309, 375, 418).  
Under aerobic conditions, srr mutants grow normally, however, in the absence of oxygen, 
growth is impaired (418). Unpublished results of P. Schlievert showed that srr is down-
regulated by agr, forming a cross-inhibition circuit (283).  
 
yyc 
yycFG (synonym vicRK) is the only known essential two-component system; its 
conditional down-regulation increases cell permeability as well as susceptibility against 
macrolide-lincosamide-streptogramin B (MLSB) antibiotics (245). Interestingly, the sensor 
histidine kinase YycG contains a PAS/PAC domain. PAS is an acronym formed from the 
names of the proteins in which the imperfect repeat sequences, accounting for the PAS 
domain, were first recognized: the Drosophila period clock protein (PER), vertebrate aryl 
hydrocarbon receptor nuclear translocator (ARNT), and Drosophila single-minded protein 
(SIM). Situated carboxy-terminally to the PAS repeat, and contributing to the PAS structural 
domain, lies another similar region; the PAC motif (155). Unlike many other sensory 
domains, PAS domains are located in the cytoplasm where they function in various proteins 
as an input module monitoring changes in oxygen, redox potential and the intracellular 
energy status (371). Akin to most Gram-positive bacteria, S. aureus YycG has, in 
combination with the downstream encoded YycH and YycI components plus an aerobic 
terminal oxidase, the capacity for electron transport (277).  
While its exact function remains to be resolved, the response regulator YycF has 
been shown to bind specifically the promoter regions, among others, of the antigens isaA 
and ssaA, but also of the lytM peptidoglycan hydrolase (86). Whether the proposed direct 
regulation is of positive or negative nature remains to be determined, however, 
overexpression of SsaA restores hypersensitivity to MLSB antibiotics in a yycF mutant to wild-
type levels (244). Therefore, ssaA regulation by YycF is most likely positive. A cell wall 
hydrolysing activity for the mainly secreted IsaA has been suggested, due to similarity with 
the soluble E. coli lytic transglycosylase and localisation of IsaA to the septal region of 
dividing cells (338). None of the so far identified targets in S. aureus are essential. A recent 
report about the yyc homologue in Streptococcus pneumonia identified this regulator to up-
regulate fatty acid synthesis genes and to inhibit both the arginine deiminase arcA and the 
ornithine carbamoyltransferase argF, involved in arginine degradation and biosynthesis, 
respectively (Fig. 26) (263). In B. subtilis, yycFG might directly modulate the expression of 
the teichoic acid biosynthesis genes tagAB/tagDEF and positively influences transcription of 
the essential cell division operon ftsAZ, which is however also controlled by SigA and SigH 
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(120, 171). Multifactorial control of gene expression complicates the identification of crucial 
target genes not only of YycF. This regulator most likely influences further, yet unidentified, 
possibly essential genes in B. subtilis and in S. aureus, whose combined aberrant expression 
leads to cell death. 
 
1.2.2.2. SarA-homologues  
 
The vast SarA protein family can be divided in two subfamilies: i) single-domain 
factors (SarA, SarR, SarT, Rot) and ii) two-domain factors (SarS, SarU), with each domain 
sharing sequence similarity to the single domain factors (reviewed in (63)). Single-domain 
factors have been shown to dimerise, whereby they acquire a similar overall structure as 
two-domain factors (Fig. 7) (221, 225) and resemble the one of winged-helix family 
transcription factors as reported for eukaryotes (121).  
 
 
 
 
 
 
Fig. 7. Comparison of overall structures from SarR 
and SarS. The SarR structure is composed of two 
identical monomers, one in green and the other in 
yellow. In contrast, SarS is composed of two 
homologous but non-identical halves (S1 and S2) 
connected by a linker region. Both are winged-helix 
structures similar to the winged-helix proteins of 
eukaryotes. Reproduced from (63).  
 
 
A central helical core is flanked by two winged-helix motifs. Within each winged-helix 
motif is a helix-turn-helix (HTH) motif and a β-hairpin turn, both putative DNA-binding 
domains (225). Conserved, basic amino acids are located on the concave surface, 
supposedly mediating DNA-binding (Fig. 8). Contrary, the convex side, functioning as the 
activating domain, displays a much higher diversity, reflecting the divergent functions of the 
SarA family members.  
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Fig. 8. The DNA binding model of SarR and DNA. 
The α4 helix and the wing region (W1) interact with 
DNA at major grooves and minor grooves, 
respectively. W1 conformation is slightly adjusted to 
fit in the minor groove. Reproduced from (225).  
rot 
Rot is a sarS activator, but has first been identified as an inhibitor of protease and 
α-toxin expression, for which it was named repressor of toxins (rot) (258, 336). Although 
transcription seems to be synergistically activated by agr and sar, rot is possibly post-
transcriptionally repressed by agr (381). While in the latter report a negative influence of SigB 
on rot was found in an 8325 derivative, microarray analyses performed in our group could not 
confirm these findings in a Newman background (38). 
 
sar 
Three overlapping transcripts are expressed from the staphylococcal accessory 
regulator A locus (sar). sarB, sarC and sarA share identical 3' ends and all code for the 
global regulator SarA (Fig. 9), which regulates positively or negatively, directly or via other 
regulators, the expression of virulence determinants like agr, fnbA, spa and hla. Activators 
and temporal patterns of the individual sar transcripts differ. sarB and sarA are both most 
abundant in exponential phase and taper off towards post-exponential phase, their 
transcription is SigA-dependent. Instead, sarC transcription is selectively promoted by the 
alternative sigma factor SigB and increases towards stationary phase (21, 39, 65, 80, 122, 
239). Indications for an involvement of the non-SarA-coding regions in post-transcriptional 
modulation of SarA activity exist. For instance, the sarB transcript contains elements located 
upstream of the SarA coding sequence which seem to be important for full SarA activity (64, 
157). In the case of ORF3, a small additional coding region contained in sarB as well as in 
sarC, the nucleotide sequence itself has been reported to be essential for SarA-mediated 
fnbA activation, but not spa inhibition (411).  Despite the diverse transcription, overall SarA 
protein levels have been reported to be rather constant during growth (41, 43, 170). 
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Fig. 9. Schematic organisation of the sar locus. Transcripts (wave lines), promoters (arrows), open reading 
frames (boxes) and an inverted repeat (hairpin loop) are indicated. The corresponding sigma (σ) factors initiating 
transcription are given above each promoter. Adapted from (239).  
 
sarR 
sar expression is modulated by SarR, which has been shown to bind to all three sar 
promoters. Interestingly, transcription from the SigB-dependent sar P3 promoter was 
reduced in a sarR mutant, while transcription from the strongest sar promoter P1 was 
enhanced. SarA levels were increased, as was consequently agr transcription (238, 239). 
 
sarS 
The staphylococcal accessory regulator S (sarS; synonym sarH1) binds to the 
promoter region of spa, thereby up-regulating transcription (122, 372). Contradictory results 
exist about SarS being a strong hla repressor (346, 372). sarS transcription is repressed by 
SarA and agr, but activated by Rot, SarT and TcaR (122, 253, 346). In an 8325-4 
background, overproduction of SigB triggered sarS transcription initiated at a SigB-promoter 
consensus sequence; the resulting mRNA was paralleled by a possible processing product 
(372). However, in a Newman background, sarS transcription was not affected by SigB (38). 
 
sarT 
sar and agr repress sarT expression. SarT in turn down-regulates the agr activator 
SarU, thereby indirectly repressing hla transcription (240, 347). On the other hand, SarT up-
regulates SarS, which positively influences spa expression (346). 
 
sarU 
Adjacent to sarT, but divergently transcribed, lies sarU. This agr activator might 
together with sarT represent an additional agr amplification loop, where increased agr activity 
decreases the expression of the SarU repressor SarT, thereby increasing agr activation by 
SarU (240). 
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1.2.2.3. Sigma factors 
 
Initiation of transcription is the most important step of gene regulation. The single 
RNA polymerase core enzyme, engaged in all transcriptional activity, requires an additional 
subunit, designated as the sigma factor, to recognise promoter sequences and to initiate site-
specific transcription (reviewed by (412)). Most bacteria synthesise several sigma factors, 
each of which recognises different consensus promoter sequences. This heterogeneity is the 
primal transcriptional regulatory mechanism, allowing the constitutive or conditional 
expression of physically unrelated genes that share the same promoter sequence. Unlike 
well-studied bacteria such as Escherichia coli and Bacillus subtilis, which have seven and 18 
sigma factors, respectively, in S. aureus, besides the housekeeping sigma factor A, only two 
alternative sigma factors have been identified.  
 
sigH 
The over-expression of this recently identified sigma factor resulted in a drastic 
induction of the expression of the com operons that encode proteins required for the natural 
genetic competence (268). Since S. aureus does not form spores, the genetic competence is 
thought to be even more significant for the single cell survival and/or for the evolution of the 
species, because the imported DNA can serve as a nutrient, a template for DNA repair, 
and/or a supplier of genes that benefit cells (85). Under which conditions S. aureus is 
genetically competent is still unknown.  
 
sigB 
SigB, a regulator mediating stress response against UV, heat, acid and hydrogen 
peroxide strain (61, 126, 129, 170, 213, 214), also plays a role in antibiotic resistance as well 
as biofilm formation (37, 269, 313, 355, 414). Recently, a murine model of septic arthritis and 
a rat model of experimental endocarditis revealed SigB to be crucial for virulence (100, 183), 
whereas in other infection models SigB seemed not to be required (61, 170, 279). SigB had 
been shown to modulate directly or indirectly over 250 genes, among which sar, hla, fnbA 
and clfA (38, 65, 100, 127, 129, 272, 279, 318).  
The sigB operon comprises apart from sigB itself, three regulators of sigma B (rsb) 
which control SigB activity in response to environmental stimuli on the post-translational 
level, and two smaller genes, SAS067 and SA1873, encoding hypothetical proteins. RsbU, 
RsbV and RsbW control SigB activity at the post-translational level (129, 262, 291). In the 
general model of SigB regulation (Fig. 10), derived from findings in B. subtilis (25, 158, 408), 
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the anti-SigB factor RsbW can form mutually exclusive complexes with either SigB or its 
antagonist, RsbV. Under normal conditions, RsbV is phosphorylated by RsbW. This 
modification impedes the formation of a stable RsbV-RsbW complex. The majority of RsbW 
can therefore aggregate to SigB, thereby hindering SigB interaction with the RNA 
polymerase core-enzyme (RNAP) and consequently transcription of genes preceded by a 
SigB consensus promoter sequence. Under stressed conditions, the RsbV~P-specific 
phosphatase activity of RsbU becomes activated by a yet unknown mechanism, 
dephosphorylates the anti-anti-SigB factor RsbV, which is thereby enabled to interact with 
RsbW. Consequently, the amount of RsbW-SigB complexes is decreased in favour of RsbW-
RsbV aggregates, leading to free SigB, which then can form a holoenzyme with the RNA 
polymerase and direct transcription from target genes. The consensus promoter sequence 
for SigB targets was found to be GttTaa(N12-15)gGGTAt (127, 169).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Model of SigB activity regulation (A, adapted from (37)) and schematic organisation of the sigB operon 
(B). A The anti-SigB factor RsbW can form mutually exclusive complexes with either SigB or its antagonist, RsbV. 
RsbV is normally phosphorylated by RsbW (RsbV~P), which hinders it to complex RsbW, leaving the latter free to 
interact with SigB. When bound to RsbW, SigB can not aggregate with the RNA polymerase core enzyme (RNAP) 
to form an active holoenzyme. Upon stress, the RsbV~P-specific phosphatase activity of RsbU becomes activated 
and recycles RsbV~P to RsbV, favouring RsbW-RsbV aggregates and decreasing the amount of RsbW-SigB 
complexes. Freed SigB is then able to form a holoenzyme with RNAP and to direct transcription from its target 
genes. Activated proteins are star-shaped, yellow arrows designate reactions taking place under stressed 
conditions. B Transcripts (wave lines), promoters (arrows) and open reading frames (boxes) are indicated. The 
corresponding sigma (σ) factors initiating transcription are given above each promoter. Translation of SAS067 
and SA1873, encoding hypothetical proteins, is not represented. 
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While in B. subtilis an additional, upstream module exists, receiving environmental 
inputs leading to RsbU activity regulation, in S. aureus the corresponding proteins are 
missing (213, 414). A further RsbV phosphatase, RsbP, which has been proposed to sense 
energy stress, is absent as well (394). SAS067 and SA1873 share similarity with the E. coli 
"addiction module" systems (for a review see (99)) mazE-mazF and pemI-pemK, mediating 
programmed cell death. MazF and PemK are sequence-specific endoribonucleases that 
cleave mRNAs to inhibit protein synthesis, whereas MazE and PemI block their 
endoribonuclease activity (421, 423). The function of SAS067 and SA1873 in S. aureus 
remains to be determined.  
 
1.2.2.4. Other regulators 
 
TRAP/RAP 
A second quorum sensing system has been proposed to exist, consisting of an 
RNAIII-activating protein (RAP) and the target of RNAIII-activating protein (TRAP). Similarly 
to the AIP of the agr quorum sensing system, the 277 aa RAP, which is identical with the 
ribosomal protein L2, functions as an autoinducer. RAP has been proposed to be somehow 
constantly secreted in S. aureus, although not containing a classical signal peptide (208). 
TRAP is phosphorylated at three conserved histidines in a RAP-dependent manner (14, 145) 
and has been found to be up-regulated in cells exposed to oxacillin treatment (354). By yet 
unknown mechanisms, phosphorylated TRAP activates agr and is itself indirectly 
dephosphorylated by AIP (14). TRAP seems to be membrane associated and at least in part 
to be extracellular. The lack of a kinase domain and a transmembrane region suggests the 
TRAP/RAP system to belong to a novel class of signal transducers and that additional 
factors might be involved. This model has been strongly debated due to apparent difficulties 
in reproduction of the isolation of RAP and its activating potential on agr (285). However, 
recombinant RAP has recently been shown to activate agr transcription (208). Although the 
significance of an extra-ribosomal function remains to be determined, it seems not be unique 
to S. aureus. For example, the ribosomal protein L11 from Helicobacter pylori, lacking any 
signal peptide, has been reported to be secreted as well (199). 
 
svrA  
The staphylococcal virulence regulator A (svrA) is a putative membrane associated 
protein of approximately 52 kDa, which is required for agr expression and virulence, as 
shown in a mouse model of peritoneal infection (124). 
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tca 
The teicoplanin-associated locus regulator tcaRAB influences teicoplanin and 
methicillin resistance by a yet unknown mechanism. tcaR belongs to the MarR-like regulators 
and activates sarS transcription, while attenuating whole-length transcription of the cell-wall 
associated, putative adhesion protein sasF and inhibiting transcription of the intercellular 
adhesin ica locus, playing a key role in biofilm formation (177, 253). tcaA, a hypothetical 
transmembrane protein with potential sensor and/or signal transducer function, is thought to 
be involved in cell wall metabolism. Its inactivation leads to elevated glycopeptide resistance. 
tcaB encodes a membrane-associated protein with similarity to a bicyclomycin resistance 
protein present in several Gram-positive bacteria (50). Transcriptional regulation of the tca 
locus is complex and assignment of the individual bands is ongoing (236). 
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1.3. Resistance 
 
Development of resistance against noxious substances encountered in the 
environment has always been part of bacteria’s evolution. Nowadays, S. aureus with 
resistance against several antibiotic classes, disinfectants, antiseptics and heavy metal 
compounds exist (298). Concerns of a potential widespread of multidrug-resistant S. aureus 
is reinforced by the isolation of a multiresistance conjugative plasmid, combining a variety of 
resistance markers (405). Basic mechanisms conferring resistance are modification of the 
target, export, exclusion, inactivation and sequestration of the agent or bypass of the affected 
pathway; some representative, not exhaustive examples follow.  
 
The erm genes, which are transposon-borne, encode rRNA methylases that modify, 
and thereby protect, the ribosomal site that is critical for the binding of group B 
streptogramins, macrolides and clindamycin (181).  
Fluoroquinolones are readily separated from their site of action on DNA gyrase and 
topoisomerase IV by mutational up-regulation of NorA-mediated efflux (288).  
Aminoglycosides can be inactivated by several cellular enzymes, such as 
acetyltransferases, adenyltransferases and phosphotransferases (353).  
Trimethoprim, an analogue of the pteridine component of dihydrofolic acid, has a high 
affinity for dihydrofolate reductase. It thereby blocks the essential regeneration of 
dihydrofolate to tetrahydrofolate (THF) by the enzyme. THF can be converted to methylene-
tetrahydrofolate, a methyl-donor for example in the conversion of dUMP into dTMP. 
Resistance is conveyed by an altered dihydrofolate reductase with reduced affinity for the 
drug (419), bypassing the blocked essential step in formation of thymidine, purines, 
methionine and glycine (275).  
Both the antibacterial and DNA-cleaving activities of bleomycin are quenched by the 
product of ble, which has a high affinity for this antimicrobial agent (215). 
Phenotypic variants with a reduced membrane potential display a decreased uptake 
of cationic antibiotics, such as aminoglycosides or host defensins, resulting in an increased 
resistance against these substances. Usually, different threshold levels are required for each 
substance (20). These so-called small colony variants are discussed later.  
1.3.1.  β-Lactam resistance and PBPs 
 
All β-lactams contain an essential four-membered lactam (azetidinone) ring that can 
be fused to form bicyclic ring structures, as exemplified by penicillin G (Fig. 11). Their 
structural analogy to the D-Ala2-end of the peptidoglycan precursor stem peptide (Fig. 12) 
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confers high affinity for the extracellular enzyme(s) usually catalysing the incorporation of the 
peptidoglycan precursor into the existing cell wall, for which proteins belonging to this class 
were named penicillin-binding proteins (PBPs) (377, 383).  
 
 
 
Fig. 11. Structures of β-lactams. In benzylpenicillin (synonym penicillin G), the characteristic bicyclic core, 
consisting of the β-lactam (red) and  the thiazolidine ring (blue), is highlighted. Arrow heads indicate scissile 
bonds. Reproduced with minor changes from (141). 
 
The first steps of Michaelis complex and acyl intermediate formation are similar to the 
transpeptidase reaction (A/B1→ A/B2 in Fig. 12). However, hydrolysis of the acyl-PBP 
intermediate is very slow (reaction B2→B3 in Fig. 12). Thus, PBPs are de facto irreversibly 
inactivated by β-lactams (141, 222). The lack of functional PBPs leads to reduced cross-
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linking of peptidoglycan and consequently to a weakened cell wall, followed eventually by cell 
lysis and death (128). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. A The transpeptidase reaction catalysed by PBP2. A1 Nucleophilic attack of the active-site serine residue 
on the D-Ala2 peptide bond. A2 Formation of a covalent acyl intermediate, which can again be split by a 
nucleophile, here the amine of the pentaglycine linker. Alternatively, hydrolysis by water results in a net cleavage 
of the terminal D-Ala, leading to an uncrosslinkable tetrapeptide side chain. This reaction corresponds to the 
D,D-carboxypeptidase activity of PBPs, modulating the degree of cross-linkage. A3 The new amide bond cross-
linking two peptidoglycan chains. B Hydrolysis of penicillin catalysed by β-lactamase. B1 Nucleophilic attack of 
the active-site serine residue on C* of the β-lactam ring. B2 Penicilloyl intermediate, which is hydrolysed by water. 
B3 Penicilloate, lacking anti-bacterial activity. Nucleophilic attacks are not given in detail but symbolised by yellow 
arrows. Only the S-X-X-K motif of the acetyltransferases is represented. As in Fig. 11, the β-lactam (red) and  the 
thiazolidine ring (blue) are indicated. M, N-acetylmuramic acid; G, N-acetylglucosamin. Adapted from (55). 
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1.3.1.1. Penicillin resistance  
 
The first resistance mechanism against classical β-lactams, such as penicillin, was 
inactivation by β-lactamase, a serine protease that is capable of fast hydrolysis of the 
β-lactam ring (reaction B2→B3 in Fig. 12). Usually, the structural gene for staphylococcal 
β-lactamase, blaZ, is located on a plasmid, together with regulatory elements controlling the 
expression (153, 282).  
Despite an almost nonexistent similarity in their overall amino acid sequence, and 
different functions, PBPs form together with β-lactamases as well as β-lactam sensors the 
SxxK superfamily comprising Gram-negative and -positive bacterial acyltransferases. A 
common feature of these enzymes is a specific bar code in the form of three motifs, SxxK, 
(S/Y)x(N/C) and (K/H)(T/S)G, occurring at equivalent places and with roughly the same 
spacing along the polypeptide chains. In the three-dimensional structures, they are brought 
close together, forming the catalytic centre (Fig. 13) (141).  
 
 
Fig. 13. Basic polypeptide fold of the 
acyltransferases of the SxxK superfamily and spatial 
disposition of the three catalytic center-defining 
amino acid groupings. The structure shown is that of 
the 262-amino-acid D, D-transpeptidase-PBP of 
Streptomyces sp. strain K15. The invariant motif 1, 
S*xxK, where S* is the essential serine nucleophile, 
motif 2 (S/Y)x(N/C); here SxC, and motif 3 
(K/H)(T/S)G are depicted by spheres. Reproduced 
from (141). 
 
The multi-modular group I acyltransferases are implicated in peptidoglycan synthesis. 
An N-terminal, hydrophobic segment, functions as both a signal sequence for secretion and 
a stop transfer signal that serves as a membrane anchor (Fig. 14). Afterwards, a non-
penicillin binding (nPB) region follows, which in class A members corresponds to a 
glycosyltransferase module, and in class B members builds a linker region. The C-terminal 
acyltransferase, common to both classes, is then linked by an intermodule junction to the 
previous module, and, like those, has (sub-) class-specific motifs. Class A enzymes are 
responsible for the incorporation of the lipid II (LII) borne precursor peptidoglycan 
components into nascent peptidoglycans. Class B enzymes control wall expansion, ensure 
cell shape maintenance, direct and carry out septum formation as well as cell division (82, 
241). This function is in part conferred by the nPB module mediating protein-protein 
interactions critical for peptidoglycan assembly in a cell cycle–dependent manner.  
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Fig. 14. Group I and III acyltransferases. A Distribution of class-specific motifs along the polypeptide chain. 
Transmembrane domain, yellow; non-penicillin binding domain, orange; intermodular junction, white; 
transpeptidase domain, blue. Adapted from (141). B Three dimensional structure of PBP2‘ (class B1, group III). 
The position of the active site of the transpeptidase domain is indicated by the red nitrocefin adduct (shown in 
stick rendering). The secondary structure elements of the transpeptidase domain were labelled in accordance 
with the labelling scheme used for Streptococcus pneumoniae R6 PBP2x (294). The N- and C-termini are labelled 
N and C, respectively. Shown to the left is a linear representation of the domain structure of PBP2‘ with residue 
numbers shown in parentheses. The colour coding is as in A, however without the intermolecular junction. 
Reproduced from (222). 
 
A free-standing class in group I PBPs are auxiliary cell cycle proteins, implicated in 
cell morphogenesis. Instead of N-terminal, they have C-terminal membrane anchoring 
domains. The S. aureus transpeptidase/D-Ala2 carboxypeptidase PBP4 belongs to this class 
and regulates the extent of peptidoglycan cross-linking (Fig. 12, A2) (106, 209). Other 
members have been reported to hydrolyse interpeptide linkages, allowing remodelling of the 
cell wall.  
Group II acyltransferases are only indirectly or not implicated in cell wall synthesis, 
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exemplified by the β-lactamases and the β-lactam sensory transducers. For a detailed 
overview of the bacterial SxxK acyltransferases, the following reviews are recommended 
(141, 142). Contrary to other organisms, which have up to 16 PBPs (112), S. aureus has only 
four (classified in Table 1), of which PBP1 and PBP2 are essential (305).  
 
 
TABLE 1. S. aureus acyltransferases belonging to the SxxK superfamily, classified according to (141). 
 
 
 
1.3.1.2. Methicillin resistance 
 
Upon introduction of β-lactamase resistant penicillins, like the semisynthetic oxacillin 
and methicillin, S. aureus acquired the resistance determinant mecA, encoding an alternative 
PBP; PBP2’ (synonym PBP2a) (17). PBP2’ is placed with other acyltransferases conferring 
β-lactam resistance in group III of the vast SxxK superfamily. Generally, the members of this 
group share to a certain extent similarity with one of the previously mentioned (sub)groups, 
but possess different, free-standing characteristics. For example, PBP2’ belonging to the 
subclass B1, is similar to the class B PBPs. However, the linker region contains an essential 
insert, for which a structural role has been suggested in giving the transpeptidase domain a 
substantial reach from the cell membrane (Fig. 14). Moreover, the closed conformation of the 
active site of the acyltransferase module differs from the one of β-lactam sensitive PBPs, 
apparently hindering the acylation-reaction (141, 222). The resulting reduced acylation rate 
(reaction B1→B2 in Fig. 12) confers an intrinsic resistance against all β-lactam antibiotics. 
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Yet, upon contact with the polymeric substrate peptidoglycan, which occurs outside of the 
catalytic region of PBP2’, a conformational change is induced, making the active site of 
PBP2’ accessible only when the desired substrate is present and limiting the exposure to 
β-lactams to a minimum (119).   
PBP2’ is not a very efficient transpeptidase and depends on the transglycosylase nPB 
module of the resident PBP2 to confer resistance (77, 306).  Apart from PBP2’ expression, 
additional chromosomal factors and cell wall characteristics are required for high-level 
methicillin resistant S. aureus (MRSA), varying with the strain’s genetic background (30, 
331). For example, deletion of the alternative sigma factor B reduces methicillin resistance 
(355, 414). Borderline resistance observed in S. aureus, caused by overexpression of 
endogenous PBP2 and/or PBP4, or by mutations that reduce the penicillin affinities, lead to 
varying resistance levels, although always far below mecA linked resistance (18, 151, 160). 
Due to segregation of subpopulations with different resistance levels, MRSA display 
heterogeneous susceptibility. 
 
The SCCmec element 
mecA is contained in the so-called staphylococcus cassette chromosome mec 
(SCCmec) elements, genomic islands ranging from 21 to 67 kb (Fig. 15). These mobile 
genetic elements, also called resistance islands, resemble neither transposons nor 
bacteriophages and integrate into orfX with the help of type-specific cassette chromosome 
recombinases (ccr). The ccr gene complex is contained within SCCmec and is responsible 
for precise site- and orientation specific excision and integration. orfX is a gene of yet 
unknown function, located close to the origin of replication. Ccrs recognise the attBSCC site, 
consisting of a characteristic 15 bp direct repeat present at the 3’ end of orfX as well as at 
the right end of SCCmec.  In addition, degenerate inverted repeats characteristic of SCCmec 
are present (197). SCCmec is classified into allotypes by the combination of which class of 
mec gene complex and which type of ccr gene complex it possesses (Fig. 15). Differences in 
additional J regions (J for junkyard) divide SCCmec elements into further subtypes. Despite 
its disrespectful meaning, J regions can contain useful resistance genes for non-β-lactam 
antibiotics or heavy metals, some of which are derived from plasmids or transposons (for an 
overview see reference (174)).  
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Fig. 15. Structures of SCCmec types. SCCmec is composed of two essential gene complexes, the mec gene 
complex (khaki) and the ccr gene complex (orange). The mec gene complex is responsible for β-lactam 
resistance and contains apart from the PBP2’ encoding mecA two regulatory genes, mecR1 and mecI. The ccr 
gene complex encodes the CcrA and CcrB recombinases. Other areas (light grey) of the SCCmec are non-
essential, can contain various drug resistance genes or type-specific orfs, and are divided into three regions, J1-3. 
Note that in type I SCCmec the regulators mecR1 and mecI are disrupted by the insertion sequence (IS) IS1272 
and that it contains only a pseudo (Ψ) ccr complex, due to a frameshift mutation in ccrB. In type II SCCmec, 
plasmid pUB110, mediating resistance against aminoglycosides and bleomycin, has integrated into IS431. The 
site-specific transposon (Tn) 554, located in J2, confers macrolide, lincosamide, streptogramin B (MLSB) and 
spectinomycin resistance. Two instead of one direct repeat sequence (red arrow heads) are found in the left 
extremity of types II and IV SCCmec elements.  Reproduced from (174). 
 
Recent emergence of MRSA carriage and disease in the community has been mostly 
linked with type IV SCCmec elements (8, 231, 289), the smallest known SCCmec. Hospital-
acquired MRSA COL, N315, Mu50 and MRSA252 and community-acquired MRSA MW2 as 
well as MSSA476 (13, 130, 167, 216) are the six strains whose complete sequences is 
nowadays published. In one of them, MSSA476, a new, non-mecA containing SCCmec type 
was found (SCCmec476). It mostly resembles type IV elements, but instead of MecA it 
encodes a putative fusidic acid resistance protein, further highlighting the potential of these 
elements to act as carriers for genes that provide a selective benefit in the absence of 
methicillin (167).  
e.g. Mu50, N315, strain 252 
e.g. CA-MRSA MW2 
e.g. COL 
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Regulation of β-lactam resistance genes 
The mec and bla operons are identically organised and expression of mecA is 
analogously regulated as blaZ (Fig. 16) (164).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. β-lactam resistance mediated by β-lactamase. A β-lactams (red-blue particles) bind and inactivate the 
PBPs (purple), enzymes catalysing the incorporation of the peptidoglycan precursor lipid II (LII) into the existing 
cell wall. B The transmembrane sensor-transducer BlaR1 (ochre) senses the presence of β-lactams. Upon 
binding, BlaR1 undergoes autocleavage and the cytoplasmic domain, a metalloprotease, is activated. Cleavage of 
the cognate BlaI (black) repressor dimer follows  and expression of the bla operon is initiated. β-lactamase BlaZ 
(green) is secreted and destroys the β-lactam ring (red square). C Thereby, PBP inhibition is abolished and 
transglycosylase as well as transpeptidase activity (indicated by purple explosions in D) of PBPs is restored, 
leading to the incorporation of the monomeric peptidoglycan unit of LII. Note that these two reactions involve 
adjacent peptidoglycan strands and that cross-linking by transpeptidase cleaves the last amino acid (D-Ala) off 
the stem peptide. Regulation of the mec operon (mecI-mecR1-mecA) occurs in an analogous way, the only 
difference being that an alternative PBP with low β-lactam affinity (mecA) instead of a β-lactamase is encoded. 
BlaZ can be secreted, as depicted here, or exist as a membrane-bound enzyme (370).  
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Upon induction by binding of β-lactams, the transmembrane sensors BlaR1/MecR1 
proteolytically split off their cytoplasmic domain. The current model of the signal transduction 
mechanism is that autocleavage leaves the putative cytoplasmic proteases tethered to the 
membrane. Possibly through interaction with an intermediary molecule, the proteases then 
cleave their cognate repressors BlaI/MecI, most probably in a DNA bound state (10, 335, 
420). Both repressors have been shown to bind, presumably as homodimers, blaZ and mecA 
DNA promoter regions and can interchangeably repress the transcription of either target 
gene (71, 257, 352). In addition, since the promoter regions of the divergently transcribed 
regulons overlap with the one of the target genes, blaI/mecI are autorepressed. In the case 
of a truncated regulator set, as seen for type-I SCCmec elements (Fig. 15), the resistance 
gene can be expressed constitutively, or can be regulated by the highly homologous Bla 
sister system, if present. Interestingly, the BlaR1/BlaI system has faster induction kinetics 
than MecR1/MecI (330). Although the MecR1 sensor is inducible by cefoxitin (a β-lactam), 
PBP2’ expression is inefficiently triggered by oxacillin or methicillin, for which strains carrying 
only the mec operon can appear susceptible.  
Due to the homologous regulatory region of the mec and bla operons it has been 
hypothesised that the mec determinant has evolved by recombination of a structural gene for 
a PBP with the regulatory region of a β-lactamase (362). The SCCmec element has spread 
in vivo between different staphylococcal species (407) and has entered at least on five 
occasions distinct S. aureus lineages (111). Still, MRSA predominantly disseminate clonally, 
suggesting that the SCCmec has a rather restricted mobility. Although the origin of mecA and 
the SCCmec element are not known, coagulase-negative staphylococci have been proposed 
to be the reservoir for MRSA, since they carry an identical SCCmec (11).  
 
Cell wall composition  
The S. aureus peptidoglycan comprises 30 -70% of the entire cell wall and forms a 
multilayered, highly cross-linked sacculus, which protects the bacterium from osmotic 
pressure and determines its shape (Fig. 3) (345). It consists of 20 or more layers of linear 
glycan chains with alternating units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic 
acid (MurNAc). The carboxylic group of N-acetylmuramic acid is substituted with the stem 
pentapeptide L-Ala-D-iGlu-L-Lys-D-Ala-D-Ala. A pentaglycine interpeptide, branching off the 
ε-amino group of the L-Lys of the stem peptide, connects one peptidoglycan chain to the 
D-Ala in position 4 of a neighbouring chain as depicted in Fig. 17. The flexible interpeptide 
allows a high, three-dimensional cross-linking of the peptidoglycan, characteristic of the 
staphylococcal cell wall.  
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Fig. 17. Cell wall biosynthesis of S. aureus. Formation of the pentaglycine interpeptide bridge does not occur 
before synthesis of the cell wall precursor lipid II is completed. When the interpeptide bridge is accomplished, the 
monomeric peptidoglycan unit is translocated across the cytoplasmic membrane to the outside and incorporated 
into the cell wall. UMP, uridine monophosphate; UDP, uridine diphosphate. The putative flippase is symbolised by 
a transparent cylinder. Reproduced from (349). 
 
Various cell wall-sorted proteins, which are important in infection and virulence of this 
pathogen, use the interpeptide as attachment site (302, 319). Anchoring of proteins to the 
cell wall is described in Fig. 18 (252). These proteins share the following features from the N- 
to the C-terminus: I) a signal peptide (~40 aa; SP) that directs the polypeptide into the 
secretory (Sec) pathway II) a segment containing a wall-spanning region, that is either rich in 
Pro and Gly residues or composed of Ser-Asp dipeptide repeats (e.g. the clumping factors) 
III) the LPXTG motif, which is recognised by the sortase A enzyme IV) a hydrophobic 
membrane-spanning domain serving as the sorting signal for the secretory pathway V) a 
series of positively charged residues at the very C-terminus remains in the cytoplasm (in Fig. 
18 symbolised by a white square with a plus). For sortase B, recognising the motif NPQTN, 
apparently only one substrate exists: IsdC, involved in heme scavenging, is most likely 
tethered to the pentaglycine of already incorporated monomers and slightly buried in the cell 
envelope (232, 243).  
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Fig. 18. Surface protein anchoring in S. aureus. (i) Export. Precursor proteins with an N-terminal signal peptide 
(SP) are initiated into the secretory (Sec) pathway, and the signal peptide is removed. (ii) Retention. The 
C-terminal sorting signal (black rectangular)  retains polypeptides within the secretory pathway. (iii) Cleavage. 
Sortase cleaves between the threonine and the glycine of the LPXTG motif, resulting in the formation of a 
thioester enzyme intermediate. (iv) Linkage. Nucleophilic attack of the free amino group of lipid II at the thioester 
bond resolves the acyl-enzyme intermediate, synthesizing the amide bond between surface proteins and the 
pentaglycine cross-bridge and regenerating the active-site sulphydryl. (v) Cell wall incorporation. Lipid-linked 
surface protein is first incorporated into the cell wall via the transglycosylation reaction. The murein pentapeptide 
subunit with attached surface protein is then cross-linked to other cell wall peptides, generating the mature murein 
tetrapeptide. Reproduced from (252). 
 
Two other possibilities for tethering wall-associated proteins are membrane 
attachment via a thioether-linked glyceride (274) and ionic binding via teichoic acids (84). 
These highly charged anionic polymers can make up 30 - 60% of the cell wall and are 
present in two forms; wall teichoic acids (WTA) and lipoteichoic acids (LTA). Together with 
peptidoglycan, teichoic acids (TA) build a meshwork providing elasticity, porosity 
(approximate cut off 50 kDa (168)) and tensile strength, while steering, among others, 
electrostatic properties and cation homeostasis of the envelope (276).  
WTA consists of a linear chain of 1,3-phosphodiester-linked ribitolphosphate residues 
that is attached via a linkage unit to the O6 of the N-acetylmuramyl residues of the 
peptidoglycan (depicted below in Fig. 22). The linkage unit consists of (Gro)2-3ManNAc-
GlcNAc-1-P, where Gro stands for glycerophosphate (206). The ribitolphosphate (Rbo-P) 
residues are substituted with D-Ala esters and N-GlcNAc residues (Fig. 19) (403).  
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Fig. 19. Organisation of wall teichoic acid. 
A Linkage unit consisting of (glycerophosphate)2-
ManNAc-GlcNAc-1-P. B Polyribitolphosphate 
(Rbo-P). C Characteristic substituents on 
poly(Rbo-P). Reproduced from (276). 
 
 
 
 
 
 
 
Fig. 20. Organisation of lipoteichoic acid. A 
Glycolipid anchor. B Poly(Gro-P) (sn-glycerol 1-P). 
C Substituents (X). Reproduced from (276). 
LTA is build by a 1,3-linked polyGro chain that is covalently linked to the membrane 
glycolipid Glc(β1-6)Glc(β1-3)acyl2Gro (88, 108). The Gro units are in part substituted with 
positively charged D-alanine esters (Fig. 20) (107, 109). While WTA and LTA have different 
biosynthetic pathways, the D-Ala-ester substituents of WTA are derived from those of LTA 
(150), into which D-Ala is incorporated by a machinery entirely encoded in the dlt operon 
(301).  
Apparently, enzymatic and non-enzymatic transacylation of the chemically reactive 
D-Ala esters can occur, among LTA and WTA, as well as along one molecule (69, 201). 
Thereby, the intrinsic negative charge of these molecules is reduced by the positive charged 
amino group conferred by D-Ala esters (Fig. 21), a prerequisite for cell-cell approaching 
previous to biofilm formation (148) and adherence to host cells, possibly by causing altered 
binding activities of adhesins (5, 6, 250). Ala-free LTA is an inhibitor of autolysins, 
peptidoglycan hydrolyases required for remodelling of the peptidoglycan (110). As shown by 
dlt deletion, an increased negative net charge of the bacterium, caused by decreased D-Ala 
content of the teichoic acids, leads to a higher susceptibility towards innate host defence 
mediated by cationic peptides (72, 212, 303). On the other hand, D-Ala substituted LTA, 
together with peptidoglycan, is a more potent inducer of a variety of proinflammatory 
mediators, e.g. IL1, 6, 8 and TNF-α, than LTA alone is (Fig. 1) (200, 265, 276). The degree of 
teichoic acid substitution with D-Ala esters further influences susceptibility towards 
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antibiotics. A non-functional dlt operon leads to increased methicillin resistance (273), 
whereas a reduced D-Ala content of teichoic acids confers a higher sensitivity towards 
glycopeptides and lysostaphin (304). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Protonated D-alanyl ester substituent linked 
to the 2' hydroxyl of a Gro-P unit (sn-glycerol 
1-phosphate). Ion pairing of the phosphodiester with 
the protonated amino group occurs on rotation of 
the phosphodiester linkage. Atoms are indicated by 
circles: hydrogen (white), carbon (black), oxygen 
(red), nitrogen (blue) and phosphorus (yellow). 
Reproduced from (276). 
 
1.3.2.  Peptidoglycan synthesis 
 
In eubacteria, a universal biosynthesis pathway supposedly exists for the production 
of the UDP-MurNAc monosaccharide (387), which is further converted into the species-
specific peptidoglycan precursor as depicted in Fig. 17. The stem peptide is added in a 
sequential fashion to the lactyl group of the MurNAc moiety by amino acid ligases (for details 
see ref. (55)). In some Gram-positive bacteria, the UDP-MurNAc-pentapeptide is used as 
substrate for the synthesis of branched peptidoglycan precursors (47, 156). The following 
steps are located to the membrane by MraY-mediated transfer of the soluble UDP-MurNAc-
pentapeptide to the lipid carrier undecaprenylphosphate (C55-P) (Fig. 17), yielding lipid I 
(C55-P-MurNAc-pentapeptide) (162). The translocase MurG subsequently links UDP-
activated N-acetyl-glucosamine (UDP-GlcNAc) to the muramoyl moiety of lipid I, thus yielding 
lipid II (C55-P-GlucNAc-MurNAc-pentapeptide) (388).  
Earlier experiments with membrane preparations did not unequivocally identify the 
substrate for interpeptide synthesis in S. aureus, although lipid II seemed to be preferred 
(193, 248). Once the synthesis of the peptidoglycan precursor is completed, it is translocated 
to the outside of the cell by a yet unknown mechanism. It has been suggested that the lipid 
anchor wraps itself around the hydrophilic glycopeptide moiety to allow crossing of the 
membrane (233). However, such a process is too slow for the high rate of cell wall synthesis 
(55, 168), given that there are not many undecaprenyl molecules (depending on the 
organism, 2000-105 per cell (260, 361, 366)) and that they have to be efficiently guided to the 
cytoplasmic compartment for recycling. Therefore, an enzymatically catalysed flip-flop 
movement is more likely. Once outside of the cell, the monomeric peptidoglycan unit is 
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incorporated by transglycosylation into the existing peptidoglycan and can be further used for 
cross-linking by transpeptidation (Fig. 12).  
 
1.3.3.  Fem factors and antibiotic resistance 
 
The factors essential for methicillin-resistance (fem) of S. aureus, belonging to the 
new FemABX family of non-ribosomal peptidyltransferases (156, 324), were found by a 
transposon based mutation screening, identifying MRSA mutants with affected methicillin 
susceptibility, despite the presence of intact PBP2’ (28). They were part of a group of house-
keeping genes, mostly involved in cell wall biosynthesis (29, 31, 78). Extensive genetic 
analysis and characterization of mutant cell walls suggested that the species-specific 
pentaglycine interpeptide bridge is synthesised in a sequential fashion by three Fem factors. 
FemX, encoded by the essential gene fmhB, was found to be required for incorporation of 
the first glycine to the stem peptide (325). The second factor, FemA, was proposed to 
catalyse the addition of the second and third glycine (234, 367), whereas FemB is supposed 
to add glycines four and five (159). The Fem peptidyltransferases use tRNAGly as donor in a 
ribosome-independent reaction (Fig. 22) (192).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22. S. aureus interpeptide bridge synthesis. Addition of the first glycine residue to L-Lys, as catalysed by the 
Fem factors (here FemX). In a similar way, FemA adds the next two, and FemB the last two glycine residues. 
Note that the direction of elongation is opposite to that which occurs during protein synthesis (and seen in the 
stem peptide). The nucleophilic attack of the ε-amino terminus of L-Lys on the carboxy group of the tRNAGly-
linked glycine is symbolised by a yellow arrow and is not given in detail. O6 of MurNAc, the attachment site for 
teichoic acid, is indicated in red. 
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Impaired cell division, leading to aberrant septum formation and pseudomulticellular 
forms with thickened cell wall in femAB mutants further pointed at the importance of an intact 
pentaglycine bridge for bacterial growth (159). Moreover, femAB mutants become 
susceptible for a variety of unrelated antibiotics (224), but, conversely, more resistant against 
the glycyl-glycine endopeptidase lysostaphin. The defect in cell division can partially be 
explained by the fact that endogenous glycyl-glycine endopeptidases are involved in cell 
separation and that their substrate is absent in femAB mutants (368). Survival with a 
shortened bridge reduced to only one glycine requires as yet uncharacterized compensatory 
mutations, indicating that the interpeptide is essential for S. aureus (224) and required not 
only by PBP2’, but also the endogenous PBPs. Very recently, Pinho et al. showed that 
recruitment of PBP2 to the division site of the cell apparently depends on substrate binding, 
which can also be mediated by PBP2’ in the presence of β-lactams, provided proper 
substrate molecules are produced (305). The substrate itself has been proposed to be 
recruited to the division site by FtsW, a hypothetical flippase, which has been shown to 
localise to the division septum in an FtsZ-dependent manner in B. subtilis and E. coli (101, 
229, 261). FtsZ is one of the key elements forming a ring structure at the future division site 
(33).  
Full length interpeptide bridges seem also to be crucial for sortase; any shortening of 
the lipid II‘s pentaglycine chain leads to an impaired surface protein anchoring, and 
consequently affects virulence (328, 378). Homologues of FemA, FemB and FemX have 
been identified in all Gram-positive bacteria, which produce a branched-chain peptidoglycan 
with either glycine and/or L-amino acids in the interpeptide (324). Interestingly, the 
pneumococcal Fem homologues, MurMN and FibAB, respectively (104, 404), were found to 
be associated in that species with penicillin resistance as well.  
 
 
1.3.3.1. Molecular structures of Fem members 
 
Recent determination of the crystal structures of the S. aureus FemA (FemASA) alone 
and the Weissella (synonym Lactobacillus) viridescens FemX (FemXWV) in complex with the 
UDP-MurNAc-pentapeptide substrate brought some light into the possible interaction modus 
of Fem factors and their substrates (Fig. 23). The overall globular structure of FemXWV is 
similar to FemASA, consisting of two almost identical subdomains separated by a cleft. Motif 
search revealed a certain similarity with the fold of the GCN5-related N-acetyltransferase 
(GNAT) superfamily, which catalyses the transfer of the acetyl group from acetyl coenzyme A 
to a primary amine. This superfamily comprises protein families associated with diverse 
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functions, including transcription factors, enzymes required for detoxification and drug 
resistances, metabolic enzymes and yet uncharacterised proteins. The conserved structural 
framework extant in all GNAT superfamily members may be modified to allow for changes in 
the structure of the acyl group donor, as in the case of the Fem factors, where the acyl-donor 
is a loaded tRNA instead of coenzyme A (393).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Comparison of soluble and membrane-associated Fem factors. A The binary complex formed by 
Weissella viridescens FemX, FemXWV, and the UDP-MurNAc-pentapeptide. FemXWV is constituted by two 
domains which are separated by a cleft: domain 1 represented in blue and domain 2 in magenta. The two 
domains have a similar fold. The UDP-MurNAc-pentapeptide, shown in green, lies in the cleft between the two 
domains and mostly contacts domain 1. B Ribbon plot of FemXWV (red) is shown optimally superimposed with 
S. aureus FemA, FemASA, (yellow). The overall structures are similar; the major structural difference is the 
absence in FemXWV of the coiled-coil region constituted by two helices inserted in FemASA domain 2. C, D Solid 
surface representation coloured by electrostatic potential (blue, positive; red, negative). C FemXWV with its two 
substrates. The UDP-MurNAc-pentapeptide is coloured in green. The secondary structure elements of FemXWV 
domains 1 and 2 that interact with the UDP-MurNAc-pentapeptide are indicated by yellow arrows. The uracil ring 
is partially buried in the pocket closed by  α11. The alanyl-tRNAAla acceptor end, coloured in cyan, was manually 
docked in the domain 2 channel. D In FemASA, the loop α7- α8 was not resolved (26). The substrate specificity of 
members of the FemABX family, lipidic or soluble, explains the presence of the additional crevice in FemASA 
(lipidic) formed by the loop β8-β9 and the helix α13 compared to FemXWV (soluble). The coiled-coil region inserted 
in FemASA domain 2 is partially represented and is indicated by an orange arrow. Reproduced from (34). 
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An L-shaped channel crossing the two subdomains has been shown to accommodate 
in FemXWV the soluble acceptor, UDP-MurNAc-pentapeptide, interacting mainly with domain 
1 (Fig. 23) (34). The uncomplexed FemASA possesses a similar channel and an additional 
crevice, approximately at the site where the uracil ring of the UDP moiety is located in 
FemXWV. This structural difference could account for the substrate specificity of the S. aureus 
Fem factors for lipid intermediates, lipid I or lipid II, as indicated by the inability of 
staphylococcal FemX to add the first glycine to UDP-MurNAc-pentapeptide (156). A further, 
less spectacular difference between FemASA and FemXWV is the absence of a β hairpin. This 
structure lengthens the β sheet of domain 2 and strengthens the junction between the two 
domains. As deduced from amino acid sequence comparison, this β hairpin is also missing in 
FemXSA, but present in FemBSA (34). Since it is only absent in the factors adding the first 
amino acid to the stem peptide, it could hypothetically serve the FemASA and FemBSA factors 
for recognition of precursors with a substituted stem peptide.  
The most striking difference between FemXWV and FemASA was the absence in 
FemXWV of an antiparallel coiled-coil domain formed by two alpha helices. This helical arm 
has been proposed to provide a flexible platform for the interaction with the tRNAGly 
substrate, as shown for tRNASer synthetase from Thermus thermophilus (26, 36). In addition, 
a 35 amino acid long region in the coiled-coil arm of the Streptococcus pneumoniae Fem 
homologue MurM has been shown to determine the preferential incorporation of alanine 
versus serine (105). In the case of FemXWV, discrimination of tRNAAla, respectively tRNASer, 
would therefore occur via the globular domain by a yet unknown interaction mechanism. 
Genome analyses of S. aureus revealed the presence of four or five different tRNAGlys, two 
of which have been proposed to be proteinogenic and three non-proteinogenic (57, 146), 
leading to the assumption that each Fem factor may use dedicated tRNAGlys. 
The S. aureus FemA protein presumably contains just one tRNAGly binding site, which 
led to the hypothesis that, after the addition of the first Gly, a subsequent round of tRNAGly 
binding and transfer would account for the addition of the second glycine (26). Recently, 
direct interactions of FemA-FemA, FemB-FemB and FemA-FemB were detected using a 
bacterial two-hybrid system. FemX did not show any interactions with FemA or FemB. This 
rather suggested that FemX acts as a monomer, while FemA and FemB may act as homo- 
or heterodimers (323).  
Staphylococcal strains producing glycyl-glycine endopeptidases, such as lysostaphin 
or ALE1 (369), protect their cell walls by FemABX-like immunity factors, termed Lif or Epr, 
which insert serine in place of glycine at positions 3 and 5 in the interpeptide (95). 
Interestingly, FemA and FemB were also found to interact with Lif, which was shown to 
substitute serine in positions 3 and 5 of the pentaglycine interpeptide chain in S. aureus in 
co-operation with FemA or FemB (95, 376). These data imply that FemA and FemB probably 
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function as homodimers in such a way that both subunits are loaded with tRNAGly to ensure 
sequential addition of both Gly to the growing interpeptide bridge. Furthermore, addition of 
Ser at the defined positions 3 and 5 upon interaction with FemA or FemB leads to the 
assumption that recognition of the lipid-bound substrate is mediated by the Fem 
peptidyltransferases, whereas Lif may not possess an appropriate binding groove. 
 
1.4. Small colony variants 
 
As already mentioned above, an additional mechanism to evade antibiotic pressure 
and host defence is observed in persisting and relapsing S. aureus infections, where 
formation of a phenotypic mutant subpopulation occurs; the so called small colony variants 
(SCV) (259, 311, 350). SCVs emerge also in other nosocomial bacteria, such as 
Pseudomonas aeruginosa and E. coli (320, 321, 400).  
Prophylactic administration of aminoglycosides (e.g. gentamicin beads as an adjunct 
to surgical therapy for osteomyelitis) and long-term administration of trimethoprim-
sulfamethoxazole (SXT) in cystic fibrosis (CF), but not AIDS patients, strongly favours the 
emergence of S. aureus SCVs (125, 133, 188, 396, 399). Importantly, treatment with SXT 
might still represent a last choice for infections with MRSA, although multidrug resistant 
MRSA strains seem to be more frequently SXT resistant (341, 424). Apart from antibiotics, 
specific environments encountered in the host have been proposed to select for SCVs. For 
example, CF strains are more frequently hemin or menadione auxotrophic (332) and in vitro 
selection with the cationic host protein protamine leads to SCV formation (333). It has been 
suggested that some of the SCVs utilise an inducible and reversible resistance mechanism, 
avoiding fitness costs in the absence of antibiotics usually associated with resistance 
markers. However, the mechanism of such a switching phenotype is still unclear (246).  
 
1.4.1.  Characteristics of SCVs 
 
Normal and SCV forms are often isolated at the same time from a patient and 
frequently are isogenic, as determined by PFGE (188). Therefore, diagnostic identification of 
SCVs requests special care, since in conventional laboratory tests the wild type phenotype 
masks the SCV phenotype for the following reasons:  
SCVs grow slowly; typically, pinpoint colonies only appear after 48-72 h on solid 
medium. Their colony size is usually 1/10 of the wild type size, for which they are often 
overlooked. Therefore, in antibiotic susceptibility testings the presence of SCVs, which are 
generally more resistant towards cationic compounds like aminoglycosides and defensins, 
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can be missed.  
Due to a reduced toxin production, hemolysis is not visible and coagulase reactions 
may take over 24 h to turn positive. In the case of auxotrophic SCVs, complex media may 
supplement the required substance(s), leading to wild type growth (259).  
SCVs have an altered metabolism, for which they are not always recognised as 
S. aureus by biochemical profiling. Not surprisingly, SCVs might be erroneously identified as 
coagulase-negative staphylococci or contaminants (350).  
Apart from these inconveniences, some SCVs even revert during the first subculture. 
The higher mortality of SCV-related infections compared to wild type infections (>70%, 
respectively 13%) (340) might be in part due to delayed or miss-identification of the highly 
resistant S. aureus subpopulation (350). More importantly, although possibly causing less 
damage in a short-term due to reduced toxin production, SCVs represent a constant threat 
since they can revert to the more virulent wild-type form, once antibiotic pressure has been 
removed. 
Thymidine-dependent SCVs are often found in the clinical setting in correlation with 
long-term SXT treatment (188). The genetic reason for thymidine auxotrophy has not been 
studied up to date. Thymidine-dependent strains form, in addition to pinpoint, also fried-egg 
colonies (190). Gram-staining and electron microscopy revealed a heterogeneous 
morphology (Fig. 24). Cells were found to be empty or dented, covered with debris from dead 
bacteria and often enlarged, which had been reported before for an uncharacterised SCV 
(56).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24. Gram-staining and scanning electron microscopy of wild-type S. aureus (blue), pinpoint (green) or fried-
egg (orange) thymidine-dependent SCVs. A The typical grape-like clustering of S. aureus was only seen with the 
parent strain. In SCVs pleomorphic forms were found, including colonies of sizes resembling fungi. Arrows 
indicate large cocci. B Fried-egg and pinpoint SCVs have enhanced intercellular substance compared to the wild 
type cells (arrows). Cells of fried-egg SCVs are in addition strongly enlarged. Reproduced from (190).  
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These observations could be attributed to impaired cell separation, as demonstrated 
by the finding of several incomplete and multiple cross walls, resulting from a reduced or 
undetectable splitting system (Fig. 25). An intercellular substance was more abundant 
compared to the normal S. aureus strain. The fried-egg variants reverted with a higher 
frequency to wild-type bacteria when cultivating without thymidine, whereas pinpoint SCVs 
were not able to grow without supplementation (190).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Transmission electron microscopy of wild-type S. aureus (blue), fried-egg (orange) or pinpoint thymidine-
dependent SCVs (green). Wild-type bacteria display regular cell separation by a cross wall (F, arrow) surrounding 
a highly contrasting splitting system. Fried-egg SCVs have atypical, incomplete or multiple cross walls (A, B, 
arrows). In C, besides incomplete cross walls (small arrow), cellular debris (intermediate arrow) and empty cells 
(large arrow) are seen. In pinpoint SCVs, atypical unrounded cells and mesosome-like structures (E, arrow) are 
found. Reproduced from (190).  
 
Another group of clinical SCV isolates is often auxotrophic for hemin, thiamine and/or 
menadione (2, 311, 350), compounds involved in the synthesis of the electron carriers 
cytochrome and menaquinone, respectively. This observation led to the attribution of the 
SCV phenotype to genetic changes affecting the electron transport, although, generally, 
clinical SCVs may harbour additional, undefined mutations. By deleting one of the genes 
involved in hemin or menadione synthesis, stable mutants can be obtained that have the 
characteristics of SCVs (19, 20, 333, 397). A short overview of the correlation of metabolism, 
electron transport and virulence follows. 
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1.4.2.  Carbohydrate metabolism and electron transport 
 
During in vitro growth, S. aureus first grows on rapidly catabolisable carbon sources 
such as glucose, which is degraded to pyruvate (359). Per glucose molecule, 2 ATP and 
2 NADH (1 NADH ≡ 3 ATP) are produced in glycolysis (Fig. 26). Pyruvate can be further 
converted to acetate under aerobic conditions or, in the absence of oxygen, to several 
fermentative products such as lactate (123, 198, 210). During the exponential phase, further 
degradation of pyruvate is prevented by catabolite repression of the tricarboxylic acid (TCA) 
cycle, producing the majority of energy from glucose in the form of 8 NADH, 2 FADH2 and 
2 GTP. Instead, pyruvate is converted into acetate, which is secreted during exponential 
growth. Upon glucose depletion in post-exponential phase, acetate is imported and directed 
to the TCA cycle in the form of acetyl-CoA (Fig. 26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26. Metabolic pathways in S. aureus under aerobic conditions. A Glycolysis and TCA cycle. Main reactions 
occurring during exponential phase (green) and in post-exponential phase (black). Blue indicates where the 
pathway in SCVs supposedly stops (bar) and which reactions occur instead. SrrA likely represses the TCA cycle 
by inhibiting the enzyme succinyl-CoA-synthase a (375). The use of glycolysis and TCA cycle yields a total of 
38 ATP, while production of lactate yields only 2 ATP (1 GTP ≡ 1 ATP, 1 FADH2 ≡ 2 ATP, 1 NADH ≡ 3 ATP). 
B Arginine degradation. Arginase, negatively regulated by SrrA (375), produces urea and L-ornithine. Instead, the 
ArcABC enzymes catalyse degradation to CO2 and NH4+ by producing ATP via the arginine deiminase pathway. 
ArcA and ArcB have been reported to be up-regulated in a strain COL hemB mutant (represented by a blue box) 
(205).  
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NADH and FADH2 are re-oxidised at the membrane, where a separation of electrons 
and protons occurs. Thereby, a proton motive force consisting of the electrical (∆Ψ) and the 
chemical gradient (pH) is generated. Electrons are guided back to the cytoplasm via several 
cell-membrane associated electron carriers with increasing redox potentials (Fig. 27). Among 
these are menaquinone and the cytochromes, with heme as prosthetic group. Under aerobic 
conditions, the final acceptor of electrons is O2, which for the reduction to H2O requires 
protons provided by the dissociation of water. This leads to an accumulation of OH- in the 
cytoplasm. Driven by the energised membrane, protons from the outside of the cell flow back 
to the inside of the cell through the ATP synthase complex. Thereby they generate a 
molecular torque which is used for ATP formation from ADP and Pi (226, 233).  
 
 
 
Fig. 27. Schematic representation of oxidative phosphorylation. Charge separation of protons (green arrows) and 
electrons (orange arrows) from the reduced equivalents NADH and FADH2 occurs by the corresponding 
dehydrogenases. While protons accumulate on the outside of the cells, electrons are guided back to the 
cytoplasm via several carriers, among which menaquinone and cytochromes. Thereby, an electrical (∆Ψ) and a 
chemical (∆pH) gradient builds up, which together provide the proton motive force driving ATP production by 
ATPase. Heme is represented by a red rhombus, menadione by two blue, fused hexagones. Isoprenylation, which 
yields menadione, is depicted with a blue wave line. 
 
An interrupted electron transport chain, as found in hemin, thiamine and/or 
menadione auxotrophic SCVs, leads to the accumulation of reducing equivalents. Metabolic 
pathways depending on the availability of the oxidising equivalents NAD(P)+ and FAD, like 
the TCA cycle, are inhibited, which drastically reduces the range of carbohydrate utilisation 
as well as energy production (317). The block in electron transport chain forces SCVs to 
reoxidize NADH via different pathways. Apparently, this happens through increased 
fermentative activity, as reflected by up-regulated lactate and alcohol dehydrogenase 
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production in a COL hemB mutant. As expected, TCA cycle enzymes are down-regulated in 
such a mutant, manifesting a divergent metabolic activity compared to wild type S. aureus 
(205). Obstruction of the electron flow furthermore hinders charge separation, leading to a 
low membrane potential and reduced ATP production (220, 310). Consequently, ATP-
requiring biosynthesis of proteins, cell-wall or nucleotides is limited and finally cells stall their 
growth. Reduction in cellular ATP levels indirectly blocks the first step of the 
phosphotransferase system, inhibiting the use of sugars such as mannitol, xylose, lactose, 
sucrose, maltose and glycerol (317). Processes requiring electron transport, such as pigment 
formation or synthesis of phosphatidyl glycerol, the precursor of teichoic acid, are affected as 
well (143, 186, 195). However, the reduced trans-membrane potential protects bacteria from 
cationic antibiotics (20), slow growth hampers the efficacy of substances targeting metabolic 
active cells and the low toxin production allows them to persist in the host cell, a relatively 
protected environment (16). 
 
1.4.3.  Expression of global regulators and virulence determinants 
 
Enzymes involved in the ATP-producing arginine dihydrolase pathway are increased 
in a COL hemB mutant (205), suggesting the alternative arginine degradation by arginase, 
which does not generate ATP, being inhibited in SCVs. Lactate and alcohol dehydrogenase, 
as well as arginase, are proteins influenced by SrrA (375), for which an involvement of this 
two-component system in hemB mutants seems probable (Fig. 26). Another regulator 
possibly involved in the control of metabolism is SigB, as it has been shown to be required 
for acetate degradation (360). The second enzyme of the highly conserved TCA cycle, the 
aconitase CitB, was found in B. subtilis and E. coli to bind in an iron-dependent fashion to 
mRNA-elements, as reported for eukaryotic aconitases (196), and therefore could be a 
candidate for post-transcriptional regulation. A non-functional TCA cycle leads to the reduced 
production of several virulence factors, such as toxins and lipase (359).  
Previous analyses of strains 8325-4 and Newman hemB mutants had revealed that 
protein A, α-toxin and coagulase are only weakly produced (184, 397). In contrast, the 
adhesion proteins FnbA and FnbB, as well as the fibrinogen-binding ClfA are up-regulated 
(391). The mRNAs from the major regulatory locus agr are differentially expressed. While 
RNAII levels are apparently not influenced, RNAIII levels are dramatically reduced in a hemB 
mutant with 8325-4 background (391). In parallel to agr, the overall sar mRNA levels are 
decreased in the hemB mutant compared to the parent. However, due to the applied RT-
PCR technique, no distinction between the three overlapping transcripts originating from the 
sar locus is made in this study.  
In the before mentioned COL hemB mutant, increased amounts of the 
Introduction 47 Approach on Resistance Strategies in S. aureus  
Dissertation Maria M. Senn 
immunodominant antigen A are found in stationary phase (205).  This extracellular protein 
has been shown to be directly regulated by YycF, although it has not been reported whether 
positively or negatively (86). 
These observations support the idea that the extraordinary physiologic state of SCVs 
is likely linked to an altered activity of global regulators and expression of virulence factors, in 
vitro as well as in vivo. 
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1.5. Aims of this work 
 
I Cell-membrane associated steps of peptidoglycan synthesis 
For further analysing the individual steps of interpeptide formation in S. aureus and to 
identify the correct substrates, the usage of undefined membrane preparations will be 
bypassed by purifying lipid I and lipid II, the essential enzymes FemA, FemB, FemX, the 
tRNAGly synthetase and total tRNA. The thereby reconstituted in vitro assay would allow the 
study of substrate-enzyme and protein-protein interactions necessary in the membrane-
bound steps of staphylococcal cell wall synthesis.  
 
II Temporal patterns of global regulators in a hemB mutant  
 
In this study, various global regulators and their effect on selected virulence determinants 
were monitored in a Newman derivative and its hemB mutant. The use of one defined 
genetic background would eliminate strain dependent variations. Analyses under the same 
experimental conditions would provide for the first time a compilation of temporal 
transcription patterns, contributing to the elucidation of the regulator’s interplay during 
growth.  
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2  RESULTS  I   
 
2.1. Setup of the assays and detection system  
 
Membrane preparations possess enzymatic activity (MraY and MurG) for the 
formation of cell wall precursors (389); membranes of S. aureus have been reported to 
contain Fem protein activities and to synthesize glycine-labelled lipid intermediates when 
complemented with soluble cellular fraction (248). As shown with Staphylococcus simulans 
22 membranes (Fig. 28), the lipid carrier molecule (C55-P) remained unmodified in the 
absence of UDP-activated precursors. Upon addition of UDP-MurNAc-PP, C55-P was 
transferred into lipid I; the conversion was incomplete because of the reversibility of the 
MraY-catalysed reaction (308). When UDP-GlcNAc was also present, most of the lipid I was 
converted to lipid II, which migrates somewhat more slowly.  
 
 
 
 
 
 
Fig. 28. Thin layer chromatography (TLC) of 
[U-14C]-glycine-labelled lipid intermediates. 
Undecaprenylphosphate (10 nmol; C55-P) was 
incubated in vitro with membranes (360 µg of 
protein) of S. simulans 22 for 60 min in the presence 
of 50 nmol of glycine lacking the UDP-activated 
precursors (lane 1). Lipid I was synthesised upon 
addition of UDP-MurNAc-PP (lane 2) and lipid II by 
addition of UDP-MurNAc-PP and UDP-GlcNAc (lane 
3). Two glycine-labelled lipid intermediates 
migrating more slowly than lipid I and lipid II were 
separated after incubation with UDP-MurNAc-PP 
and UDP-GlcNAc and addition of supernatant I 
(330 µg of protein) (lane 4). Reproduced from (349).  
 
 
Using lipid II from a preparative batch, its position on the chromatogram was verified, 
and its molecular mass was confirmed by mass spectroscopy (Fig. 29.1). 
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Fig. 29. 1 ES-MS spectra were obtained with an API-I single quadrupole instrument (PE-SCIEX) running in a 
positive mode. Peaks at m/z 1878 correspond to lipid II (A), at m/z 1935 to lipid II-Gly1 (B), at m/z 2049 to 
lipid II-Gly3 (C) and at m/z 2163 to lipid II-Gly5 (D). Other peaks correspond to the non-covalent sodium or 
potassium ion adducts. 2 With prolonged incubation time (90 min) and elevated enzyme concentrations (molar 
ratio of enzyme:lipid II, 1:50), lipid II-Gly2 (B) at m/z 1992 and lipid II-Gly4 (C) at m/z 2106 were detected in 
addition to the correct products. Reproduced from (349). 
 
When radiolabelled glycine was added to the assay, no further bands were observed 
(Fig. 28), and both bands representing lipid I and lipid II did not contain radiolabel. In 
contrast, when the assay mixture was supplemented with the soluble cytosolic fraction 
obtained after low-speed centrifugation (supernatant I), two additional bands occurred with 
Rf-values lower than that of lipid II (Fig. 28, lane 4). Both bands were radiolabelled, strongly 
suggesting that they represent lipid I/lipid II intermediates with different segments of the 
glycine interpeptide bridge attached. Moreover, from the intensities of the various bands 
obtained after phosphomolybdic acid (PMA) staining, it appeared that lipid II was the major 
substrate for the Fem-catalysed reaction, as it was strongly reduced on the chromatogram in 
favour of the two newly formed glycine-containing intermediates. 
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2.2.  In vitro activity of FemX, FemA and FemB  
 
Although the above system, based on the use of soluble cytosolic fractions, was 
sufficient to determine that all factors necessary for interpeptide formation (i.e. the Fem 
factors, glycyl-tRNA-synthetase and tRNA) were present, it did not allow for a detailed step-
by-step analysis of bridge formation. In particular, the presence of MurG activity in the 
supernatant prevented unequivocal determination of whether lipid I or lipid II was the 
substrate for FemX. High-speed ultracentrifugation (supernatant II) clearly reduced MurG 
activity; however, the overall reaction was strongly reduced, presumably because of 
simultaneously removing the Fem enzymes and/or glycyl-tRNA-synthetase and tRNAs (data 
not shown).  
Therefore, FemX, FemA, FemB and the tRNAGly-synthetase (GlyS) of S. aureus  
strain 8325 were His-tagged and purified (Fig. 30).  
 
 
 
 
Fig. 30. 10% SDS PAGE of recombinant proteins. His-tagged enzymes were purified on a Ni-NTA column. Three 
500 µl fractions were collected, to which an equal amount of 100% glycerol was added for preservation at -20 °C. 
GlyS fractions (10 µl) and 1 µl of FemABX fractions were loaded onto the gel. Prestained broad-range standard 
marker from Bio-Rad was used to estimate molecular masses. Fractions 1-3 of GlyS (A). Fractions 1-3 of FemX 
(B). Fractions 1-3 of FemA (C). Fractions 1-3 of FemB (D). The following fractions were selected for further 
experiments: A2 (GlyS); B2 (FemX); C1 and C2 (FemA); D1 and D2 (FemB). Reproduced from (349). 
 
 
In addition, total tRNAs were isolated from both S. simulans 22 and S. aureus. 
Replacing the supernatant by recombinant FemX, FemA and FemB, GlyS and purified 
tRNAs resulted in the formation of glycine-labelled lipid intermediates (Fig. 31).  
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Fig. 31. Influence of increasing tRNA concentrations on the FemXAB reaction. Purified lipid II was incubated with 
[U-14C]-glycine in the presence of FemXAB and recombinant tRNA synthetase with increasing concentrations of 
purified tRNAs. Reaction products were separated by TLC, and incorporation of [U-14C]-glycine was determined 
by scintillation counting. Reproduced from (349). 
 
 
Under the conditions chosen, i.e. with an excess of [U-14C]-glycine and a defined 
amount of 5 nmol of lipid II in the system, the availability of dedicated glycyl-tRNA was rate 
limiting. At a concentration of 25 µg of total tRNA per assay volume, the maximum amount of 
pentaglycine bridge formation was obtained. There was no difference observed using purified 
tRNAs from S. simulans 22 or S. aureus. Assuming that all lipid II molecules were available, 
a 5:1 ratio of glycine to lipid II was expected in the final product. As indicated in Fig. 31, the 
maximum amount of glycine incorporation obtained in the in vitro system corresponded to an 
average of 4.3 mol of glycine incorporated per mol of lipid II.  
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2.3. The cell wall precursor lipid II is the only substrate of FemX  
 
Identification of the substrates of the FemX- and subsequently of the FemA- and 
FemB-catalysed reactions was achieved by incubation of lipid I or lipid II (Fig. 32) in the 
presence of GlyS and tRNAs, with FemX, FemX and FemA and FemX, FemA and FemB. 
Analysis of the reaction products by thin-layer chromatography (TLC) after incubation of lipid 
I with the Fem proteins identified lipid I as a poor substrate for FemX, and no further 
incorporation of glycine was detected after incubation with additional FemA and FemB (Fig. 
32B). 
 
 
 
 
 
Fig. 32. A TLC of glycine-labelled lipid intermediates synthesized by recombinant FemX, FemA and FemB. 
Purified lipid II (lanes 1-3) and lipid I (lanes 4-6) were incubated with [U-14C]-glycine in the presence of 
recombinant tRNA-synthetase and purified tRNA with FemX (lanes 1 and 4), FemX and FemA (lanes 2 and lane 
5) and FemX, FemA and FemB (lanes 3 and 6). B [U-14C]-glycine:lipid ratio of the analysed glycine lipid 
intermediates. Mean values of five experiments are given. Reproduced from (349). 
 
 
In contrast, incubation of lipid II resulted in the formation of glycine lipid II 
intermediates migrating stepwise more slowly in the TLC system upon addition of glycine to 
the pentapeptide side-chain of lipid II (Fig. 32A). The molar ratio of radiolabelled glycine to 
lipid intermediate indicated that FemX (glycine:lipid II, 1.3:1) added the first glycine to lipid II. 
The glycine:lipid incorporation ratios for the FemXA and the FemABX reactions were 2.76:1 
and 4.17:1 as expected after the formation of lipid II-Gly3 and -Gly5 (Fig. 32B). Lipid II itself, 
i.e. without the first glycine added by FemX, was not used by FemA and Fem B, either on 
their own or combined. Only background Gly incorporation levels, in the range of 
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0.02-0.2 Gly incorporated per lipid II molecule, were observed. Although the incorporation 
levels were somehow lower than expected theoretically, especially for the FemABX reaction, 
analysis of the products by mass spectrometry confirmed the formation of lipid II-Gly1 by 
FemX, lipid II-Gly3 by FemXA and lipid II-Gly5 by FemXAB (Fig. 29.1). It should be noted that 
determination of glycine incorporation ratios required, first, extraction of radiolabelled 
intermediates from the synthesis assay using n-butanol/pyridine-acetate, subsequent TLC 
and, finally, counting of excised bands; this procedure is likely to cause some loss of 
radiolabelled products and, obviously, the extraction yields decrease with increasing bridge 
length of the products. 
Lipid II with intermediate glycine contents (lipid II-Gly2 and lipid II-Gly4) was not 
detected under these conditions (Fig. 29.1). However, when the assay conditions were 
changed (90’ incubation and a lipid II:enzymes ratio of 50:1), such products were detectable 
(Fig. 29.2). Under the experimental conditions chosen, i.e. lipid II in micellar form and in the 
presence of 0.8% Triton X-100, FemX not only accepts lipid II as a substrate but also 
lipid II-Gly1. Accordingly, after 90 ’ of incubation, the reaction products of FemXA contained 
lipid II-Gly3 and lipid II-Gly4 (Fig. 29.2). Obviously, FemA can also accept lipid II-Gly2 as a 
substrate and then incorporate two additional glycine residues. 
As reported previously, UDP-MurNAc-PP is the substrate for the soluble recombinant 
FemX proteins of Weissella viridescens and Enterococcus faecalis (48, 156). To exclude 
UDP-MurNAc-PP as a substrate for the Fem proteins of S. aureus, 5 nmol of lipid II was 
incubated with FemXAB, glycyl-tRNA-synthetase and tRNAs in the presence of 5-100 nmol 
of purified UDP-MurNAc-PP isolated from S. simulans 22. Analysis of the reaction products 
revealed that the addition of glycine to lipid II was not affected even in the presence of a 
20-fold molar excess of UDP-MurNAc-PP. This competition experiment demonstrated that 
the FemXAB enzymes of S. aureus catalyse the addition of glycine to the pentapeptide side-
chain only after the formation of lipid II. This result is in good agreement with the fact that 
UDP-MurNAc hexapeptides were detectable in the cytoplasm of W. viridescens (307), but 
not in S. aureus (364) or in the staphylococcal strains used in this study (data not shown). 
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2.4. Time course of the FemXAB reactions  
 
The formation of the Gly-containing lipid II intermediates was followed over time 
(Fig. 33). Initial Gly addition by FemX was already completed after 5’ and resulted in a 
glycine:lipid II ratio of 1.22:1(see above). In contrast, the presence of FemA in the synthesis 
assay decreased the formation of lipid II-Gly1 reaction products, indicating that, in our in vitro 
system, the presence of FemA interferes with Gly addition by FemX. The maximum level of 
the FemXA reaction was reached after an incubation period of 60’ with a final glycine:lipid II 
ratio of 3:1. An even stronger effect was observed upon addition of FemB. The FemX 
reaction was retarded further, and glycine lipid II intermediates were not detected before 15’ 
of incubation. The synthesis was not completed within 90’ of incubation. 
 
 
 
 
Fig. 33. Time dependency of the FemXAB reactions. Purified lipid II was incubated with [U-14C]-glycine in the 
presence of recombinant tRNA synthetase and tRNA with addition of FemX (circles), FemX and FemA (squares) 
and FemX, FemA and FemB (triangles); mean values of three experiments are given. Reproduced from (349). 
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2.5. Analysis of the individual Fem protein reactions  
 
As the maximum catalytic activity of FemX was observed in the absence of FemA and 
FemB (Fig. 33), the unlabelled FemX and FemA reaction products were purified to study the 
FemA and FemB reactions independently (Fig. 34). Using the standard assay, comparable 
amounts of labelled Gly per lipid were added to lipid II-Gly1 by FemA alone (1.73:1) and by 
FemA when FemX was present (1.90:1). Again, the observed incorporation was somewhat 
lower than the theoretically expected value of two Gly per lipid II-Gly1 incorporated, as 
discussed above. This result clearly demonstrates that FemA activity in vitro does not 
depend on the presence of FemX. Neither FemX nor FemB catalysed further addition of 
glycine to lipid II-Gly1, proving the preference of FemX for lipid II and of FemB for lipid II 
intermediates containing at least three Gly. 
 
 
 
 
Fig. 34. Analysis of the FemA and FemB reaction 
using purified lipid II-Gly1 (grey columns) and 
lipid II-Gly3 (white columns). Purified FemX product 
(grey) and FemXA product (white) were incubated 
with [U-14C]-glycine in the presence of recombinant 
tRNA-synthetase and purified tRNA with FemX 
(columns 1 and 5), FemX and FemA (column 2), 
FemA only (columns 3 and 6), FemA and FemB 
(column 7) and FemB only (columns 4 and 8); mean 
values of two experiments are given. Reproduced 
from (349).   
 
 
The overall incorporated radioactivity by FemB and FemAB suggested that only one 
more Gly residue may have been added to the lipid II-Gly3 (Fig. 34); however, mass 
spectroscopy clearly showed that only lipid II-Gly5 occurred as a product (Fig. 29.1). This 
further indicates that extraction yields from the synthesis assay decrease strongly with 
interpeptide chain length (see also above). 
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3  DISCUSSION I  
 
Earlier studies on peptidoglycan precursor synthesis used crude extracts of the 
membrane and cytoplasmic compartment which were further fractionated.  Thereby, it could 
be shown that S. aureus uses mainly lipid II as acceptor for pentaglycine bridge formation 
and that only part of the tRNAGlys could be used as donor for pentaglycine bridge formation 
(193, 248, 249). However, due to the presence of contaminating molecules or suboptimal 
reaction conditions, these assays did not clearly identify the substrates for pentaglycine 
addition. Furthermore, the proposed biochemical function of each Fem factor had not been 
tested in vitro, leaving the question of whether multienzyme-complex formation or additional 
proteins were required for activity unanswered. 
The established in vitro system using purified bactoprenol-bound and soluble cell wall 
precursors as well as His-tagged enzymes allowed detailed analysis of single steps of 
glycine addition. Together with purified staphylococcal tRNAs and GlyS from S. aureus, this 
synthesis assay constituted an entirely homologous and defined system. In contrast to earlier 
studies (192), glycine incorporation using tRNA-synthetase and tRNAs isolated from 
Escherichia coli when used in combination with S. aureus tRNAs or tRNA-synthetase, 
respectively, could not be observed (data not shown). Neither the soluble UDP-MurNAc-
pentapeptide, nor lipid I, was converted to glycine-labelled precursors by the FemABX 
peptidyltransferases.   
Since lipid II was therefore the only substrate of the Fem factors, analyses of the 
single steps of glycine incorporation by the Fem proteins was performed only with lipid II. The 
substrate was completely converted to lipid II-Gly1 by FemX within 5’, which corresponds to a 
turnover rate of 19 lipid II molecules per FemX molecule minute-1. The ratio of FemX:lipid II in 
the in vitro assay was ≈1:100. Such a turnover rate is in the same order of magnitude as that 
calculated recently for E. coli K-12. 24 disaccharide peptide units need to be transported per 
minute per bactoprenol carrier (3.5 · 106 disaccharide peptide units per cell; generation time 
36’; 50% turnover per generation; about 2000 lipid II molecules per cell) (260). However, it is 
not known whether the turnover of lipid II in Gram-negative and Gram-positive bacteria is 
similar, since the amount of peptidoglycan per dry weight differs greatly, with about 10% in 
Gram-negative and about 30-70% in Gram-positive bacteria. Still, when compared with 
E. coli, the number of lipid II molecules in staphylococci is 25 times higher than that 
determined for E. coli (361), leading to the assumption that synthesis of the cell wall in Gram-
positive bacteria depends on the amount of lipid II rather than on an increased synthesis 
rate. 
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A rate-limiting factor for the FemABX reaction in vitro was the availability of glycine 
donor tRNAs. Although increasing concentrations of tRNAs lead to increasing amounts of 
incorporated glycine, the FemABX reaction never reached the expected values of Gly5. 
Similarly, amino acid analysis of peptidoglycan synthesized in vivo revealed submaximal 
values of incorporated glycine, reflecting a minor presence of Gly3 and Gly1 interpeptide 
bridges (95, 326, 367, 380). However, as confirmed by mass spectrometry, the only in vitro 
FemX product is lipid II-Gly1, and FemXA only produced lipid II-Gly3, and no lipid II-Gly2 
(Fig. 29.1). This observation agrees with the hypothesis that FemAB add two glycine 
molecules per cycle, not releasing a lipid II-Gly2, respectively lipid II-Gly4, product, whereas 
FemX clearly adds only one Gly per cycle to the lipid intermediates. The molecular basis for 
such a difference in the catalytic mechanism has not yet been resolved. Benson et al. 
proposed that the 12 amino acids of FemA, which had not been resolved by X-ray analyses, 
could close down over the channel during the addition of each glycine and then reopen for 
release of the product (26). Another possibility could be a quick and save handing-over of the 
intermediates lipid II-Gly2, respectively lipid II-Gly4 from one FemA/B factor to the other 
FemA/B factor, probably by homodimerisation.  
The fact that only lipid II and its Gly additives were substrates of the Fem factors 
(Fig. 32), suggested the Fem factors to discriminate GlcNAc-MurNAc versus MurNAc lipid 
intermediates. Whether this function is accomplished in the L-shaped groove found in FemA 
remains to be determined; as judged by the size, an accommodation of the disaccharide 
seems to be possible (Fig. 23). Competitive, non-productive binding of lipid II by recognition 
of the disaccharide unit alone, regardless of the amount of Gly added, could explain the 
stepwise reduced incorporation rates in the presence of further Fem factors (Fig. 33). 
Correspondingly, the non-productive binding by FemA and FemB would delay lipid II-Gly 
formation, FemX and FemB the one of lipid II-Gly3, and binding by FemX and FemA the 
production of lipid II-Gly5. Still, the appropriate number of Gly in the interpeptide bridge is 
clearly required for FemAB to be active, i.e. for FemA at least one and for FemB at least 
three Gly need to be present (Fig. 34).  
The enzymatic activity of an individual FemXAB peptidyltransferase does not require 
the presence of a second species, and the formation of a stable Fem-multienzyme complex 
is not necessary to achieve a turnover rate in vitro that is close to the in vivo situation. 
However, in vivo, production of byproducts as observed during in vitro synthesis upon 
increased incubation time and elevated enzyme concentration must be prevented, and it 
seems reasonable to assume that the interpeptide bridge formation is a highly co-ordinated 
process, tightly interlinked with the other membrane-associated steps of cell wall 
biosynthesis (Fig. 17). Possibly, the Fem proteins are transiently associated with each other 
as well as with other cell wall biosynthesis enzymes. Synthesis of a complete lipid II-Gly5 
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may be further favoured in the in vivo situation with ongoing translocation of the completely 
modified cell wall precursor to the outside of the cell. One possible candidate catalysing the 
flipping of lipid II-Gly5 to the outside is the above mentioned hypothetical flippase FtsW, a 
protein associated with the division apparatus complex. Further components with as yet 
unidentified functions may contribute to co-ordinating the intracellular and extracellular 
processes to ensure the proper formation of the vital bacterial cell wall. Especially ORF1055, 
encoded by a gene co-transcribed with fmhB and predicted to have 12 putative 
transmembrane domains as well as two large extracellular domains, would be an interesting 
candidate for such a role. ORF1055 is most likely essential as well, however, its function 
remains to be attributed (322). Proteins sharing up to 59 % similarity with ORF1055 belong to 
the widely distributed RND (resistance-nodulation-division) family of proteins, a ubiquitous 
group of transmembrane efflux transporters, which have been reported to function in 
eukaryotes as enzymes or receptors, too (382). 
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4  OUTLOOK I   
 
The FemABX peptidyltransferases are interesting drug targets for several reasons; i) 
they are essential, ii) their product is unique and specific for S. aureus, iii) blocking of their 
activity would very unlikely affect the host, since no comparable reaction exists in 
eukaryotes. Furthermore, their inhibition confers sensitivity for a variety of antibiotics and 
restores susceptibility towards methicillin (218, 224). Using the here developed in vitro assay, 
the peptidoglycan synthesis in S. aureus will be further elucidated. On one hand, cross-
linking experiments should reveal whether the Fem factors come close for adding Gly to lipid 
II in this system. By adding purified tRNASer-synthetase of S. aureus and the immunity factors 
Lif and Epr of S. simulans biovar staphylolyticus and S. capitis, respectively, we will try to 
determine whether incorporation of Ser at third and fifth position requires interaction with 
FemAB factors and, if yes, whether it occurs simultaneously with Gly incorporation or not. 
Assuming that interaction among the FemAB factors is equivalent to interaction of FemA or 
FemB with Lif/Epr, it can be thereby extrapolated whether dimerisation occurs and how the 
length of the interpeptide is determined. For this work, financial support from the “Theodor 
und Ida Herzog-Egli” as well as the “EMDO” foundation has been accorded. As the 
development of the described in vitro assay system was carried out in very fruitful 
collaboration with the group of H.G. Sahl, University of Bonn, Germany and with A. Tossi, 
University of Trieste, Italy, it will be continued. 
 
A long-term project would be the development of an in vitro assay using vesicles 
instead of micelles. This would allow the study of cytoplasmic, membranous and extracellular 
processes of peptidoglycan synthesis. Of greatest interest, not only for S. aureus, would be 
the identification of lipid II flippases and coordinator proteins, which most likely need a double 
lipid layer for being active. Once such a “natural” system will be established, testing of 
putative inhibitors might reveal new approaches for combating pathogens with branched 
peptidoglycan, not only S. aureus, but also pneumococci and enterococci. 
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5  RESULTS II  
 
5.1.   Analysis of the hemB mutants MS17 and MS62  
 
To study the interrelationship of global regulators and the role of SigB in a stable 
mutant mimicking the SCV phenotype, a set of isogenic strains with an interrupted hemB 
gene was constructed in a strain Newman background. hemB, which encodes the 
aminolevulinic acid dehydratase, is essential for hemin synthesis (187). Use was made of the 
hemB gene disrupted by a 1.4 kb fragment containing an ermB cassette from the strain 
8325-4 derivative I10 (397), which has been well characterised (19, 20, 391). Strain MS17 
was obtained by transducing the hemB mutation with phage 85 (27) into the Newman 
derivative MB79 (Fig. 35). This strain contains an integrated reporter construct carrying the 
firefly luciferase gene (luc+) fused to three solely SigB dependent alkaline shock protein 23 
promoters (Pasp23) (129). Strain MS62 was created by transducing the sigB1 (Am) mutation 
into the Newman derivative III33 (hemB::ermB) (Fig. 35) (37, 184). PCR and Southern blot 
analysis of the hemB region of MS17 confirmed that only the desired modification of the hem 
operon had occurred.  PFGE-patterns of SmaI-digested DNA from the hemB mutants MS17 
and MS62 compared to the corresponding parent strain were identical. 
 
 
 
Fig. 35. Relevant loci of strains MB79 (wt), MS17 (hemB) and MS62 (hemB sigB). A sigB operon, where a 2 bp 
deletion in sigB lead to a premature stop and a non-functional SigB protein (37). B asp23 operon, into which a 
plasmid, carrying a fusion of the two proximal asp23 promoters to the reporter gene luc, had been integrated by a 
single cross over mechanism (129). C hemB, contained within the hemAXCDBL operon, was interrupted by a 
ermB resistance cassette (397). SigA-dependent promoters, black; SigB-dependent promoters, red. 
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While MB79 reached an OD600 of 10 in LB, both the mutants MS17 and MS62, 
attained a maximal OD600 of 0.8 (Fig. 36). The hemB mutants entered post-exponential phase 
later compared to MB79, i.e. after five hours instead of three. Supplementation with 1 µg/ml 
hemin conferred a normal phenotype to the hemB mutants, as determined previously (397).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36. Growth and viability of MB79 (wt), MS17 (hemB) and MS62 (hemB sigB). A Growth curves and B colony 
forming units (cfu) of cultures, inoculated with overnight cells and an initial OD600 of 0.01, were monitored over 
7 days. C Growth curves from cultures with a ten times higher inoculum (OD600 of 0.1) than in A and B, using 
washed overnight cells. Cfu/ml were determined after 15 hours. MB79, diamonds; MS17, triangles; MS62, dots. 
Cfu were determined by spreading appropriate culture dilutions on selective plates. 
 
 
MS17 and MS62 formed tiny colonies of 0.1 mm on Müller-Hinton (MH) plates, 
whereas on sheep blood agar cells could apparently scavenge enough hemin to grow up to 
normal-sized (1 mm), hemolytic colonies (Fig. 37). Viability was not reduced in the hemB 
mutants as judged from colony forming units (cfu) determined over several days (Fig. 36). 
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Fig. 37. Colony morphology 
of strains MB79 (wt) and 
MS17 (hemB). Bacteria were 
streaked on sheep blood 
agar (A, B) or Müller-Hinton 
agar (C, D). MB79, A and C; 
MS17 B and D. 
Magnification of insets is 
shown below. 
 
  Etests on MH medium showed that MS17 and MS62 were more resistant towards 
gentamicin (4-fold) and amikacin (8-fold) compared to the parent strain. Susceptibility for 
vancomycin did not differ. Unexpectedly, MS17 and MS62 were more sensitive for oxacillin 
and teicoplanin by a factor two, respectively four (Table 2). Although higher resistance 
against cell-wall active antibiotics is often encountered with SCVs, not all the SCVs 
necessarily display this feature and strain singularities might even lead to a slightly opposite 
effect (20, 350).  
 
TABLE 2. Antibiotic susceptibility of strains MB79 (wt), MS17 (hemB) and MS62 (hemB sigB). 
 MIC [µg/ml] 
 MB79 MS17 MS62 
Amikacin 4 32 32 
Gentamicin 1 4 4 
Oxacillin 0.38 0.19 0.19 
Teicoplanin 3 0.75 0.75 
Vancomycin 2 2 2 
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Growth phase disparity between slow and normally growing cells makes interpretation 
of temporal profiles difficult. In cultures with an initial OD600 of 0.01, the lag phase of hemB 
mutants was more than 4 hours longer compared to that of the parent strain and without a 
characteristic transition via a post-exponential phase as seen in the parent (Fig. 36). To 
overcome the growth phase discrepancy, cultures were started with a relatively high 
inoculum of OD600 0.1, which synchronised the beginning of wt and hemB mutant exponential 
phases (Fig. 36) without influencing their growth phase dependent pattern of gene 
expression (see agr and sar profiles below). Still, hemB mutants entered the post-exponential 
growth phase two hours later than their parent. Cells were therefore more frequently sampled 
in the beginning to obtain representative profiles for both strains and to allow comparison of 
the temporal gene expression profiles from the respective growth phases. Special care was 
taken to avoid carry-over of extracellular signal molecules, which might mask growth-
dependent processes, by washing cells before inoculation. Growth was monitored over 15 h 
to include late stationary phase data. To exclude that contamination or reversion had 
occurred during cultivation, colony forming units (cfu) were routinely determined for all strains 
on selective and blood agar plates after 15 h; faulty cultures were not used for analyses. 
 
5.2.   Transcription of the major regulators agr, sar and sigB  
 
agr expression is initiated in late exponential phase. In the parent strain MB79 RNAII 
(3.2 kb) preceded RNAIII (0.5 kb) as expected (Fig. 38). In the hemB mutant MS17, RNAIII 
was missing as reported before for hemB mutants in strains of 8325-4 and COL backgrounds 
(205, 391). However, contrary to what Vaudaux et al. observed (391), RNAII was absent as 
well (Fig. 38). Complementation of the growth medium with hemin restored the agr profile in 
MS17 to the wild type pattern, ruling out an unrelated deletion or mutation affecting agr (data 
not shown).  
 
hours 1 2 3 5 7 9 11 13 15 1 2 3 5 7 9 11 13 15
MB79 (wt) MS17 (hemB)
RNAII3.2 kb
RNAIII0.5 kb
 
 
 
 
 
 
Fig. 38. Northern blot analyses of the two 
component system agr (RNAII and RNAIII) in MB79 
and MS17 (hemB). The sizes of relevant bands are 
given on the left. Ethidium-bromide stained 16S 
rRNA is shown as an indication of RNA loading. 
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The wild type strain MB79 showed characteristic sar profiles (21, 39, 239): sarA 
(0.5 kb) and a weak sarB (1.2 kb) transcript were mainly present in exponential phase, while 
the SigB-dependent sarC (0.8 kb) transcript appeared in mid-exponential phase reaching a 
maximum intensity in post-exponential phase (Fig. 39). Interestingly, in the hemB mutant 
MS17 all three sar transcripts were maximally expressed in the beginning and were strongly 
increased compared to MB79. While sarA and sarB were restricted to the exponential phase, 
sarC was transcribed throughout growth, although slightly decreasing towards stationary 
phase. The initially enhanced and continued sarC transcription directed our interest towards 
SigB, since sarC transcription is exclusively initiated by SigB (61, 126, 129, 170, 214). The 
sarC transcript was confirmed to be SigB-dependent in the hemB background as well, since 
it was abolished in the hemB sigB double mutant MS62 (Fig. 39).  
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0.8 kb
0.5 kb
hours
 
 
Fig. 39. Northern blot analyses of the SigB-influenced sar locus in MB79, MS17 (hemB) and MS62 (hemB sigB). 
The sizes of relevant bands are given on the left. Ethidium-bromide stained 16S rRNA is shown as an indication 
of RNA loading. 
 
Transcription of the sigB operon is initiated by two SigA-dependent promoters (P1 
and P2) producing 3.6 kb and 2.5 kb transcripts containing SAS067-SA1873-rsbUVWsigB 
(P1-sigB) and rsbUVWsigB (P2-sigB) (M. Bischoff, unpublished). In addition, a 1.6 kb stress-
inducible, autoregulated, SigB-dependent transcript covering rsbVWsigB (P3-sigB) is initiated 
from a third promoter, P3 (126, 129). In strain MB79, both the 3.6 and the 2.5 kb transcripts 
were expressed weakly and only during early growth, while the 1.6 kb mRNA displayed a 
more complex pattern: it peaked in late exponential phase, in early post-exponential phase 
and surprisingly increased again towards stationary phase (Fig. 40). In contrast, in the hemB 
mutant MS17 the 3.6 kb and the 2.5 kb transcripts were almost undetectable. The 1.6 kb 
transcript, initially stronger than in the parent, disappeared after the exponential phase. As 
expected, the 1.6 kb SigB-dependent transcript was absent in the hemB sigB mutant MS62 
(data not shown).  
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Fig. 40. SigB expression in the Newman 
background. A SigB-activity in MB79 and MS17 
(hemB) followed by quantifying the amount of 
luciferase which is transcribed in a SigB-dependent 
manner from the Pasp23::luc+ reporter construct. 
Luciferase activity is given by relative light units 
(RLU) per mg protein of cleared lysate. MB79, 
diamonds; MS17, triangles. Filled symbols indicate 
time points of sampling for Northern and Western 
blot analyses. B sigB, C asp23 and D luc Northern 
blot analyses. The sizes of relevant bands are given 
on the left. Ethidium-bromide stained 16S rRNA is 
shown as an indication of RNA loading. The 
observed double band at the site of the 1.5 kb 
asp23 mRNA might be caused by interference of 
bulk 16S rRNA. E Western blot analyses of SigB 
(30 kDa) and Asp23 (19 kDa). Cytoplasmic protein 
fractions were separated by SDS-10% PAGE and 
stained with Coomassie Blue dye (upper panel). 
Alternatively, blotted proteins were analysed with 
antigen-purified anti-SigB antibodies (middle panel) 
or anti-Asp23 antibodies (lower panel). The 
molecular sizes of the Precision Plus Protein All 
Blue Standards (Bio-Rad) marker are indicated on 
the left.  
 
Despite the difference in transcriptional activity, Western blot analyses of cytoplasmic 
protein fractions of the wild type MB79 and the hemB mutant MS17 revealed that the SigB 
protein was present at similar, constant levels in both strains throughout growth (Fig. 40).  
Presence of the SigB protein alone, however, is not necessarily indicative of its activity. As 
described earlier, the anti-SigB factor RsbW complexes SigB under normal conditions, 
thereby impeding interaction with the RNA polymerase core-enzyme and consequently 
transcription of genes preceded by a SigB consensus promoter sequence. Therefore, despite 
similar levels of SigB protein, there could have been a difference between MB79 and MS17 
in SigB activity.  
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5.3.   Expression of the SigB-dependent asp23 and luc genes 
  
A reporter construct consisting of the SigB-dependent promoters of the alkaline shock 
protein 23 (asp23) fused to the firefly luciferase gene (luc+) was used to analyse the actual 
SigB activity (Fig. 35). The parent strain MB79 displayed increased SigB activity in early 
post-exponential growth phase, with an additional peak at hour 7. In the hemB mutant MS17, 
almost no SigB-activity could be detected by the luciferase assay. Only during the first two 
hours of growth were relative light unit (RLU) values higher in the hemB mutant than in 
MB79. Thereafter, RLUs dropped quickly below the values measured in the parent (Fig. 40). 
Western blot analysis of Asp23, which was here under the same control as luciferase, 
revealed this protein to decrease in the mutant too (Fig. 40), while in MB79 Asp23 seemed to 
increase from the end of exponential towards stationary phase. Down-regulation of Asp23 in 
our hemB mutant was in accordance with previous findings for a gentamicin-selected SCV 
(247). 
In MB79 and MS17, the resident asp23 gene is preceded by two SigB-consensus 
sequence promoters producing 0.7 and 1.5 kb transcripts with identical 3’ ends (Fig. 35) 
(129). Both asp23 transcripts paralleled the expression profile of the 1.6 kb sigB mRNA in the 
parent strain MB79, peaking at five hours and reaching maximal levels during the last three 
hours (Fig. 40). In the hemB mutant, however, only the 0.7 kb asp23 mRNA paralleled the 
MS17 1.6 kb P3-sigB transcription profile, with transcription stopping after five hours of 
growth. Surprisingly, the upper asp23 transcript was present at low levels throughout the 15 
hours. Contrary to what luciferase measurements had suggested, these data indicated SigB 
activity in the mutant. Both transcripts were clearly SigB-dependent, since there were 
absolutely no asp23 transcripts in the hemB sigB double mutant MS62 (data not shown). 
SigB-dependent transcription of luciferase took place throughout growth in the hemB mutant 
(Fig. 40); therefore a yet undefined, hemB-linked post-transcriptional process must be 
responsible for down-regulation of luciferase activity. Surprisingly, the Pasp23-driven luc 
transcripts displayed a slightly different transcription pattern than the asp23 transcripts, with 
peaks at 7 and 9 hours. None of them stopped being transcribed after 5 hours, as did the 0.7 
kb asp23 transcript. Although they were under the control of identical SigB-dependent 
promoters, for yet unknown reasons asp23 and luc transcription seemed to be regulated by 
different, additional factors.  
The reduction of Asp23 levels over time in MS17 was significantly slower than the 
corresponding decrease in luciferase activity. Luciferase is known to be rather unstable with 
a half-life of two hours, making it suitable as a reporter system for detecting fluctuating gene 
expression (172). In contrast, chloramphenicol acetyl-transferase for example, with a half-life 
of 50 hours, accumulates and can not reflect changes in transcription (374). Higher Asp23 
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protein levels compared to luciferase might be due to intrinsic increased protein stability, 
although still reflecting fluctuations in asp23 transcription (Fig. 40). This might also explain 
the relatively high amount of Asp23 in exponential phase in MB79, compared to asp23 
transcription, by a carry over effect from inoculating cells. Availability of ATP within the SCVs 
as the reason for the slight discrepancy observed between luciferase activity and Asp23 
content could be ruled out, as luciferase measurements were performed with cell extracts in 
excess of ATP. 
Interestingly, in the wild type strain MB79, the increased SigB-dependent transcription 
of luc after nine hours (Fig. 40) lead to only minor peaks in luciferase activity (Fig. 40). 
Whether this inconsistency is due to a similar physiological state of wild type stationary 
phase cells and SCVs remains to be determined. Preliminary long-term monitoring of 
luciferase activity further supported the observation that this reporter system does not reflect 
SigB activity after 10 h (appendix 9.3., Fig. 52), since auto-regulated sigB transcription 
seemed to occur in a fluctuating way during 7 days, without being reflected in luciferase 
activity. 
 
5.4.   Transcription of SigB-regulated genes  
 
Due to the apparent poor performance of the luciferase reporter system in the hemB 
mutant, SigB activity was measured directly by monitoring transcription of SigB-controlled 
genes such as clfA and fnbA by Northern blot analyses (38, 272).  
The clfA gene is preceded by a SigA- and a SigB-dependent promoter, which initiate 
transcripts of 3.7 kb and 2.9 kb, respectively (100, 272). The 3.7 kb SigA-dependent 
transcript was seen in all three strains during exponential growth phase, irrespective of the 
changes triggered by hemB or sigB inactivation (Fig. 41). The SigB-dependent 2.9 kb clfA 
mRNA roughly followed the 1.6 kb P3-sigB transcription profile in MB79, with peaks at 3 and 
13-15 h. Main expression of clfA in late growth phase was in accordance with previously 
made observations (38, 100, 409). In the hemB mutant MS17 however, the 2.9 kb clfA 
transcript displayed a quite different transcriptional pattern than the 1.6 kb P3-sigB mRNA. 
After a strong initial signal, transcription diminished, and then increased again towards 
stationary phase, comparable to what was observed in the parent strain. In the hemB sigB 
double mutant MS62 the 2.9 kb clfA mRNA was absent, demonstrating its SigB-dependence 
in strain MS17. 
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Fig. 41. Northern blot analyses of the SigB-influenced genes clfA and fnbA in MB79, MS17 (hemB) and MS62 
(hemB sigB). The sizes of relevant bands are given on the left. Ethidium-bromide stained 16S rRNA is shown as 
an indication of RNA loading. 
 
Although not preceded by an apparent SigB consensus promoter sequence, the fnbA 
gene is positively influenced by SigB (38, 100, 272, 415). While the recently reported, SigA-
dependent 4.5 kb fnbA transcript (100) was not observed in the Newman background (data 
not shown), a 3.1 kb fnbA transcript was detected during the first hours after inoculation in 
MB79 and MS17, but was completely missing in the hemB sigB mutant MS62 (Fig. 41). In 
the hemB mutant MS17, fnbA transcription was slightly prolonged compared to the parent 
strain MB79. Transcription of fnbA mainly in early exponential phase was in agreement with 
previous reports (38, 100, 415). 
The presence of SigB-dependent asp23, 2.9 kb clfA, fnbA and sarC transcripts in the 
hemB mutant MS17, and their respective absence in the hemB sigB mutant MS62, proved 
that SigB was required and active at all time points in MS17. Nevertheless, in this strain, 
differences in the extent of stimulation of the directly SigB-regulated genes were observed, 
which might be attributed to the involvement of additional regulators other than SigB.  
 
5.5.   mRNA stability of sarC and 2.9 kb clfA  
 
Another explanation might be that the mRNA half-lives of these SigB-dependent 
transcripts may vary; in which case the 2.9 kb clfA and sarC transcripts would be the most 
stable. However, there was neither a significant difference in mRNA stability between parent 
and mutant, nor between sarC and 2.9 kb clfA (Fig. 42). The approximate half-life of 
transcripts was 3 minutes, which was similar to values determined for the asp23 transcripts 
(M. Bischoff, unpublished results) and too short to persist over hours. As a comparison, half-
life for norA mRNA of S. aureus is 7 minutes (117). The half-life of the majority of B. subtilis 
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mRNAs has been determined to be below 7 minutes, that of 90 % of S. aureus mRNA is 
below 5 minutes (91, 152). 
 
 
 
 
 
Fig. 42. Stability of 2.9 kb clfA and sarC mRNAs in 
MB79 (wt) and MS17 (hemB). The relative amount 
of transcript (RAT) is expressed as a percent of the 
quantity at the time of rifampin addition. Regression 
lines are based on mean values from at least two 
independent experiments. 
 
5.6.   Transcription of global regulators  
 
S. aureus is known to produce a vast array of regulatory elements that allow the 
pathogen to fine tune its transcriptional profile in response to environmental stimuli. To gain a 
more comprehensive view of regulation in MB79 and its hemB mutant MS17, regulators 
which are important for virulence, have been reported to influence the genes altered in SCVs 
or are involved in cellular processes likely to play a role in the SCV phenotype were 
monitored. Surprisingly, the hereafter described regulatory elements were only transcribed in 
exponential phase in the hemB mutant MS17, contrasting with individual profiles generally 
spanning the entire monitored time in the parent strain MB79.  
 
5.6.1.  Two component systems  
 
Previous findings about arl, sae and srr expression were basically confirmed in MB79 
(Fig. 43):  
The 2.7 kb arl transcript was seen throughout growth and increased slightly in the late 
stationary phase, paralleled by a weaker band of 1.5 kb probably encoding arlS alone (116).  
Of the three overlapping sae transcripts, containing saePQRS (3.1 kb), saeQRS 
(2.4 kb), or saeRS (2 kb), saeQRS was the most prominent and peaked in the late post-
exponential phase. A fourth transcript starts at the same promoter as the 3.1 kb transcript but 
ends at a stem loop sequence after 0.7 kb; it only contains saeP and basically paralleled the 
profile of the other three mRNAs (data not shown) (135, 284, 363). Variations in transcription 
profiles exist for different genetic backgrounds, for example the 2 kb transcript is hardly 
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detectable in Newman (363). However, overall sae transcript levels are highest towards 
stationary phase of growth, as seen in MB79 as well.  
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Fig. 43. Northern blot analyses of the two 
component systems arl, sae, srr and yyc in MB79 
and MS17 (hemB). The sizes of relevant bands are 
given on the left. Ethidium-bromide stained 16S 
rRNA is shown as an indication of RNA loading. 
 
 
 
The weaker 2.5 kb srrSR and the 
generally stronger 0.7 kb srrA mRNA, 
reported to be produced until post-
exponential phase (418), showed peaks 
here at 3 and 9 h and were expressed 
throughout the 15 h monitored.  
The profile of yyc was similar to 
that of arl. A transcript of approximately 
5.8 kb was observed, suggesting that 
yycFG was cotranscribed with at least two 
of the yet uncharacterised downstream 
genes. In B. subtilis, promoter fusion 
experiments monitoring transcription of 
yycFG during 6 hours (102), indicate 
transcription in early growth; data for 
S. aureus were not published until now.  
arl, sae and srr  transcription were 
up-regulated in the hemB mutant MS17 
during exponential growth and 
disappeared thereafter except for a very 
faint band of srrA was detected throughout 
growth. yyc was expressed at comparable 
levels to those in MB79 (Fig. 43).  
 
 
5.6.2.  SarA homologues  
 
The rot transcript has been reported to be present throughout growth (258, 336). In 
MB79, rot mRNA of approximately 0.6 kb was maximally expressed in post-exponential 
phase and declined in stationary phase, similar to the 0.4 kb sarR mRNA (Fig. 44), whose 
transcription profile had been analysed up to early stationary phase (238).  
In an 8325-4 background a 0.95 kb SigA-dependent transcript of sarS had been 
found to be present mainly in early exponential growth. Upon overproduction of SigB, a 
1.55 kb mRNA initiated from a SigB-promoter consensus sequence is produced, paralleled 
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by a 0.8 kb mRNA possibly a processing product of the larger transcript (372). In the 
Newman background sarS transcription is however not affected by SigB, as determined by 
microarray analyses (38). A 0.8 kb sarS transcript in MB79 was found in low amounts mainly 
in early exponential and towards stationary phase (Fig. 44).  
 
 
hours 1 2 3 5 7 9 11 13 15 1 2 3 5 7 9 11 13 15
MB79 (wt) MS17 (hemB)
rot
~ 0.8 kb
0.6 kb
sarS
sarR0.4 kb
 
 
 
 
 
 
 
 
Fig. 44. Northern blot analyses of the SarA 
homologues rot, sarR and sarS in MB79 (wt) and 
MS17 (hemB). Ethidium-bromide stained 16S rRNA 
is shown as an indication of RNA loading. The sizes 
of relevant bands are given on the left. Ethidium-
bromide stained 16S rRNA is shown as an 
indication of RNA loading. 
 
 
In the hemB mutant MS17, rot, sarR and sarS transcription were reduced compared 
to MB79 and absent after 5 hours. 
 
5.6.3.  The regulators SvrA and TcaR 
 
RT-PCR has shown that svrA is expressed in post-exponential phase. However, there 
is no information available on the size of the transcript(s) or their temporal pattern (124). A 
very faint transcript of approximately 2.5 kb was detected in both strains only during early 
growth, suggesting that svrA (1.35 kb) is co-transcribed with the surrounding genes of yet 
unknown function (Fig. 45). Paralleling the larger transcript, a shorter, approximately 1.5 kb 
transcript might be present. In MS17, the transcripts were almost undetectable. At the height 
of 23S rRNA, a stronger band was observed, which however is most probably due to 
unspecific binding. 
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Fig. 45. Northern blot analyses of the virulence 
regulator svrA and the tcaR transcripts in MB79 (wt) 
and MS17 (hemB). The sizes of relevant bands are 
given on the left. Ethidium-bromide stained 16S 
rRNA is shown as an indication of RNA loading. 
 
 
In MB79, tcaRAB (3.5 kb), tcaRA (2.3 kb) and an un-assigned band of 1.8 kb were 
only present in early growth phase. tcaR (0.45 kb) was present throughout growth, with an 
apparent decrease around hour seven (Fig. 45). An additional band of 0.8 kb which might 
comprise tcaR and a part of tcaA, was extremely strong early in growth but then diminished 
towards stationary phase. The tcaR probe used does not hybridize to the tcaA transcript 
(1.6 kb), which has been shown to be almost undetectable under normal growth conditions, 
although it is strongly induced by teicoplanin (236). Therefore, the two bands observed at 
both the 23S and 16S rRNA height are most probably due to unspecific binding of the probe 
to the respective nucleotides. In the hemB mutant MS17, transcription was generally reduced 
in exponential phase and almost undetectable thereafter. 
 
5.7. Transcription of the virulence determinants spa, hla and isaA 
  
spa is generally transcribed slightly earlier in the exponential phase, followed by hla 
(92, 372, 390). Most of the above described regulators influence directly or indirectly either 
spa or hla expression. In MB79, spa was maximally transcribed in post-exponential phase; 
hla transcription started shortly after spa, but reached its maximum level earlier and was 
thereafter rather constant (Fig. 46).   
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Fig. 46. Northern blot analyses of the virulence 
determinants spa, hla and isaA in MB79 (wt) and 
MS17 (hemB). The sizes of relevant bands are 
given on the left. Ethidium-bromide stained 16S 
rRNA is shown as an indication of RNA loading. 
 
isaA expression has been reported to occur during early growth (38), which was 
confirmed for MB79. Transcription of isaA was prolonged and increased in the hemB mutant 
MS17 compared to MB79, in a similar fashion to fnbA (Fig. 41).  
 
Discussion II Temporal patterns of global 75 Approach on Resistance Strategies in S. aureus  
regulators in a hemB mutant 
 
Dissertation Maria M. Senn 
6  DISCUSSION II  
 
6.1.   Rationale for the applied methods 
 
S. aureus SCVs recovered from clinical specimens and SCVs selected by gentamicin 
exposure are genetically undefined and may carry mutations in more than one site, 
especially since these strains show multiple phenotypic changes compared to the parent 
strains. In addition, clinical SCVs exhibit an unstable phenotype and easily revert to wild-type 
phenotype during cultivation. These inconveniences can be circumvented by disruption and 
inactivation of hemin or menadione synthesising enzymes. Several studies involving hemB 
mutants, including the comparison of 8325-4 and COL hemB mutants with clinical SCVs, had 
previously shown that these mutants mimic the SCV phenotype during prolonged in vitro and 
in vivo growth (20, 54, 184, 333, 397). Although no information about the molecular 
characterisation of clinically emerged S. aureus hemin-auxotrophic SCVs is available, in vitro 
gentamicin-selected SCVs did carry mutations in the hemAXCDBL and hemEHY operons 
(343). Moreover, a clinical isolate of Gram-negative SCVs had been found to carry a deletion 
of hemB, further indicating that defects in hemin synthesis are relevant for in vivo SCV 
formation (320, 321).  
The laboratory strain Newman was chosen because this frequently used strain has an 
intact sigB operon and had been reported to produce large amounts of FnBPs, proteins up-
regulated in SCVs (93, 363). Only recently point mutations in both fnbA and fnbB were found, 
leading to a truncation of the FnBPs and making this strain unsuitable for pathogen-host 
interaction studies. However, transcriptional regulation of fnbAB is very unlikely affected 
(149).  
Differences in the genetic background as well as minor changes in growth conditions 
can have major impacts on the profile of a regulator. Temporal transcription patterns 
stemming from few time points easily miss fluctuations occurring in between. Published 
results are therefore not always connectable. Hence, this study provides a useful overview of 
wild type transcription profiles of the most important regulators. New information for several 
regulators was presented (sarR, svrA and yyc). In addition, the experiments confirmed 
previous findings concerning the transcriptional patterns of agr, arl, rot, sae, sarS, srr, tca 
and sigB, while completing their data regarding stationary phase expression. 
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6.2. Altered gene expression in the hemB mutant 
 
The temporal pattern of the analysed global regulators in the hemB mutant did not 
reflect any particular growth phase of the parent strain, nor was it attributable to the absence 
or predominance of one single regulatory element. Deviations from the wild-type pattern 
were found for all global regulators and could be classified in three groups: i) no transcription, 
as observed for agr, ii) transcripts that were only present until cells entered post-exponential 
phase; during this time they were either up-regulated (arl, sae, sarA, sarB, sigB and srr), 
down-regulated (rot, sarR, sarS, svrA and tca) or similarly expressed as in the parent strain 
(yyc), and iii) transcription throughout the observed time course, as seen for sarC. In the 
general model of regulator interplay (Fig. 2) these relative overall transcript levels were 
indicated in Fig. 47, serving as an orientation for the following discussion. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 47. Interplay of global regulators and regulation 
of virulence determinants in strain Newman and its 
hemB mutant. Higher (black boxes), similar (grey 
boxes) or lower overall transcription levels (white 
boxes) during exponential phase in the hemB 
mutant compared to the parent strain are indicated. 
A Regulatory network. B Target genes and factors 
influencing their expression.  
 
6.2.1.  agr 
 
The complete absence of the major regulator agr in the Newman hemB mutant is 
supposed to have an influence on the expression of several genes. It could explain for 
instance the lack of sae transcription after the exponential phase in the hemB mutant since 
its transcription depends in post-exponential phase on agr (135, 284). In contrast, the 
increase of the adhesion factors FnbA and ClfA was not caused by the absence of RNAIII, 
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which in the case of fnbA seemed feasible, because agr is a known inhibitor of fnbA. 
However, up-regulation of fnbA (and clfA) transcription is reported to occur in a hemB mutant 
of an RNAIII-defective 8325-4 strain as well (391). In both MS17 and MB79 agr was not (yet) 
expressed when fnbA transcription began to decline. These findings support the idea that 
some additional repressor of fnbA must exist (411). arlRS was up-regulated in the hemB 
mutant in exponential phase compared to the parent, probably by SarA, because the other 
known stimulator, agr, was absent. Since it has been shown that arlRS depends both on sar 
and agr for spa down-regulation (116), arl might only have contributed to down-regulation of 
agr (thereby forming a negative feedback loop) and hla in the hemB mutant. 
Preliminary long term monitoring experiments over 7 days revealed both RNAII and III 
being transcribed in the hemB mutant after 30 hours (appendix 9.3., Fig. 52). In addition, 
both agr transcripts could be detected during the exponential phase in unrelated, menadione-
auxotrophic clinical SCV isolates (appendix 9.4., Fig. 53), showing that, despite the low cell 
density, agr transcription can be induced in SCVs. Together, these findings indicate that in 
hemB mutants and SCVs, depending on the strain’s genetic background, differences in agr 
regulation exist. Therefore, absence of agr upon entry into post-exponential phase might not 
be a common characteristic of SCVs, although in the Newman background analysed here it 
certainly influenced other genes. 
SvrA has been proposed by Garvis et al. to play a role in transducing the extracellular 
RAP signal to the cytosolic TRAP protein (124), which upon phosphorylation becomes 
activated and up-regulates the agr locus by a yet unknown mechanism (145, 208). This 
model would favour an early expression of svrA, as observed here. Interestingly, the stop of 
the 2.5 kb svrA transcription nicely coincided with the start of agr expression in the wild type. 
However, due to low transcription levels of the hypothetical 1.5 kb mRNA (Fig. 45) containing 
svrA alone, its transcription pattern was difficult to determine, for which we can not exclude 
the presence in post-exponential phase, as previously found (124). No information 
concerning the function of the neighbouring genes was available to date. While the existence 
of an SvrA-RAP-TRAP network still awaits prove, the reduction of ATP encountered in the 
hemB mutant could indeed hamper such a phosphorylation-dependent signal transduction 
pathway, not only in the case of the agr locus. 
 
6.2.2.  sar 
 
In the above mentioned study, sar transcription in an 8325-4 hemB mutant had been 
shown to be reduced (391). While the overall sar transcription was found to be increased in 
exponential phase in the hemB mutant, thereafter the amount of transcripts decreased to 
similar or lower levels compared to the parent. However, by using Northern blot techniques 
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and by monitoring the entire growth cycle a more detailed image was obtained. In the hemB 
mutant, sarC was the only regulator encoding transcript present throughout growth and, in 
consequence, its exclusive and required activator SigB was present and active as well. The 
strongly reduced sarR transcript levels in the hemB mutant MS17 could lead to decreased 
SarR activity, potentially contributing to increased SarA levels as shown in a sarR mutant 
(238). 
Since findings of reduced sar, but increased fnbA and clfA transcription in an 8325-4 
hemB mutant stem from just one time point of late-log phase (391), comparison with our 
results is difficult. Evaluating mRNA levels during late exponential phase in MB79 (2 and 3 h) 
and MS17 (3 and 5 h), increased fnbA transcription were found in the Newman hemB 
background as well, however, overall sar mRNA levels were increased while clfA seemed to 
be lower in late-log phase (Figs. 39 and 41). Apart from sampling differences, the diverse 
genetic background might have had an influence on relative expression levels as well, as 
seen for agr. 
In the wild type strain, at all time points either sar or agr, or both, were supposedly 
present, thereby assuring sae transcription throughout growth (Fig. 43). Since the only 
known activator expressed in the hemB mutant was sar, it might have been responsible for 
sae activation, similarly as for arl. Alternatively, an unknown activator could have played a 
role.  
A sequence upstream of the SarA coding region has been reported to be essential for 
fnbA transcription and is contained in sarB and sarC transcripts, but not in sarA (411). Since 
in the hemB mutant MS62 sarB, but neither sarC nor fnbA were transcribed, it looked as if 
only sarC could provide the required elements for fnbA expression. Still, this could not have 
been the case in the wild type, where transcription of fnbA started before sarC was present. 
Possibly fnbA transcription requires SigB and either sarB or sarC. However, fnbA regulation 
might be much more complicated, since sae, sar and sigB have been reported to be equally 
required for fnbA expression (38, 272, 363, 411).                                             
 
6.2.3.  Virulence determinants 
 
isaA seems to be directly regulated by the response regulator YycF, although it has 
not been reported whether positively or negatively. While yycFG mRNA levels during 
exponential phase were similar, transcription of the target isaA was much more pronounced 
during the first five hours in MS17 compared to MB79 (Fig. 43 and 46). SarA and SigB have 
been shown to have a positive influence on isaA (38, 86, 425, 426). Together, these 
regulators might be responsible for the up-regulation of isaA. 
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The only known direct activator of spa is SarS, which in turn is positively regulated by 
Rot, SarT and TcaR, and negatively influenced by SarA (253, 336, 346, 372). Apparently, 
although relatively weakly transcribed, SarS dominated over ArlR, SarA, SrrA and RNAIII in 
the wild type, all of which have been reported to negatively influence spa transcription (21, 
23, 115, 116, 175, 309, 418). In the hemB mutant MS17, decreased spa levels suggested 
that SarS was overridden by SarA or SrrA, since ArlR has been shown to require both sar 
and agr for its action on spa (Fig. 46) (116). In addition, the SarS-activator TcaR and Rot 
levels were possibly reduced. However, as seen for Asp23, reduced transcription is not 
necessarily correlated with similarly decreased protein levels, let alone activity.  
Regulation of hla is more complicated since sae, sar and agr are equally important for 
its transcription in vitro (138). Both ArlR and SigB negatively influence hla transcription (38, 
116, 129, 426). As discussed for spa, activating factors must have prevailed in the wild type 
MB79; agr-independent initiation of hla transcription by sae (or sar) was seen around hour 2 
in the wild type, when agr had not yet been induced. On the contrary, in the hemB mutant 
MS17 the inhibitors were stronger, although they could not impede weak, agr-independent 
transcription during exponential growth. 
 
6.2.4.  sigB 
 
Long term follow-up of SigB-dependent transcription revealed that SigB was active 
with fluctuations until stationary phase in the parent strain, possibly in response to general 
changes in growth conditions. Surprisingly, SigB-driven expression of known SigB-
dependent genes varied significantly in the Newman hemB mutant. While sarC, the 2.9 kb 
clfA and the 1.5 kb asp23 transcripts were detectable throughout growth, this was not the 
case for the 1.6 kb P3-sigB and the 0.7 kb asp23 transcripts. Based on these observations, 
the presence of factors modulating SigB activity in the recognition of its promoter consensus 
sequences under certain circumstances is postulated. Such SigB-modulators may also 
explain diverging results concerning SigB activity in different genetic backgrounds and 
varying experimental conditions.  
Because of the lack of the major SigB-activator RsbU in strains with an 8325 
background, SigB activity in these bacteria is generally strongly reduced (39, 129). However, 
apparently another, yet unidentified activator protein of SigB exists, since some reports about 
transcription of the sar locus revealed that, despite the absence of functional RsbU, SigB-
dependent transcription of sarC can take place (21, 41), but not always does (39, 157). The 
factors responsible for induction of this bypass are not yet identified, neither are the 
mechanisms. Since up-regulation of the SigB-dependent fnbA and clfA transcripts was 
observed in an rsbU background, one could speculate that in the hemB mutant this 
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alternative SigB activator is induced (391). The signal responsible for enhancing SigB activity 
in SCVs remains to be determined; a possibility would be energy stress. Glucose starvation 
has been found to induce SigB activity (M. Rüegg & M. Bischoff, unpublished results). Still, 
since glucose seems to be depleted later compared to parent strains, as seen in 8325 and 
COL hemB mutants, another, earlier signal must exist for SigB activation (under the 
assumption that those observations apply to strain Newman as well) (20).  
In B. subtilis, energy stress has been shown to influence SigB activity by two 
mechanisms. In the first one, a low ATP/ADP ratio affects RsbW kinase activity in that 
binding to RsbV is not followed by phosphorylation, leading to higher amounts of RsbW-
RsbV aggregates and consequently free SigB. The second mechanism involves an 
alternative phosphatase, RsbP, which seems to be missing in the S. aureus genome. In 
B. subtilis, RsbP becomes activated upon energy stress, dephosphorylates RsbV and tilts 
the amount of RsbW-SigB towards RsbW-RsbV, increasing levels of uncomplexed SigB (79).  
 Although sigB was not an essential locus for the in vitro SCV phenotype, as its 
inactivation did not affect colony morphology, growth, or antibiotic resistance in MS62, it is 
nevertheless strictly required for the maximal expression of at least two important virulence 
factors; FnbA and ClfA. Expression of FnbA, the more effective adhesion and invasion factor 
of the two redundant FnBPs A and B (149), together with ClfA, which recently has been 
shown to protect bacteria from phagocytosis by macrophages (292), might significantly 
contribute to persistence in the host. 
 
As already mentioned, one can not deduce from transcript levels the amount of active 
protein. However, keeping in mind that SigB was present and active, the observed transcript 
levels in exponential phase fit relatively well to the model of regulator interplay and regulation 
of virulence determinants (Fig. 47). For instance, positively SigB-influenced genes were 
found to be up-regulated or at least expressed at similar levels (sar, asp23, clfA, fnbA, isaA), 
whereas negatively influenced genes were down-regulated (agr, hla). The reduced spa 
mRNA levels correlate with increased inhibitor transcripts (sar, arl and srr). Still, even after 
assessing the presence and activity of each of these regulators, due to complex mutual 
interactions, the net result of activation or inhibition can hardly be predicted and needs to be 
assessed for each target. Factors responsible for the down-regulation of rot, sarR, svrA and 
tcaR remain to be identified. 
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6.3. General deviation of transcriptional activity in the  
hemB mutant 
 
Although most of the analysed genes’ transcription is concentrated in exponential 
phase in the hemB mutant, some of their products were presumably present until stationary 
phase, as was found for SigB. Results for fnbA and isaA transcription combined with data 
reported for FnbA and IsaA strongly suggest that these proteins persist until the stationary 
stage as well (205, 391). Speculating that the energy-restricted hemB mutant does not 
express needless genes, the increased transcription of arl, sae, sar and srr suggests that 
these regulators are involved in the control of its transcriptome. A role for srr in hemB 
mutants has already been proposed due to the fact that several metabolic genes influenced 
by srr were changed in a COL hemB mutant (205). The finding of Kohler et al. that the 
aconitase citB, a TCA-cycle enzyme controlled by srr, is down-regulated in a hemB COL 
mutant (205) was confirmed by us. In addition, srr could have contributed to agr and spa 
down-regulation.  
Interestingly, both spa and hla transcription started earlier in the mutant (Fig. 46). This 
was also observed for rot, asp23 and 2.9 kb clfA transcription (Figs. 40, 41 and 44), arguing 
against the idea that SCVs are cells stalled in early growth phase, as suggested by the 
absence of agr, exoprotein production and prolonged transcription of genes typically 
expressed in early growth phase, like fnbA (Fig. 41). Whether the almost uniform stop of 
transcriptional activity upon exit of the exponential phase is a coincidence or correlates to a 
yet uncharacterised transition process remains open. A link to reduced ATP levels seems 
difficult to make, since the reduced ATP levels are rather constant in a COL hemB mutant 
(205). Various metabolic enzymes have been reported to be transcribed after the exponential 
phase, suggesting transcription to focus on selected and required genes (205).  
 
Both the premature transcription and the drastic reduction of transcription observed in 
the hemB mutant, for SigB dependent and independent loci, indicate that global alterations of 
gene expression do happen. Thus, the extraordinary cellular state caused by the interrupted 
electron transport in hemB mutants is linked to an altered activity of global regulators and 
expression of virulence factors. 
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7  OUTLOOK II   
 
A subject of future work would be to determine the presence and activity of the 
regulators whose transcription was found to be up-regulated during the exponential phase in 
the hemB mutant (arl, sae, sar and srr). Results found for Newman and COL backgrounds 
would have to be confirmed in other types of SCVs; menadione- and thymidine-auxotrophs 
but also in clinical isolates. Most likely none of the above mentioned regulators will prove to 
be crucial for the SCV phenotype, as seen for SigB (and agr). However, SigB still could 
influence virulence of these variants, especially by increasing factors needed for adhesion 
and uptake into host cells, important steps for SCVs to establish themselves and persist. 
This could be tested by comparing hemB with hemB sigB mutants in a simple animal model 
like C. elegans. However, a strain other than Newman, expressing functional FnBPs, should 
be used to study host-pathogen interactions. 
 
The identification of factors modulating SigB activity would be of general interest. Due 
to the constitutive energy stress, hemB mutants might be a useful tool to identify missing 
factors involved in regulation of SigB activity. Since these additional factors could be 
enriched in the hemB mutant, pull-down experiments of SigB incubated with cell extracts 
from these bacteria might be a promising approach to find proteins involved in SigB 
regulation. RsbU activity might be changed as well; identification of interaction partners could 
bring light into the mode of SigB activation in response to energy stress; a pathway still 
missing in S. aureus.   
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8  MATERIALS AND METHODS 
8.1.   Oligonucleotide primers 
 
TABLE 3. Oligonucleotide primers used in this work. 
Name Sequence (5’-3’) Remarks Reference 
Dig- 
tcaRF 
CGTTAACGCATTAACTGCAA tcaR DIG-labelled probe, fwd (236) 
Dig- 
tcaRR 
GCGATGATTGATGACTTCTA tcaR DIG-labelled probe, rev (236) 
IK14 ACGCGAAGGTGGCCTAG sigB DIG-labelled probe, fwd (213) 
IK15 
 
ATGGTCATCTTGTTGCCCC sigB DIG-labelled probe, rev (213) 
MS14 CGAAGACGATCCAAAAC RNAII DIG-labelled probe, fwd This work 
MS15 TTATCTAAATGGGCAATGAGT RNAII DIG-labelled probe, rev This work 
MS16 GGGATGGGACAAGATAAAGAAGC fnbA DIG-labelled probe, fwd This work 
MS17 ACGACACGTTGACCAGCATG fnbA DIG-labelled probe, rev This work 
MS20 AGAAAATGGCATGCACAAAAA hla DIG-labelled probe, fwd This work 
MS21 TGTAGCGAAGTCTGGTGAAAA hla DIG-labelled probe, rev This work 
MS22 GGCAATCAAATCATTCCGGATACTG luc+ DIG-labelled probe, fwd This work 
MS23 ATCCAGATCCACAACCTTCGCTTC luc+ DIG-labelled probe, rev This work 
MS24 CTAGCTAGCGCAAAAGATATGGATAC glyS+, NheI site, no ATG, for cloning 
into pET-24b 
This work 
(349) 
MS25 CATCTCGAGGAATTTTGTTTTTTCAGTT
AAG 
glyS-, XhoI site, no TAA, for cloning into 
pET-24b 
This work 
(349) 
MS26 CGGAGTGCTTAATGCGTTAG SArRNA10 DIG-labelled probe, fwd This work 
MS28 
 
AGATCTCGATCCCGCGA  pET-24a(+) fwd, position 342 at BglII 
site, for sequencing 
This work 
MS29 GCTCAGCGGTGGCAG pET-24a(+) rev, position 80 at 
BpU1102I site, for sequencing 
This work 
 
MS30 CAATGGGCGAAAGCCTG SArRNA10 DIG-labelled probe, rev This work 
MS31 CATTGCCAATGATGATAGGGAC svrA DIG-labelled probe, fwd This work 
MS33 CGTGGCTTCAGTGCTTGTAG clfA DIG-labelled probe, fwd This work 
MS34 GAGTTGTTGCCGGTGTATTAGC clfA DIG-labelled probe, rev This work 
MS39 CAAGTTTTGGGATTGTTGGGATG rot DIG-labelled probe, fwd adapted from 
(336) 
MS40 GCTCCATTCATTTGTGCCATAG rot DIG-labelled probe, rev This work 
MS41 CAGCATGGTCTTGCTGC sarS DIG-labelled probe, rev This work 
MS42 CAAGCCTGAAGTCGATATGAC sarS DIG-labelled probe, fwd This work 
MS45 GACCCACTTACTGATCGTG  saeR DIG-labelled probe, fwd This work 
MS46 CCTAATCCCCATACAGTTGTG saeR DIG-labelled probe, rev This work 
MS59 CGAAATACTTATCGTAGATGATGAGGA
TAG 
srrA DIG-labelled probe, fwd This work 
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MS60 CAGCAAGTACGCGATGTGC srrA DIG-labelled probe, rev This work 
MS61 GAGTCCATTACCGCCTTGAC arlS DIG-labelled probe, rev This work 
MS62 GCCAGGTGTATACCAAATCAG hemB DIG-labelled probe, fwd This work 
MS63 CGGTTAGCAGGGTCCATC hemB DIG-labelled probe, rev This work 
MS64 CATTGCTGCTAAAGCACAAAG svrA DIG-labelled probe, rev This work 
MS66 GCGCCGCCGAAG sae T4 DIG-labelled probe, rev This work 
MS67 GAAGGATACGATGTGTACTGTGC yycFG DIG-labelled probe, fwd This work 
MS68 CGTTTCGACCTCTACTCATGTTG yycFG DIG-labelled probe, rev This work 
MS71 GCCACGATGCGTCC pET24a(+) fwd, position 375, for 
sequencing 
This work 
MS74 GAATCCCCAAGCACCTAAAC isaA DIG-labelled probe, rev This work 
MS75 GGCATCATCATTAGCAGTGG isaA DIG-labelled probe, fwd This work 
RNAIII+ GTGATGGAAAATAGTTGATGAG RNAIII DIG-labelled probe, fwd (60) 
RNAIII GTGAATTTGTTCACTGTGTCG RNAIII DIG-labelled probe, rev (60) 
SAasp23+ ATGACTGTAGATAACAATAAAGC asp23 DIG-labelled probe, fwd (129) 
SAasp23- TTGTAAACCTTGTCTTTCTTGG asp23 DIG-labelled probe, rev (129) 
sae285U CAAATTGAAGAAATGAGGAGTTA sae T4 DIG-labelled probe, fwd (363) 
spa TGAATTCGTAAACTAGGTGTAGG  spa DIG-labelled probe, fwd (327) 
spa for rev CGGTACCAGGCTTGTTATTGTCTTCC spa DIG-labelled probe, rev (327) 
sarR CTTCTAATTCTGAAATCAG sarR DIG-labelled probe, fwd (327) 
sarR for rev GACATTAATGATTTAGTCAAC sarR DIG-labelled probe, rev (327) 
SasarA+ AGGGAGGTTTTAAACATGGC sar DIG-labelled probe, fwd (60) 
SasarA CTCGACTCAATAATGATTCG sar DIG-labelled probe, rev  (60) 
 
 
 
8.2.   Plasmids 
 
TABLE 4. Description of plasmids used in this work. 
Name Description Reference 
pET24b(+) expression plasmid, N-terminal T7-Tag® or C-terminal His6-Tag®, T7 
promoter, Kmr, low copy origin 
Novagen 
pMS10 pSR3, femX replaced by Strep-TagII® (Asp718-EcoRI[lost]), introduction of 
RBS and PstI-SacI-EcoRI, Tcr 
This work 
pMS13 pMS10, femA (PstI-EcoRI), Tcr This work 
pMS14 pET24b(+) glyS (NheI-XhoI), Kmr This work 
pSR3 pAW8 xylRPO  femX (HindIII-EcoRI), Tcr S. Rohrer, 
unpublished 
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A       B 
      
C 
BglII         T7 promoter     lac operator   XbaI 
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAAT  
 
 
              T7-Tag                              
        RBS   NdeI  NheI                       BamHI   
AATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCCG 
    MetAlaSerMetThrGlyGlyGlnGlnMetGlyArgAspPro  
 
                                     
      NotI       His6-Tag 
EcoRISacI   SalI  HindIII      XhoI 
AATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAAC 
AsnSerSerSerValAspLysLeuAlaAlaAlaLeuGluHisHisHisHisHisHisEnd 
 
 
           Bpu1102I           T7...  
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAA 
 
...terminator 
CGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT  
 
D 
His6-Tag       
          RBS   NdeI  NheI   XhoI    
GTTTAACTTTAAGAAGGAGATATACATATGGCTAGC-glyS-CTCGAGCACCACCACCACCACCACTGAGATCCG 
            MetAlaSer-GlyS-LeuGluHisHisHisHisHisHisEnd 
 
Fig. 48. pET24b(+) cloning vector (A) and its derivative pMS14 (B). C Multiple cloning site of pET24b(+). 
D pMS14 region encoding the recombinant protein GlyS-His6.  
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A      B 
   
 
 
C 
 
 
D 
 
         Strep-TagII 
Asp718  RBS          PstI  SacI  EcoRI 
GGTACCAGGAGGAATATTATGTGGTCACATCCACAATTTGAAAAACTGCAGGAGCTCGAATTCTAGT 
   MetTrpSerHisProGlnPheGluLysLeuGlnGluLeuGluPheEnd 
 
E 
 
         Strep-TagII 
Asp718  RBS          PstI        EcoRI 
GGTACCAGGAGGAATATTATGTGGTCACATCCACAATTTGAAAAACTGCAG-femA-GAATTCTAGT 
   MetTrpSerHisProGlnPheGluLysLeuGln-FemA-GluPheEnd 
 
 
 
Fig. 49. pSR3 (A) and its derivatives pMS10 (B) and pMS13 (C). D pMS10 region covering the Strep-TagII®. 
E pMS13 region encoding the recombinant protein Strep-TagII®–FemA.  
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8.3.   Strains 
 
TABLE 5. Strains used in this work. 
Organism Name Description Reference 
E. coli    
 BL21 expression strain, DE3 (λ prophage carrying T7 RNA 
polymerase), ompT lon (protease mutations) 
Novagen 
 DH5α cloning strain, blue-white selection, recA1 ∆(lacIZYA-
argF) 
Invitrogen 
 MS1 DH5α, pMS10 plasmid, Tcr This work 
 MS10 DH5α, pMS13 plasmid, Tcr This work 
 MS32 DH5α, pMS14 plasmid, Kmr This work 
S. aureus    
 III33 Newman hemB::ermB, SCV (184) 
 A22616/3 Clinical isolate, SCV of A22616/5, auxotrophic for 
menadione  
(398) 
 A22616/5 Clinical isolate, wt of A22616/3 (398) 
 AS145 BB270 femAB::tetK, lysostaphinr, Mcs (367) 
 BB255 Essentially the same as NCTC8325, rsbU (27) 
 BB270 BB255 mec (28) 
 BB308 NCTC8325 mec Ω2003(femA::Tn551), Mcs, Emr (28) 
 BB1591 LS1 ∆rsbUVWsigB::ermB, Emr (272) 
 GP266 RN4220 rsbU+ sigB1 (Am) -tetL, Tcr (37) 
 GP268 BB255 (rsbUVWsigB)+-tetL, Tcr (129) 
 IK181 BB255 ∆rsbUVWsigB::ermB, Emr (214) 
 IK184 Newman ∆rsbUVWsigB::ermB, Emr (214) 
 LS1 Clinical osteomyelitis isolate (51, 52) 
 MB79 Newman Pasp23::luc+-tetL, Tcr M. Bischoff 
 MB138 BB255 rsbW7 Pasp23::pEC-Pasp23-luc+, Emr (37) 
 MS13 RN4220, pMS10 plasmid, Tcr This work 
 MS14 RN4220, pMS13 plasmid, Tcr This work 
 MS15 UK17, pMS13 plasmid, lysostaphins, Mcr, Tcr This work 
 MS16 UK17, pMS10 plasmid, lysostaphinr, Mcs, Tcr This work 
 MS17 MB79 hemB::ermB, SCV, Amir, Emr, Gmir, Tcr This work 
 MS62 Newman hemB::ermB sigB1 (Am), Emr,Tcr This work 
    
 Newman Clinical isolate, high level of clumping factor, truncated 
fibronectin-binding proteins A and B 
(93, 149) 
 OM1a Clinical isolate, wt of OM1b C. von Eiff 
 OM1b Clinical isolate, SCV of OM1a, auxotrophic for 
menadione 
C. von Eiff 
 RN4220 NCTC8325-4, restriction-, modification+, prophage-free (211) 
 SR18 BB270 PfmhB::Pxyl, Emr (325) 
 UK17 BB270 femA (207) 
 UT342 NCTC8325 mec Ω2006 (femB::Tn 551), Mcs (159) 
S. simulans    
 22 Clinical isolate (35) 
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8.4. Materials 
 
8.4.1.  Culture media 
 
for 1 litre if not otherwise stated. 
 
Agar/soft agar  
15 g / 6 g Bacto Agar (Difco). 
BHI  
37 g Brain Heart Infusion (Difco); 200 g calf brain infusion, 250 g beef brain infusion, 10 g 
proteose peptone, 2 g dextrose, 5 g NaCl, 2.5 g Na2PO4. 
LB  
10 g Bacto-Tryptone (Difco), 5 g Bacto Yeast extract (Difco), 10 g NaCl, adjusted to pH 7 
with NaOH, autoclaved. 
MH 
21 g Bacto Mueller-Hinton (Difco); 300 g beef infusion, 17.5 g caseine hydrolysate, 1.5 g 
starch. 
Sheep blood agar 
39 g Columbia Blood Agar Base No. 2 (Difco); 12 g Bacto Panton, 6 g Bacto Biton H, 3 g 
enzymatically digested animal tissue, 1 g starch, 5 g NaCl, 12 g Bacto agar, 50 ml sheep 
blood. 
Skim milk 
100 g skim milk (Difco). 
Medium A (500 ml) 
2.5 g yeast extract (0.5 %),10 g tryptone (2 %), 1 ml 5 M NaCl, 1.25 ml 1 M KCl (2.5 mM), 
5 ml 1 M MgCl2 (10 mM), 5 ml 1 M MgSO4 (10 mM), adjusted to pH 7 with NaOH; autoclaved 
and stored at room temperature. 
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Medium B (250 ml) 
12.5 ml 0.2 M PIPES pH 6.4 (10 mM), 13.75 ml 1 M MnCl2 (55 mM), 3.75 ml 1 M CaCl2 
(15 mM), 62.5 ml 1 M KCl (250 mM), sterilized by filtration through a 0.2 µm filter and stored 
at RT. 
 
8.4.2.  Buffers 
 
Solutions not listed here were made according to standard protocols (12). 
 
1 M guanidine thiocyanate (100 ml) 
11.816 g dissolved in dH2O. 
10 x Blocking reagent (100 ml) 
10 g Blocking reagent (Roche) dissolved in 1 x maleic acid buffer, autoclaved. 
5 x Maleic acid buffer (1 litre) 
58.4 g Maleic acid (0.1 M), 43.83 g NaCl (0.15 M), adjusted to pH 7.5 with solid NaOH 
pellets, autoclaved. 
Detection buffer pH 9.5 (1 litre) 
12.11 g Tris (0.1 M), 5.844 g NaCl (0.1 M), pH has not to be adjusted, autoclaved. 
5 x Blue (White) Wonder 
4.4 M Urea, 2.7 % Nonidet P-40 (NP-40), 2.7 % β-mercaptoethanol, 0.16 M Tris, pH 6.8, 
6.2 % SDS, 4.5 % glycerol and 0.01 % bromophenol blue. For White Wonder, the 
bromophenol blue was omitted to allow measurement of protein concentration, which was 
possible for protein concentrations ranging from 3 to 5 µg/µl as determined with BSA (despite 
the detergents present). 
SMM buffer 
0.5 M Sucrose, 0.02 M maleate, 0.02 M MgCl2, pH 6.8, sterilized by filtration through a 
0.22 µm filter and stored at RT. 
Membrane buffer 
0.1 M NaCl, 0.1 M Tris, 0.01 M MgCl2, 0.2 mM PMSF (freshly added), pH 7.5. 
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8.4.3.  Reagents 
 
All chemicals and reagents were either purchased from Fluka, Sigma or Merck, 
unless stated otherwise. 
 
Biofluor      Packard  
Isopropyl β-D-thiogalactopyranoside (IPTG) MBI Fermentas  
TRIZolTM      GibcoBRL  
U-14C-glycine       Amersham   
 
8.4.4.  Enzymes 
 
All enzymes were purchased from Sigma or Roche, unless stated otherwise. 
 
T4 DNA ligase     MBI Fermentas 
Lysostaphin      AMBI 
 
8.4.5.  Molecular weight markers 
 
1 kb DNA ladder     Gibco Life Technologies 
1 kb Plus DNA ladder    Gibco Life Technologies 
RNA ladder      New England Biolabs 
Precision Plus ProteinTM Standards,    BioRad 
All Blue  
Prestained SDS-PAGE Standards,    BioRad 
Broad Range 
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8.4.6.  Antibiotics 
 
All antibiotics were purchased from Sigma or Roche. Etest® strips were from 
AB Biodisk. 
 
The following concentrations were used for selection: 
Ap: 100 µg/ml 
Em:  20 µg/ml (in the case of selection of hemB mutants; 2.5 µg/ml) 
Km: 20 µg/ml 
Mc: 5-10 µg/ml 
Tc: 10 µg/ml 
 
8.4.7.  Apparatus 
 
Bio-imaging systems for  
documentation    CN-08 Photo-Print, Vilber Lourmat 
documentation and quantification  ImageMaster VDS-CL and ImageQuant 
version 5.2, Amersham Pharmacia 
Centrifugal filter devices,    Centricon, Millipore 
cutoff 10 kDa 
Electroporator/cuvettes    GenePulserTM, BioRad 
Glass bead vials for reciprocating shaker  Lysing Matrix B, Bio101  
Luminometer  Turner Designs TD-20/20 luminometer, 
Promega 
Sterile filters, 0.45 µm and     Millex®, Millipore 
0.22 µm pore size    
PCR Cycler       Thermocycler Progene, Techne, Witec 
PFGE       Chef-DRTM II Electrophoresis Cell, 
       BioRad 
Reciprocating shaker     Fast Prep FP120, Bio101 
Research centrifuge     Sorvall® RC 5C Plus, Kendro 
Scintillation counter     Liquid Scintillation Analyzer, 
       TRI-CARB® 1900CA, Packard   
Sequencer      ABI PRISMTM 310 Genetic Analyzer, 
Perkin- Elmer 
Sonifier      B-12, Branson 
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Spectrophotometer     Ultrospec® 3000, Amersham Pharmacia  
Table top centrifuges     5415D, Eppendorf Vaudaux 
       5804R, Eppendorf Vaudaux 
Ultracentrifuge     L-60, Beckman  
UV Crosslinker (DNA/RNA)    UV-Stratalinker® 1800, Stratagene 
Vacuum concentrator     SpeedVac Concentrator, Inotech 
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8.5. Molecular biology techniques 
   
General molecular biology techniques were performed as described (12, 237). 
 
8.5.1.  Preparation of E. coli plasmid DNA  
 
Plasmid minipreps were prepared from 4 ml of LB culture using the Nucleospin 
Plasmid mini Kit (Macherey-Nagel) according to the instructions of the manufacturer. For 
preparation of large amounts of plasmid DNA, midiprep kits (QIAGEN) were used. Plasmid 
DNA was dissolved in water. DNA concentration was determined by measuring the 
absorbance at 260/280 nm (1 OD260 unit = 50 µg/ml DNAds). Plasmid DNA was considered to 
be sufficiently clean if the ratio 260/280 nm was above 1.8. Plasmid DNA was stored at 
-20 °C. 
 
8.5.2.  Preparation of S. aureus genomic DNA 
 
A 20 ml overnight culture was harvested and the pellet resuspended in 3 ml lysis mix 
(0.1 M Tris-HCl, pH 7.5; 0.1 M EDTA; 0.15 M NaCl) containing 0.05 mg lysostaphin and 
0.25 mg lysozyme. The suspension was incubated at 37 °C until it became translucent and 
viscous. 0.3 ml of 5 % SDS in 50 % ethanol was added and the mixture was vortexed for 
10’’, then left on the benchtop for 5’. 1 ml of phenol/chloroform/isoamyl alcohol (25:24:1) was 
added and the mixture was vortexed for 10’’, then centrifuged at 20000 g for 10’. The 
aqueous phase was removed with a truncated Pasteur pipette, taking care not to disturb the 
proteinaceous interphase. The aqueous phase containing DNA was overlaid with 2 volumes 
of ice-cold 100 % ethanol and the DNA was spun out on a sterile glass rod. Spooled DNA 
was washed twice for 30’’ in 70 % ethanol, briefly left to air-dry and dissolved in 0.5 ml TE 
buffer (10 mM Tris-HCl, pH 8; 1 mM EDTA, pH 8). 1 µl of RNAse (1 mg/ml, DNAse free, 
Roche) was added and incubated at 37 °C for 1 h. DNA concentration was determined by 
measuring the absorbance at 260/280 nm (1 OD260 unit = 50 µg/ml DNAds). Genomic DNA 
was stored at 4 °C and was stable for more than 3 years. 
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8.5.3.  Preparation of S. aureus plasmid DNA 
 
Plasmid minipreps were prepared from at least 4 ml of LB overnight culture using the 
Nucleospin Plasmid mini Kit (Macherey-Nagel) with the addition of 5 µl of 10 mg/ml 
lysostaphin to the resuspension buffer 1 and incubation at 37 °C for about 10’, or until the 
suspension became clear. 
 
8.5.4.  Preparation of S. aureus tRNA 
 
50 ml of exponential phase culture (OD600 ≈ 1.5) was resuspended in 1 ml TRIZol® 
(GibcoBRL), transferred to glass bead vials and lysed for 40’’ at a speed of 6.0 in the 
FastPrep beat-beater (Bio101). 0.2 ml chloroform was added. The mixture was vigorously 
shaken for 15’’, and then left for 2’ at RT before centrifuging for 2’ at 13,400 g. The upper, 
aqueous phase was transferred to an Eppendorf tube, 0.5 ml isopropanol was added and 
shortly mixed before leaving for 10’ at RT. Precipitated RNA was collected by centrifuging for 
10’ at 13000  g and 4 °C. The pellet was washed with 0.5 ml 70 % ethanol and centrifuged 
for 5’ at 5400 x g and 4 °C. After briefly leaving to air-dry, RNA was dissolved in 0.5 ml dH2O 
(DMPC treated) for 10’ at 60 °C and shortly cooled at RT. Then, 0.325 ml 5 M NaCl was 
added, the mixture was vortexed and incubated 24 h on ice to precipitate high molecular 
weight RNA, which was collected by centrifuging for 30’ at 16000 g and 4 °C. The opaque 
pellet was discarded and the supernatant mixed with 2 volumes 100 % ice-cold ethanol to 
precipitate small RNA at -20 °C overnight. The precipitate was collected by centrifuging for 5’ 
at 2300 g and 4 °C. The pellet was washed with 0.5 ml 70% ethanol and centrifuged for 5’ at 
2300 g and 4 °C before drying up to 50’ at 40 °C. tRNA was dissolved in 150 µl DMPC-
treated dH2O (if necessary for 10’ at 60 °C). To allow correct folding of 3° structure tRNA was 
melted for 5’ at 65 °C and slowly cooled to RT. tRNA concentration was determined at 
260/280 nm (1 OD260 unit = 40 µg/ml RNAss). tRNA was stable for 8 months at – 20 °C. 
 
8.5.5.  Purification of DNA fragments 
 
Restriction digests or impure PCR products were run on preparative 0.8 % agarose 
gels in 0.5 x Tris-borate EDTA (TBE) buffer according to (12). Bands were visualized on a 
long-wavelength ultraviolet light box for as short a time as possible to reduce DNA damage, 
excised using a scalpel and purified using the Nucleospin extract 2 in 1 kit (Macherey-Nagel) 
according to the manufacturer's specifications. Elution was usually done in 30 µl of elution 
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buffer. Yield and purity of the isolated fragments was judged by running them on a 0.8-2 % 
agarose gel and comparing the band intensity to a standard 1 kb DNA ladder (Gibco). 
 
8.5.6.  PCR 
 
Preparative PCR reactions were generally carried out in 50 µl volumes. Usually, 
about 100 ng template DNA, 1/10 vol 10 x Pwo polymerase buffer (containing MgCl2), 0.5 µM 
of each primer, 0.2 mM dNTPs, and 1 unit Pwo polymerase (Roche) was used. Alternatively, 
ProofStart polymerase (QIAGEN) was used. Reactions were run on a Techne Thermocycler 
(Witec) using the following conditions: initial denaturation at 95 °C for 4’ followed by 25 
cycles of 95 °C for 30’’, annealing at 45-65 °C 30’’, extension at 72 °C for 1-10’, as the 
processivity of DNA polymerases is roughly 1-1.5 kb per minute. Annealing temperatures 
were usually chosen 2-3 °C below the theoretical melting temperature of the primer as 
calculated by the (2 AT+ 4 GC) rule. Usually, an initial 5 cycles using a touchdown protocol 
were inserted. In this method, the annealing temperature is reduced by 1 °C per cycle to 
ensure a more specific amplification of the desired product if the optimal annealing 
temperature of the primers has not been established. A final elongation at 72 °C for 8’ was 
added. 
For DIG-labelling of DNA probes the PCR DIG Probe Synthesis Kit (Roche) was used 
and the instructions of the manufacturer were followed. The ratio of unlabelled dNTPs (2 mM 
each) to Synthesis mix dNTPs (dATP, dCTP and dGTP 2 mM each; DIG-11-dUTP 0.7 mM) 
was 2, resulting in an end concentration of the labelled dUTP of 0.23 mM and of 1.33 mM 
dTTP. Annealing temperature was generally 50 °C, 30 cycles were run. 
 
8.5.7.  Cloning  
 
8.5.7.1. Plasmid digestion  
 
For preparative digestions, 3-10 µg plasmid DNA were digested with 10-30 U of 
enzyme in the appropriate 1 x restriction buffer for 2 hours. Alternatively, DNA was digested 
with 1-5 U of enzyme overnight. A list of enzymes that can be used in overnight digests can 
be found in the New England Biolabs catalog. Enzymes were from Roche. 
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8.5.7.2. Digestion of PCR fragments 
 
PCR Fragments were routinely digested overnight, under the same conditions as for 
plasmids. Oligonucleotide primers that contained an overhang to incorporate a restriction site 
were designed with at least 3 extra nucleotides to ensure efficient cleavage by the restriction 
enzyme. Information about the restriction efficiency of different enzymes can be found in the 
back of the New England Biolabs catalog. 
 
8.5.7.3. Dephosphorylation of 5’ ends  
 
Digestion with enzymes producing non-compatible ends but cutting at sites lying 
close together (which is usually the case when utilising an MCS) can produce linearised 
vectors cut just by one enzyme and consequently having compatible ends (running at 
practically the same height as the double-cut vector on a preparative agarose gel). 5‘ ends 
were therefore routinely dephosphorylated to inhibit self-ligation. Alkaline phosphatase from 
arctic shrimp was used (SAP, Roche or Promega). Dephosphorylation was done by 
incubating maximally 2 µg of linearised vector with 1 x SAP buffer and 1 U of SAP for 30’ at 
37 °C, followed by an inactivation step at 75 °C for 10’. After inactivation, an additional unit of 
SAP was added, incubation was continued at 37 °C for 30’ and the reaction was terminated 
by incubation at 75 °C for 10’. In most cases, dephosphorylation was carried out directly after 
digestion in the restriction enzyme buffer since SAP is active in all restriction buffers. 
 
8.5.7.4. Ligation of DNA fragments  
 
DNA fragments were quantitated on agarose gels as described above. Generally, 
ligations were performed in 20 µl volumes using 20-50 ng of vector and insert:vector ratios of 
3:1, 6:1 and nil:1 (negative control). The ratio is based on pmol molecules, assuming 1 bp = 
649 Da. For convenience, the following formula can be used: ng insert = ((ng vector * insert 
size in kb) / vector size in kb) * insert:vector ratio. Ligation mixtures containing the 
appropriate insert:vector amount, 1 x ligation buffer and 0.5-1 µl of T4 DNA ligase (NEB) 
were incubated at 16 °C overnight. For electroporation, ligation reactions were precipitated 
using 1 µl of a 20 mg/ml solution of Blue Dextran (Sigma) in dH2O, 2 µl of 5 M NaOAc pH 
5.5, and 20 µl isopropanol. The reactions were precipitated on ice for 20’, centrifuged at 4 °C 
and 16000 g for 20’ in an Eppendorf table top centrifuge, washed twice with 70 % ethanol 
and left to air-dry at 37 °C for 10’ or dried in a SpeedVac for no longer than 5’. 
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8.5.8.  Sequencing 
 
The ABI PRISM® BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit 
(Perkin-Elmer) was used. This kit consists of an optimised Thermus aquaticus DNA 
polymerase for sequencing with less discrimination against dideoxynucleotides, eliminated 
5’→ 3’ nuclease activity and thermally stable inorganic pyrophosphatase. Included is a set of 
high-sensitivity dye terminators. Instructions of the manufacturer were followed for cycle 
sequencing (reaction volume 20 µl) and precipitation of products, with the exception of 
utilisation of 3 M NaOAc pH 5.5 instead of 4.5 and 100 % ethanol. The precipitate was 
dissolved in 20 µl formamide, heated to 90 °C for 2’, vortexed, briefly centrifuged and kept on 
ice until sequencing. The ABI PRISMTM 310 Genetic Analyzer (Perkin- Elmer, 47cm x 50µm 
i.d. capillary) was used. Typically, 300-400 bases were sequenced with an injection of 60’’ 
and reading for 120’’. 
 
8.5.9.  Southern blot analyses 
 
2 µg genomic DNA was digested with 10 U of restriction enzyme overnight and 
separated on a large (15 cm) 0.8 % agarose gel. The separation was documented using 1 kb 
DNA ladder (Gibco Life Technologies) for later size estimation of the hybridizing bands. The 
DNA was depurinated using 0.25 M HCl for 20’ and denatured using 0.4 M NaOH for 30’. A 
capillary blotting method was applied for 3 h to transfer DNA fragments to a Biodyne A nylon 
membrane that had been prewetted in 0.4 M NaOH. The DNA was UV-crosslinked in a 
Stratalinker at the autocrosslink setting. The membrane was then briefly washed in dH2O and 
prehybridised in 5 x SSC, 1 % Blocking reagent (Roche), 0.1 % N-lauroylsarcosine, 0.02 % 
SDS in maleic acid buffer. After prehybridisation for 30’ at 55 °C, the heat-denatured, DIG-
labelled PCR probe was added and hybridization was carried out overnight. The membrane 
was then washed twice for 15’ at RT in 2 x SSC, 0.1 % SDS, and twice for 15’ at 65 °C in 
0.1 % SSC, 0.1 % SDS. The membrane was briefly rinsed in maleic acid buffer and 
incubated for 30’ in 1 % blocking reagent in maleic acid buffer supplemented with 0.3 % 
Tween 20 (BioRad), and the alkaline phosphatase-coupled anti-DIG-Fab fragments were 
added at 1:20,000 dilution. After incubation for 1 h, the membrane was washed twice for 10’ 
in maleic acid buffer/0.3 % Tween, then briefly rinsed in detection buffer. Detection was 
carried out using CDP-Star diluted 1:100 in detection buffer. Approximately 500 µl detection 
solution was distributed over a 12 x 15 cm membrane before sealing in plastic foil for 
detection. 
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8.5.10.  Northern blot analyses 
 
Total RNA was isolated as described previously (67), using the FastRNA kit and a 
Fastprep reciprocating shaker (Bio 101). For Northern blots, 5 to 10 µg of total RNA was 
loaded per lane, separated on a 1.5% agarose - 20 mM guanidine thiocyanate gel and 
transferred overnight onto a positively charged nylon membrane (Roche). The blots were 
hybridized with specific DIG-labelled DNA probes. Membranes were stripped by boiling twice 
in 0.1 SSC-0.5 % SDS for 30’ and were reprobed up to four times.  
 
8.5.11.  mRNA half-life determination  
 
Half-life of potentially more stable transcripts was determined at that time point of 
growth where the supposedly less stable transcripts began to disappear as observed by 
Northern blot analyses (see text). Bacteria grown for 5 hours in LB were supplemented with 
300 mg/ml rifampin and samples were taken at three minute intervals. Total mRNA was 
isolated and analysed by Northern blots, as described above. Band intensities were 
quantified densitometrically with an ImageMaster VDS-CL using the ImageQuant version 5.2 
(Amersham Pharmacia Biotech). Values were corrected against the background and 
normalized. Half-life of mRNA was determined from regression lines obtained by plotting 
mean values of at least two independent experiments against time on a semi-logarithmic 
graph. The regression line was calibrated to intercept with the initial amount of transcripts, 
which was set to 100. 
 
8.5.12.  Preparation of protein extracts 
 
Total protein was isolated by resuspending cells in PBS, pH 7.4, at an OD600 
corresponding to 2/ml. Glass beads (Sigma) were added up to the meniscus and the cells 
were lysed for 40’’ at a speed of 6 in a Fastprep reciprocating shaker (Bio 101). After briefly 
cooling on ice, 0.1 ml PBS and 50 µl 5 x Blue Wonder were added. The mixture was 
vortexed and boiled for 5’, shortly centrifuged and the supernatant transferred to a fresh tube. 
For cytoplasmic fractions, pelleted bacteria were resuspended in 0.07 M phosphate buffer, 
pH 6.8, containing lysozyme, lysostaphin and DNase, each at 0.018 mg/ml, as well as 2 mM 
phenylmethylsulphonylfluoride (PMSF).  After incubating at 37 °C for 30’ the solution was 
sonicated thrice for 10’’ with a Branson B-12 sonifier on ice. Cell debris were pelleted by 
centrifuging for 20’ at 14000 rpm and 4 °C. Protein concentration of the supernatant was 
determined by the Bradford method (49) with BSA as a standard. 
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Fractionated extracts were obtained by resuspending cells in half the original volume 
of SMM buffer, containing lysostaphin 0.1 mg/ml. Cells were lysed at 37 °C for 10’ and 
centrifuged for 4’ at 30000 g. The supernatant contained the cell wall fraction and was 
precipitated with TCA as described below. The pellet, containing protoplasts, was 
resuspended in a quarter of the original volume of membrane buffer and subjected to a 
freeze-thaw cycle in dry ice/ethanol. Membranes were collected by centrifuging for 1 h at 
50000 g in an ultracentrifuge. The pellet was resuspended in phosphate buffer, the 
supernatant containing the cytoplasmic proteins was TCA precipitated as follows. 
Supernatants were precipitated by addition of TCA up to an end-concentration of 
10 %. This mixture was left on ice for 30’, then centrifuged for 15’ at 30000 g. The pellet was 
washed with ice-cold acetone, followed by centrifugation for 5’ at 30000 g. After drying the 
precipitate, proteins were dissolved in 5 x Blue Wonder. If the buffer turned yellow because 
the sample was too acidic, 1 M Tris, pH 8, was added until neutralisation (blue colour).  
 
8.5.13.  Overexpression and purification of His-tagged proteins 
 
Recombinant protein bearing a C-terminal hexahistidine tag was expressed in E. coli 
BL21(DE3) cells using the pET system (Novagen). BL21(DE3) cells are all-purpose strains 
for high-level protein expression and easy induction. BL21(DE3)pLysS cells provide tighter 
control for expression of toxic proteins. In addition, BL21 cells can be used for non-T7 RNA 
polymerase protein expression systems. All BL21 strains are deficient in the OmpT and Lon 
proteases, which may interfere with isolation of intact recombinant proteins. The pET vector 
series contains a phage T7 promoter, while the DE3 determinant of the BL21 strains 
encodes a T7 RNA polymerase under the control of the lac promoter. Induction of the T7 
polymerase using IPTG allows controlled expression of high amounts of recombinant protein 
(148). GlyS was cloned in E. coli DH5α into pET24b(+) (Novagen) using PCR primers tailed 
with NheI and XhoI sites such that the hexahistidine tag was fused in frame to the C-
terminus. This was done to ensure the purification of full-length protein only.  
Plasmids encoding FemA-, FemB- or FemX-His6 (which had been previously 
constructed (323)) and GlyS-His6 were freshly transformed into BL21(DE3) electrocompetent 
cells. Transformed BL21 cells were not stored as frozen stocks; instead, they were 
electroporated freshly every 4-5 weeks. In each case one transformant was used to inoculate 
10 ml LB + 20 µg/ml Km pre-cultures, grown overnight at 37 °C. 500 ml main cultures were 
started with an OD600 of 0.01 and incubated at 30 °C to favour proper folding of protein and 
decrease the risk of inclusion bodies. Induction with 0.5 mM IPTG was started when the 
cultures had reached an OD600 of 0.6. The cells were harvested after 90’ and stored at 
-20 °C. Cells were lysed in 20 ml of lysis buffer (50 mM Na-Phosphate pH 8.0; 300 mM NaCl; 
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10 mM imidazole; 1 mg/ml lysozyme; 0.1 mg/ml DNAse; 0.01 mg/ml RNAse) for 30’ on ice. 
An aliquot of this total lysate was taken for SDS-PAGE analysis. The lysate was sonicated on 
ice; 3 bursts of 10’’ were applied. The lysates were then centrifuged at 20'000 g for 20’ to 
yield cleared lysate. An aliquot of the cleared lysate was taken for SDS-PAGE to observe the 
ratio of soluble versus insoluble recombinant protein.  
The cleared lysate was incubated with 1 ml Ni-NTA-agarose resin (QIAGEN) for 1 h, 
on an overhead shaker, at 4 °C. The Ni-NTA resin has a binding capacity of 5 mg protein per 
ml of column volume. A mini-column method was used, for which small columns with a 
porous frit (Quickspin, Roche) had been welded to a 10 ml plastic syringe. A small amount of 
the post-incubation supernatant ("flow-through") was retained for SDS-PAGE analysis. The 
resin was washed with 5 ml of wash buffer (50 mM Na-phosphate, pH 8.0, 300 mM NaCl, 
10 mM imidazole). The bound protein was eluted with 3 x 0.5 ml of elution buffer (50 mM Na-
phosphate, pH 8.0, 100 mM NaCl, 200 mM imidazole). To concentrate the eluted protein the 
eluates were centrifuged in Centricon centrifugal filter devices with a cutoff of 10 kDa 
(Millipore) at max. 5000 g up to 5 x for 20’. 0.5 ml glycerol was added as an antifreeze in 
order to store the enzymes at – 20 °C, where they remained stable and active for at least one 
year. 
The recombinant proteins obtained with this procedure were highly, but not absolutely 
pure. Contaminating bands with affinity to the Ni-NTA-agarose resin were not removed 
(Fig. 30). These proteins are estimated to make up less than 10 % of the total protein 
obtained. Since GlyS and the Fem factors eluted from the column at imidazole 
concentrations higher than about 20 mM, a more stringent wash procedure could not be 
applied. 
  
8.5.14.  SDS-PAGE and Western blot analyses 
 
Standard protocols for discontinuous SDS-polyacrylamide gel electrophoresis (219), 
electroblotting (379), and staining (12) were used. Precision Plus Protein All Blue Standards 
(Bio-Rad) was used as a molecular size marker. Antibodies were generally incubated in 
PBS, 0.5 % skim milk powder, 0.3 % Tween 20 (BioRad) at appropriate dilutions ranging 
from 1:1000 to 1:10000 for 1 h, followed by washing in PBS, 0.3 % Tween for 3 x 5’. 
Detection of horse radish peroxidase (HRP)-conjugated antibodies was with ECL 
(Amersham) or Super Signal West Pico (Pierce) reagents according to the recommendations 
of the manufacturers. For SigB detection, blocked membranes were preincubated with 
40 µg/ml human IgG (Calbiochem) to saturate protein A and thereby prevent cross-reactivity 
of antigen-purified, rabbit antibodies against SigB.  
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8.5.15.  Protein sequencing  
 
Recommendations from BioRad for Immun-Blot® and Sequi-Blot® were followed. An 
estimated 6 µg of recombinant SigB-His6 protein isolated from BL21 was gel-purified by 
SDS - 10 % PAGE and transferred onto a PVDF-membrane (BioRad). Transfer efficiency 
was determined by comparing stained gel and membrane (33.3%).  The band of interest was 
excised with a scalpel, thoroughly rinsed with 0.45 µm filtered dH2O and air-dried. The first 
five amino acids were determined by Edman sequencing performed at the Protein Service 
Laboratory of ETH, Zürich (http://www.biol.ethz.ch/dienstleistungen/Protein_Service_Lab). 
 
8.5.16.  Antibody production  
 
An estimated 0.86 mg of recombinant SigB-His6 protein isolated from BL21 was gel-
purified by SDS - 10 % PAGE, Coomassie-stained and excised with a scalpel. Gel-
homogenisation and chicken polyclonal antibody-production was performed by Davids 
Biotechnology, Regensburg, according to the DabioPrepI protocol (www.dabio.de). 
 
8.5.17.  Antigen-purification of antibodies 
 
Recombinant, His6-tagged target protein (1.5 µg – 1 mg) isolated from BL21 was gel-
purified by SDS-PAGE (10 – 12%) and blotted onto a nitrocellulose membrane (Hybond, 
Amersham Pharmacia). The membrane was stained with Amido Black and the desired band 
was excised with a scalpel. After blocking with 5 % skim milk/PBS for 30’ at RT, the 
membrane was briefly washed twice with PBS. Crude antibody-containing solution was 
added and either incubated for 2 hours at RT or overnight at 4 °C. After washing twice for 15’ 
with PBS, bound antibodies were eluted with 0.1 M glycine, pH 2.2, and immediately 
neutralised with 1 M Tris-HCl, pH 7.5. 15 mM Na-azide was added as a preservative. 
Optionally, BSA was added to a concentration of 0.1 mg/ml for stabilising the antibodies. 
 
8.5.18.  Luciferase assay 
 
Bacteria were harvested by centrifugation and the pellet was flash-frozen in liquid 
nitrogen. Cells were resuspended to an OD600 of 10/ml, corresponding to 109 cells/ml, in 
0.7 M phosphate buffer, pH 6.8, containing lysozyme and lysostaphin, each at 0.036 mg/ml. 
After shaking for 10’ at 37 °C, 10 µl supernatant of lysed cells was mixed with an equal 
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volume of luciferase assay substrate (Promega) and luminescence was measured for 15’’ 
after a delay of 3’’ on a Turner Designs TD-20/20 luminometer (Promega). According to the 
manufacturer’s information the luciferase assay substrate contains excess ATP; addition of 
2 mM ATP did not increase signals. Protein concentration of the supernatant was determined 
by the Bradford method (49) with BSA as a standard.  
 
8.5.19.  GlyS activity assay 
 
GlyS-His6 activity was tested in a 50 µl reaction mixture containing 9 µg enzyme 
(negative control dH2O), 10 µg total tRNA, 4 mM ATP, 0.8 mM DTT and 0.5 nmol/2µl 
U-14C-glycine (Amersham, 50 µCi/ml) in 50 mM Tris-HCl , pH 7.5, 20 mM MgCl2, 50 mM 
NaCl. The mixture was incubated for 1 h at 30 °C and then applied to 1 cm2 of Whatman filter 
paper No.1. 0.3 ml of ice-cold 10 % TCA was added and mixtures were briefly kept on ice to 
precipitate tRNA. Afterwards filters were washed twice with 0.3 ml ice-cold 5 % TCA and 
once with 0.3 ml ice-cold 100 % ethanol. Filters were briefly air-dried before transferring into 
a scintillation-counter vial. 5 ml biofluor (Packard) was added, incorporation of radioactivity 
determined with a TriCarb scintillation counter. Standard curves were determined in parallel 
by dilution series of U-14C-glycine in dH2O. 
 
8.5.20.  In vitro cell wall synthesis assay 
 
Experimental procedures for the establishment, and experiments performed with the 
in vitro assay for peptidoglycan synthesis are described in (349). 
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8.6. Bacteriological methods 
 
8.6.1.  Stock cultures 
 
Stock cultures were maintained at –80 °C in skim milk medium. 
 
8.6.2.  Preparation of competent cells and transformation 
 
Chemically competent cells (173)  
E. coli DH5α cells were streaked out on LB plates from a skim milk stock and 
incubated over night at 37 °C. 5-10 single colonies were transferred into 250 ml Medium A 
and incubated at RT (or less) with shaking until they reached an OD600 of 0.5 (usually 
2-3 days). Cells were incubated on ice for 10’ and pelleted at 4000  g for 10’ and 
resuspended in 80 ml ice-cold medium B, followed by 10’ on ice. Cells were pelleted again, 
resuspended in 20 ml ice-cold medium B and slowly stirred on ice. While stirring, 1.4 ml 
dimethyl sulfoxide (DMSO) was added dropwise and cells were incubated on ice for another 
10’. 400 µl aliquots were flash-frozen in liquid nitrogen and stored at -80 °C.  
For transformation, cells were thawed on ice, divided into 100 µl aliquots and 10 µl 
ligation mixture or 1-100 ng supercoiled plasmid DNA was added. The transformation mix 
was incubated on ice for 30’, heat-shocked at 42 °C for 90’’, incubated on ice for 3’, and 
400 µl LB medium was added. Cells were grown at 37 °C for 30’ – 1 h. After a short 
centrifugation step approximately half of the supernatant was discarded, cells were 
resuspended in the remaining 200 µl, spread on selective plates and incubated at 37 °C 
overnight. This protocol yields approximately 107 to 108 transformants per µg plasmid DNA. 
 
Electrocompetent E. coli cells  
A 500 ml culture of E. coli was grown to an OD600 of 0.7 and harvested at 10000 g for 
10’. The cell pellet was resuspended in 250 ml of ice-cold dH2O and centrifuged again at the 
above settings. The procedure was repeated with 0.25 and 0.125 volumes of the original 
culture. The pellet was resuspended in 20 ml of ice-cold 10 % glycerol, centrifuged, 
resuspended in 2 ml of ice-cold 10 % glycerol and finally dispensed in 120 µl aliquots, which 
were subsequently flash-frozen in liquid nitrogen.  
For electroporation, 60 µl of cells were mixed with 1 µl of precipitated ligation mixture 
or approximately 100 ng plasmid miniprep DNA and incubated on ice for 1’. Electroporation 
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was carried out with a BioRad GenePulser using 0.2 cm electrode gap cuvettes at 25 µF, 
200 Ω, 2.5 kV. This protocol yields up to 109 transformants per µg of plasmid DNA. 
 
Preparation of electrocompetent S. aureus cells  
A 500 ml culture was grown to an OD600 of 0.7 and harvested at 10000  g for 10’ at 
4 °C. The cell pellet was resuspended in 250 ml (0.5 volume of the original culture) of ice-
cold 0.5 M sucrose and centrifuged again at the above settings. The procedure was repeated 
with 0.25, 0.125 and 0.0625 volumes of the original culture, with an incubation step of 
2-3 hours at the third wash cycle. The pellet was then resuspended in 20 ml of ice-cold 10 % 
glycerol. After the following centrifugation step, the cells were resuspended in 2 ml of ice-cold 
10 % glycerol, dispensed in 120 µl aliquots and flash-frozen in liquid nitrogen. 
For electroporation, 60 µl of cells were mixed with 1 µl of plasmid miniprep DNA and 
incubated on ice for 30’. Electroporation was done in 0.1 cm electrode gap cuvettes at 25 µF, 
100 Ω, 1.5 kV. Immediately after electroporation, 1 ml of cold BHI broth was added and cells 
incubated for 90’ at 37 °C before selective plating. 
 
8.6.3.  Phage transduction  
 
For the production of phage lysate, CaCl2 was added to 20 ml overnight cultures of 
the donor strain in LB to an end concentration of 5 mM. 300 µl aliquots of culture were mixed 
with 100 µl of serial dilutions (10-1 to 10-5) of phage lysate (80α or 85α) and incubated at RT 
for 15’. 4 ml of soft agar (approx. 55 °C) containing 5 mM CaCl2 was added and the mixtures 
plated on sheep blood agar plates. After overnight incubation at 37 °C, a plate that had a 
confluent lysis pattern, but a brown colour due to hemolysis to indicate growth of the cells 
was selected. The soft agar layer was scraped off into 4 ml of LB with 5 mM CaCl2 and 
centrifuged at 13000  g for 10’ at 4 °C. The supernatant was sterile filtered through a 0.22 µm 
filter. 
For phage transduction, the recipient strain was grown overnight in LB and CaCl2 
added to 5 mM. 300 µl aliquots were mixed with 100 µl of serial dilutions of transducing 
phage lysate and incubated at RT for 15’. 4 ml of soft agar (approx. 55 °C) containing 20 mM 
trisodium citrate was added and the mixtures plated on selective media. Colonies appeared 
after 24-72 hours. 
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8.6.4.  Susceptibility testing 
 
Etests  
The MIC of standard antibiotics was measured by Etest (AB Biodisk, Solna, Sweden) 
on sheep blood or Müller-Hinton agar. A McFarland 0.5 (approximately 108 cfu/ml) 
suspension of the strains was swabbed on an agar plate in three directions and briefly left to 
dry. The test strip was then applied and the plates were incubated for at least 24 h at 37 °C. 
In the case of hemB mutants, the MICs were first read after 24 h, the last reading was after 
72 hours.  
 
Gradient plates  
Gradient plates were prepared in rectangular inoculum dishes (Dynatech) using 40 ml 
of LB bottom agar containing the required maximal amount of antimicrobial, and 40 ml of LB 
top agar. Plates were dried for 2 h before application of a bacterial suspension adjusted to 
McFarland 0.5 with a cotton swab along the gradient. Growth was assessed after 24 h 
incubation. 
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9  APPENDIX 
 
9.1.   Sublocalisation of Fem-Factors 
 
The X-ray crystal structure of two Fem factors revealed that they do not contain 
membrane-spanning domains (26, 34). However, it was plausible to assume that these 
factors are somehow membrane-associated, as their substrates are lipid intermediates (156, 
193, 249). FemA had previously been found in the cytoplasma (182). In our group, 
M. Tschierske detected FemB both in the cytoplasmic and the membrane fraction.  
To complete data, it was planned to detect FemX with chicken antibodies in fractionated cell 
preparations. Chicken antibodies (IgY) have the advantage to be bound less by protein A, 
which usually cross-reacts with the constant region of IgGs.  
A different approach allowing more convenient determination of in situ expression and 
localisation of the Fem factors, was followed in parallel. In a first attempt, a StrepTag II® was 
fused to the N-terminus of FemA, which, as deduced from the X-ray structure, is not buried in 
the protein and thus theoretically suitable for labelling (Fig. 50). The StrepTag II® is an 
octapeptide mimicking biotin and therefore recognised by streptavidin conjugates (235, 348). 
 
 
 
Fig. 50. A Ribbon structure of FemA positioned as in Fig. 23. B FemA, after tilting in the plane -90 ° and rotating 
-90 ° out of the plane; the coiled-coil domain pointing to the front. The N-term is indicated by a red, the C-term by 
a blue arrow, respectively. Image created with RasTop (version 2.6) from Protein Data Bank entry 1LRZ, 
determined by (26). 
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FemX 
IgYs produced against recombinant FemX-His6 were collected at different time points 
of immunisation and tested for specific recognition of FemX-His6 (performed by S. Rohrer, 
M. Peter). The best fractions were pooled and antigen-purified. As determined by 
comparison with recombinant FemA-His6 and FemB-His6, the antibodies recognised only 
FemX-His6. When comparing cell membrane fractions of strains BB308 (femA), UT342 
(femB), AS145 (femAB) and SR18 (conditional femX under the control of the xyl operator) 
grown in the presence of xylose (enhanced FemX production) or glucose (repressed FemX 
production) (325), FemX was detected strongest in SR18 grown with xylose. A distinct, but 
weaker band was visible also under repressed conditions, indicating that repression had not 
been complete. Fractionated cell preparations from BB270 (wt) showed that, similar as found 
for FemB, FemX could be isolated both from the cytoplasmic as well as membranous 
compartment. Apparently, with the methods used, the soluble proteins FemB and FemX 
were not completely separated from the membrane fraction, possibly because they associate 
with the membrane, e.g. by binding to their substrate or to membrane proteins.  
 
FemA 
For expression of the StrepTag II®-FemA fusion protein, a shuttle vector containing 
the above mentioned xyl operator region, was used (pMS13). Without induction, sufficient 
functional fusion protein as to restore methicillin resistance was produced in the mecA 
containing strain UK17 (femA) when pMS13 was transduced into it. StrepTag II®-FemA-
linked complementation was confirmed by allowing plasmid loss under non-selective growth 
conditions, whereby methicillin resistance (conferred by the functional FemA) as well as 
tetracycline resistance (mediated by the plasmid backbone) was lost. Therefore, the tagged 
FemA fusion protein was functional and no other unwanted chromosomal modification was 
responsible for complementation. Unfortunately, Western blot analyses with Streptavidin-
alkaline phosphatase (AP) comparing protein extracts from UK17, respectively UK17 
containing pMS13, did not identify a specific band of the expected size. Possibly, protein 
levels were too low, and StrepTag II®-FemA fusion protein needs to be induced. However, 
since the same regulatory element as for FemX was used in the same genetic background 
BB270 (see above), levels should be comparable. It could be that, despite appearances from 
the crystal structure of FemA, the N-term and the relatively small StrepTag II® were not 
accessible for Streptavidin-AP. Therefore, a linker region might be added and/or tagging at 
the C-term attempted. To reduce the background, blocking with egg white avidin, which is not 
recognised by Streptavidin, but can bind to biotinylated host proteins, should be tried.  
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9.2.   Altered protein levels in the hemB mutant 
  
The pattern of cytoplasmic protein fractions in the hemB mutant MS17 was strikingly 
different compared to wild type MB79 (Fig. 40D). Besides a prominent band at about 48 kDa, 
seen in both strains, strong bands appeared at approximately 40 and 85 kDa in MS17.  Two 
nearby migrating bands of 40 and 38 kDa most probably correspond to ornithine 
transcarbomylase (39 kDa) and lactate dehydrogenase (37 kDa), shown to be strongly up-
regulated in SCVs (205, 247). The band of 85 kDa might correspond to pyruvate-formate-
lyase (85 kDa) or the ATP-dependent Clp protease chain ClpL (81 kDa), cytoplasmic 
proteins found to be produced in large amounts in a COL hemB mutant (205). 
 
9.3.   Monitoring of strains MB79 and MS17 during 7 days 
 
Bacteria grown in batch culture for several days pass through five distinct phases. 
During exponential phase, which follows an initial lag phase, the population grows rapidly. 
Carbohydrates initially serve as the primary carbon and energy source but are quickly spent, 
and other nutrients, including peptides, amino acids, nucleic acids, nucleotides, and fatty 
acids, are utilized to sustain growth. As these remaining nutrients are depleted, the 
population enters stationary phase, during which little change is observed in the number of 
viable cells in the culture for 2 to 3 days. As the culture enters death phase, cell viability 
abruptly declines and approximately 99% of the cells die. Finally, during long-term stationary 
phase, there is a long period of slow decline in the remaining viable cell population (103).  
In order to characterise the two strains MB79 and MS17 in terms of fitness and 
survival capacity over prolonged growth, as well as to find out whether the agr locus can be 
activated in the hemB mutant irrespective of low cell densities, bacteria were monitored 
during 7 days. Growth, colony forming units (cfu), luciferase activity, sigB and agr 
transcription were analysed. Contrary to the above described study of Newman and its hemB 
mutant, bacterial cultures were started with unwashed overnight cells and an OD600 of 0.01.  
 
Gene expression 
RNA from wild-type cells grown for more than three days seemed to degrade more 
easily, as determined from analytical agarose gels; RNA from the hemB mutant looked more 
stable (Fig. 51). Therefore, RNA from days 2-6 was blotted onto membranes by the use of a 
BIO DOT SF apparatus (BioRad). This method does not allow differentiating between 
overlapping transcripts of one gene, but made it possible to detect mRNA even in its 
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degraded form. To determine the amount of RNA blotted, aliquots were hybridised with DIG-
labelled 16S rRNA probes.  
 
 
 
 
 
Fig. 51. RNA integrity of strains MB79 (wt) and 
MS17(hemB). RNA sampled over seven days was 
isolated as described in Materials and Methods. 
3 µg were separated on a 1.5 % agarose-MOPS 
gel. The MB79 sample of day 6 is missing. 
 
Interestingly, transcription of agr and sigB was strongly reduced in MB79 on day 4 
(81 h); in MS17 it was slightly reduced on day 3 (61 h); thereafter transcription increased 
again (Fig. 52). Luciferase activity decreased rapidly in MB79 to levels similar as found in 
MS17, in agreement with the trend observed during stationary phase described earlier for 
MB79 (Fig. 40).  
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Fig. 52. Gene expression of strains MB79 (wt) and 
MS17 (hemB) during seven days. A Growth as 
determined by measuring OD600 (MB79, diamonds; 
MS17, triangles) and luciferase activity (circles). A 
different luciferase substrate batch had been used 
than in Fig. 40, giving maximal RLUs during the first 
day (not shown) of 9179 (MB79 ) and 2603 (MS17). 
B agr and fnbB expression. C sigB expression, 
stemming from another growth curve which was 
sampled differently and only monitored during 
127 hours. Samples were taken every 24 hours, 
prepared as described in Materials and Methods 
and transferred onto a nylon membrane by slot 
blotting. Bacteria were grown as described in 
Fig. 36A and B; data shown here under A and B are 
the same and originate from that growth curve.  
 
A fluctuating on/off gene expression might be explained by adaptation of a few 
bacteria during the stationary phase, where depletion of nutrients and pH increase of the 
medium are the major adverse factors. After reduction of the initial bacterial population in 
death phase, a new generation of bacteria might then be able to grow up, going through an 
entire growth cycle again with its corresponding characteristic gene expression. Why 
luciferase activity does not resume, remains to be determined.  
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9.4.    Gene expression in clinical SCV isolates 
 
Gene expression of the global regulators agr, sar, sigB and the virulence 
determinants spa and hla was analysed in two clinical menadione-auxotrophic SCVs and 
compared to their isogenic wild-type parents. Bacterial cultures were started with unwashed 
overnight cells and an OD600 of 0.01, explaining the lag of approximately 5 hours before 
SCVs started growing. In the wild-type strains, representative samples of exponential and 
post-exponential phase were taken.  For SCVs, a sample at OD600 = 0.1 and at the exit of 
exponential phase was taken. Therefore, the expression profiles could not be compared 
between parent and SCVs, but roughly reflected the time course of gene expression. 
 
Transcription of the analysed genes corresponded in the wild-type strain to what was 
expected; agr, spa and hla transcription started after the exponential phase (Fig. 53). 
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spa transcripts differed in size in 
these two genetic backgrounds, 
exemplifying the heterogeneity of this 
gene (53).  All sar transcripts were present 
early in growth (corresponding to hour 2 of 
MB79), thereafter sarB and sarA 
transcripts decreased. Only the 1.6 kb 
P3-sigB mRNA of the sigB operon was 
analysed, which in both parent strains was 
stronger in exponential phase. It is well 
possible that this transcript strongly 
fluctuates, for which the second time point 
might have missed the increase observed 
in MB79.  
 
Fig. 53. Gene expression in two clinical SCV 
isolates and their isogenic wild-type parents. RNA 
sampling for wild-type bacteria (I: A22616/5, 
diamonds; II: OM1a, squares) was performed at 
mid- and post-exponential growth phase, whereas 
SCVs (I: A22616/3, triangles; II: OM1b, crosses) 
were sampled at early and post-exponential phase 
(indicated by dark fillings). Ethidium-bromide stained 
16S rRNA is shown as an indication of RNA loading. 
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In the SCVs partly varying profiles were observed. In both strains spa and hla were 
strongly reduced or absent. While agr was not at all transcribed in the SCV OM1b, similar to 
the hemB mutant MS17, in the SCV A22616/3 agr was expressed. Surprisingly, RNAII was 
present very early in growth, triggering RNAIII transcription earlier than in the parent strain 
A22616/5. In both SCVs, the 1.6 kb P3-sigB mRNA was weaker than in the corresponding 
parent strains and reduced to the first time point of sampling. However, as seen for the 
stationary phase of MS17, low sigB transcription does not necessarily equal low SigB 
activity. At least in the SCV A22616/3, expression of the SigB-dependent sarC transcript 
seemed to be induced, suggesting that SigB might play a role in a subgroup of clinical SCVs.   
As seen for OM1b, reversion to wild-type phenotype can occur during cultivation of clinical 
SCVs. While the expression profile of OM1b still corresponded at the two time points 
analysed to the one of an SCV, the culture might have already been a mixture of SCVs and 
wild-type strains.  
 
Approach on Resistance Strategies in S. aureus 112 Appendix 
 
Dissertation Maria M. Senn 
9.5.   Abbreviations 
 
aa   amino acid(s) 
AIP  auto-inducing peptide 
Am  amber (UAG stop codon) 
Ap  ampicillin 
AP   alkaline phosphatase 
ATCC   American Type Culture Collection, Manassas, Virginia 
BHI   brain heart infusion 
bp   base pairs 
cfu  colony forming units 
DIG   digoxigenin 
ECM  extracellular matrix 
Emr/s   erythromycin resistant/sensitive 
fwd   forward primer 
His6-Tag  hexahistidine tag 
HRP  horse radish peroxidase  
ICAM   intercellular adhesion molecules 
IL  interleukin 
IPTG   isopropyl-β-D-thiogalactopyranoside 
ir  intermediate resistant 
IS   insertion sequence  
Kmr/s   kanamycin resistant/sensitive 
LB   Luria-Bertani (medium) 
Mcr/s    methicillin resistant/sensitive  
MCS   multiple cloning site 
mec   methicillin resistance determinant 
MH  Müller-Hinton 
MIC   minimal inhibitory concentration 
MLS  macrolide, lincosamide, streptogramin 
MOPS  morpholinepropanesulfonic acid 
MRSA  methicillin-resistant Staphylococcus aureus 
MS   mass spectrometry 
Mw   molecular weight 
NCCLS  National Council on Clinical Laboratory Standards (USA) 
NCTC   National Collection of Type Cultures 
Ni-NTA  Ni2+-nitrilotetraacetate 
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nt   nucleotides 
OD   optical density 
ORF   open reading frame 
ori   origin of replication 
P  promoter 
PFGE   pulsed field gel electrophoresis 
PFT   platelet-fibrin thrombi  
PMA  phosphomolybdic acid 
PMN  polymorphonuclear leukocyte 
PMSF   phenylmethylsulfonylfluoride 
PVDF  polyvinylidene difluoride 
RBS   ribosomal binding site 
rev   reverse primer 
RNAP   RNA polymerase core enzyme 
rpm   revolutions per minute 
RT   room temperature 
SCCmec  staphylococcal cassette chromosome mec 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
SEM  scanning electron microscopy 
SXT  trimethoprim-sulfamethoxazole 
TEM  transmission electron microscopy 
TCA  trichloroacetic acid 
Tcr/s    tetracycline resistant/sensitive 
Tn   transposon 
TLC  thin layer chromatography 
TNF  tumor necrosis factor 
TSST  toxic shock syndrome toxin  
U   unit of enzyme activity 
VCAM  vascular-cell adhesion molecules  
wt   wild type 
xylRPO  xylose regulon 
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Individual strains of Staphylococcus aureus have different capacities to become internalized by osteoblasts.
Here we report that the levels of B expressed by S. aureus correlate with the capacity of this bacterium to be
internalized by osteoblasts. However, B is not essential for internalization and does not necessarily account
for the differences in the capacities of strains to be internalized.
Staphylococcus aureus is an important human pathogen that
causes a range of infections, including those of bone. S. aureus
bone infections can be extremely difficult to treat, requiring
prolonged antibiotic treatment and surgical intervention (18).
We, and others, have shown previously that S. aureus is inter-
nalized by the bone-forming cells, osteoblasts (10, 14, 15, 19).
The capacity of S. aureus to be internalized by osteoblasts has
been proposed as an explanation for the recurrent nature of,
and the difficulty in treating, bone infections with this organ-
ism.
We have previously shown that osteoblasts employ a recep-
tor-mediated pathway in the uptake of S. aureus (15) and that
the expression of fibronectin binding proteins (FnBPs) by the
bacterium is essential to the process of internalization (1).
However, the capacities of different isolates of S. aureus to be
internalized by osteoblasts varied and could not be accounted
for by differences in the levels of expression of FnBPs by these
strains. In fact, S. aureus strain LS-1, which expressed lower
levels of FnBPs, was internalized to a greater extent than strain
8325-4 (1). Although the mechanism underlying the differences
in the capacities of these two strains to be internalized is
unknown, it is interesting that strain 8235-4 is a derivative of
NCTC8325, which is a natural rsbU mutant (13, 17).
In Bacillus subtilis, a network of protein-protein interactions
regulates the activity of the alternative sigma factor, B, post-
translationally. One of the proteins in this network, RsbU, is
essential for the activation of B. It has recently been shown
that B activity in S. aureus also depends on RsbU (13). De-
rivatives of S. aureus NCTC8325 have an 11-bp deletion in
rsbU, resulting in the introduction of a stop codon into this
gene, and hence these strains are essentially deficient in B
activity.
In many bacteria the alternative sigma factors of RNA poly-
merase are important in cell adaptation to environmental
stress (20). Association of B with the core RNA polymerase
results in the recognition of a specific subset of promoters and
to the initiation of transcription of their genes. To date only
one alternative sigma factor has been identified in S. aureus,
B. Although B has primarily been associated with responses
to environmental stress, it has been shown that expression of
the global virulence regulator SarA is influenced by B in S.
aureus (8, 9, 12, 17), and it has been suggested that B func-
tions as a global regulator of virulence genes in this bacterium
(16). It has recently been demonstrated that B expression
influences transcription of both the sar and agr loci, and it has
been suggested that B might prolong the production of cell
surface proteins such as the FnBPs, while preventing upregu-
lation of secreted exoproteins (4).
Given the apparent importance of B in the regulation of
virulence genes in S. aureus, we have examined the hypothesis
that B activity may influence the capacity of S. aureus to be
internalized by osteoblasts and thus account for our previous
observation of strain-dependent differences in this capacity (1).
The bacterial strains used in this study are listed in Table 1.
Strain BB1591 was obtained by phage 80-mediated transduc-
tion of (rsbUVWsigB)::ermB from IK181 (16) into strain LS-1,
selecting for erythromycin resistance. Strain MB258 was ob-
tained by transduction of the reporter construct asp23p::
pBTasp23p-luc from MB61 (13) into strain LS-1, selecting for
tetracycline resistance. The levels of B activity in S. aureus
strains were analyzed during growth by using an asp23 reporter
gene system as previously described (13). S. aureus strain
BB255 is our laboratory stock of NCTC8325 and carries a
mutation in rsbU5. Table 2 shows that the MB33 reporter
strain of BB255 expressed very low levels of B activity.
Complementation of this strain with an intact rsbU allele from
strain COL, as in strain GP268, resulted in expression of sig-
nificant levels of B activity, as indicated by the reporter strain
MB49 (Table 2). The level of B activity in MB49 is similar to
that found in other RsbU strains of S. aureus (13). Replace-
ment of the B operon in S. aureus strain BB255 with an
erythromycin cassette, as in strain IK181, resulted in no ex-
pression of B activity as shown by the reporter strain MB90
(Table 2). S. aureus strain MB138, BB255 with a point muta-
tion in the anti-sigma factor rsbW, produced high levels of B
activity (Table 2). S. aureus strain LS-1, represented by strain
MB258, produced levels of B activity which were similar to
those of strain GP268, as indicated by the reporter strain
* Corresponding author. Mailing address: Cellular Microbiology
Research Group, Eastman Dental Institute, University College Lon-
don, 256 Gray’s Inn Rd., London WC1X 8LD, United Kingdom.
Phone: 44(0)20 79151118. Fax: 44(0)20 79151127. E-mail: snair
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MB49 (Table 2). Replacement of the B operon in S. aureus
LS-1 with an erythromycin cassette, as in strain BB1591, led to
a complete loss of B activity as indicated by the reporter strain
MB259 (Table 2).
The capacity of S. aureus strains to be internalized by the
osteoblastic cell line MG63 was determined as previously de-
scribed (1) with the modification that overnight cultures of
bacteria were diluted 1:20 in 10 ml of fresh brain heart infusion
and grown to an optical density at 600 nm of approximately 1
before use. S. aureus strain BB255 was internalized by osteo-
blasts as shown in Fig. 1. Strain GP268 (BB255 rsbU) had a
twofold-greater capacity to be internalized by osteoblasts than
did BB255 (Fig. 1). The capacity of strain IK181 (BB255 rs-
bUVWsigB) to be internalized by osteoblasts was slightly lower
than that of strain BB255, although the difference was not
statistically significant (Fig. 1). S. aureus strain MB138 (BB255
rsbW) had a 10-fold-greater capacity to become internalized by
osteoblasts than did strain BB255 (Fig. 1). To determine if B
activity had an effect on the ability of S. aureus to grow and/or
survive within osteoblasts, cocultures were extended for a pe-
riod of up to 6 h as previously described (1). There was no
significant difference in the percentages of the natural rsbU
mutant BB255 and its isogenic mutants GP268 and MB138
recovered, at hourly intervals up to 6 h, from the number
recovered after 2 h (data not shown).
It has previously been shown that S. aureus strain LS-1 has a
10-fold-greater capacity to be internalized by osteoblasts than
does the NCTC8325 derivative 8325-4 (1). In this study we
compared the capacity of the NCTC8325 derivative BB255 to
be internalized by osteoblasts with that of LS-1. Figure 2 shows
that S. aureus strain LS-1 had a greater capacity to be inter-
nalized than did strain BB255 (sevenfold) or its rsbU deriva-
tive GP268. Strain BB1591, LS-1 in which the B operon had
FIG. 1. Capacity of S. aureus strain BB255 and its isogenic mutants
to be internalized by osteoblasts. The isogenic strains BB255 (rsbU),
GP268 (BB255 rsbU), IK181 (BB255 rsbUVWsigB), and MB138
(BB255 rsbW) were cocultured with osteoblasts at a multiplicity of
infection of 100:1. The figure shows the results from one representative
experiment of at least three, and the data are the means and standard
deviations of three replicate cultures.
FIG. 2. Comparison of the capacities of S. aureus strains BB255
and LS-1 and their respective isogenic mutants to be internalized
by osteoblasts. S. aureus strains BB255 (rsbU), GP268 (BB255
rsbUVWsigB), LS-1, and BB1591 (LS-1 rsbUVWsigB) were cocul-
tured with osteoblasts at a multiplicity of infection of 100:1. The figure
shows the results from one representative experiment of at least three,
and the data are the means and standard deviations of three replicate
cultures.
TABLE 1. Strains used in this study
Strain Relevant genotype and phenotypea Reference(s)or source
BB255 Laboratory stock of NCTC8325, rsbU 2
MB33 BB255 asp23 asp23p::pECasp23p-luc Emr 13
IK181 BB255 (rsbUVWsigB)::erm(B) Emr 16
MB61 RN4220 asp23 asp23p::pBTasp23p-luc Tcr 13
MB90 IK181 asp23 asp23p::pBTasp23p-luc Tcr
Emr
13
GP268 BB255 (rsbUVWsigB)-tetL Tcr 13
MB49 GP268 asp23 asp23 asp23p::pECasp23p-luc
Emr Tcr
13
MB138 MB33 rsbW7 Emr 3
LS-1 6, 7
MB258 LS-1-asp23 asp23p::pBTasp23p-luc Tcr This study
BB1591 LS-1 (rsbUVWsigB)::erm(B) Emr This study
MB259 BB1591 asp23 asp23p::pBTasp23p-luc Tcr
Emr
This study
a asp23 is the gene for the 23-kDa alkaline shock protein of S. aureus.
TABLE 2. Strain-dependent differences in B activity
Strain Relevant genotypea B activityb
MB33 BB255 34.0  3.00
MB49 BB255 rsbUVW sigB 301.3  23.8
MB90 BB255 rsbUVWsigB 0.62  0.10
MB138 BB255 rsbW7 1,084.0  46.5
MB258 LS1 rsbUVW sigB 256.6  17.2
MB259 LS1 rsbUVWsigB 0.31  0.14
a Detailed relevant genotypes and phenotypes are listed in Table 1.
b B transcriptional activity (relative light units) was determined from cells
grown to an optical density at 600 nm of 1.5 by measuring the luciferase activity
of Luc, the product of the luc reporter gene fused to the B-dependent
promoters of asp23. The values shown are the results of four independent assays.
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been deleted, had a twofold-lower capacity to be internalized
by osteoblasts than did its parent LS-1 (Fig. 2).
One mechanism by which the B operon may influence in-
ternalization of S. aureus by osteoblasts is alteration of the
expression of bacterial cell surface proteins such as the FnBPs.
To investigate this possibility, Northern blot analysis for fnbA
and clfA expression was performed. Bacterial overnight cul-
tures were diluted to an optical density at 600 nm of 0.1 and
grown at 37°C. RNA samples were prepared from cells col-
lected after 1 h and after 8 h. Specific, digoxigenin-labeled
fnbA and clfA probes were used for hybridizing 1-h and 8-h
RNA extracts (7 g), respectively. As can be seen in Fig. 3, the
levels of expression of fnbA and clfA were highest in strains
LS-1, MB138, GP268, and MB79, all of which possessed high
B activity. The capacities of S. aureus strains to bind to fi-
bronectin were determined as previously described (1). The
capacity of the rsbU mutant BB1591 to bind fibronectin was
reduced to 24%  6% (mean  standard deviation) of that of
the wild-type rsbU strain LS-1. Similarly the capacity of the
natural rsbU mutant BB255 to bind to fibronectin was only
35%  9% (mean  standard deviation) of that of the rsbU-
complemented strain GP268.
It has been postulated that the capacity of S. aureus to be
internalized by mammalian cells may contribute to the patho-
genicity of this organism. In particular this capacity could ac-
count for the persistent nature of some S. aureus infections.
The molecular details of the bacterial-host cell interactions
that result in uptake of S. aureus by host cells are beginning to
be elucidated. It has become evident that the FnBPs of S.
aureus play an important, if not essential, role in the uptake
process. However, we have previously reported that strain-
dependent differences in the capacity of S. aureus to be inter-
nalized by osteoblasts do not necessarily correlate with the
levels of expression of the FnBPs, suggesting that other factors
are also important in this process (1). Since we were aware that
one of the strains used in the previous study was an rsbU
mutant that was deficient in B expression, we have examined
the possibility that this may account for strain-dependent dif-
ferences in the capacity of S. aureus to be internalized by
osteoblasts.
Complementation of the natural rsbU mutant BB255 with a
functional rsbU gene resulted in the expression of significant
levels of B activity and increased the capacity of this strain to
be internalized by osteoblasts by twofold. Deletion of the en-
tire B operon in BB255 resulted in no expression of B ac-
tivity and had little effect on the capacity of this strain to be
internalized by osteoblasts. On the other hand, an isogenic
strain with a point mutation in rsbW, which resulted in the
expression of very high levels of B activity, had a significantly
increased capacity (5- to 10-fold) to be internalized by osteo-
blasts compared to that of the parental strain. Upon entry into
the osteoblast S. aureus is found within intracellular vacuoles,
as well as free within the cytosol. If the intracellular vacuoles
containing S. aureus fuse with the lysosomal system, then the
bacteria may be subject to environmental stresses such as low
pH. Since the alternative sigma factor, B, regulates the ex-
pression of general stress response genes (11, 12), it might
affect the ability of S. aureus to survive and/or grow within the
intracellular environment of the osteoblast. If this were the
case, the numbers of staphylococci recovered from within os-
teoblasts incubated with isogenic strains producing high levels
of B activity would not be a reflection of the capacity of these
bacteria to be internalized by osteoblasts. However, our studies
show that the levels of B expressed by isogenic mutants do not
affect the ability of S. aureus to survive and/or grow within the
intracellular environment of the osteoblasts. These data taken
together clearly demonstrate that the level of B activity ex-
pressed by S. aureus affects the capacity of this bacterium to be
internalized by osteoblasts.
Given that the level of expression of B activity in S. aureus
affects the capacity of this bacterium to be internalized by
osteoblasts, it could account for strain-dependent differences
in this capacity. Our previous studies and data presented
herein show that S. aureus strain LS-1 has a much higher
capacity (7- to 10-fold) to be internalized by osteoblasts than
do the NCTC8325 derivatives 8325-4 (1) and BB255. S. aureus
strain LS-1 also produces significant amounts of B activity in
comparison to the NCTC8325 derivatives. In fact the levels of
B produced by LS-1 are equivalent to those produced by
BB255 complemented with an intact rsbU gene as in GP268.
However LS-1 has a three- to fourfold-higher capacity to be
internalized by osteoblasts than does strain GP268. Deletion of
the B operon in LS-1 resulted in a complete loss of B activity
but only halved its capacity to be internalized by osteoblasts.
These data demonstrate that, while B activity affects the ca-
pacity of S. aureus to be internalized by osteoblasts, it cannot
fully account for the strain-dependent differences that have
previously been reported (1). Thus, other as-yet-undefined fac-
tors must also play a role in the strain-dependent differences in
the capacity of S. aureus to be internalized by osteoblasts. In
the present study we have also shown that the B operon
affects the level of expression of two microbial surface compo-
nents recognizing adhesive matrix molecules (MSCRAMMs),
fnbA and clfA. Furthermore we have found that the capacities
of S. aureus strains to bind to fibronectin correlate with their
B activities. We have previously reported that at least two
MSCRAMMs, the FnBPs A and B, play an important role in
the process of internalization of S. aureus by osteoblasts. This
suggests that one possible mechanism by which the B regulon
may influence the internalization of S. aureus by osteoblasts is
through alteration in the level of expression of MSCRAMMs.
FIG. 3. Northern blot analyses of fnbA and clfA expression by S.
aureus strains LS1, BB1591 (LS1 rsbUVWsigB), MB138 (BB255
rsbW), IK181 (BB255 rsbUVWsigB), BB255 (rsbU), and GP268 (BB255
rsbU).
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Summary
 
Staphylococcus aureus
 
 peptidoglycan is cross-linked
via a characteristic pentaglycine interpeptide bridge.
Genetic analysis had identified three peptidyltrans-
ferases, FemA, FemB and FemX, to catalyse the for-
mation of the interpeptide bridge, using glycyl t-RNA
as Gly donor. To analyse the pentaglycine bridge for-
mation 
 
in vitro
 
, we purified the potential substrates
for FemA, FemB and FemX, UDP-MurNAc-pentapep-
tide, lipid I and lipid II and the staphylococcal t-RNA
pool, as well as His-tagged Gly-tRNA-synthetase and
His-tagged FemA, FemB and FemX. We found that
FemX used lipid II exclusively as acceptor for the first
Gly residue. Addition of Gly 2,3 and of Gly 4,5 was
catalysed by FemA and FemB, respectively, and both
enzymes were specific for lipid II-Gly
 
1
 
 and lipid II-Gly
 
3
 
as acceptors. None of the FemABX enzymes required
the presence of one or two of the other Fem proteins
for activity; rather, bridge formation was delayed in
the 
 
in vitro
 
 system when all three enzymes were
present. The 
 
in vitro
 
 assembly system described here
will enable detailed analysis of late, membrane-asso-
ciated steps of 
 
S. aureus
 
 peptidoglycan biosynthesis.
Introduction
 
The 
 
Staphylococcus aureus
 
 peptidoglycan comprises
about 50% of the entire cell wall and forms a multilayered,
highly cross-linked sacculus, which protects the bacterium
from osmotic pressure and determines its shape. It con-
sists of 20 or more layers of linear glycan chains with
alternating units of 
 
N
 
-acetylglucosamine (GlcNAc) and 
 
N
 
-
acetylmuramic acid (MurNAc). The carboxylic group of 
 
N
 
-
acetylmuramic acid is substituted with the stem pentapep-
tide 
 
L
 
-Ala-
 
D
 
-iGlu-
 
L
 
-Lys-
 
D
 
-Ala-
 
D
 
-Ala. A pentaglycine inter-
peptide, branching off the 
 
e
 
-amino group of the 
 
L
 
-Lys of
the stem peptide, connects one peptidoglycan chain to the
 
D
 
-Ala in position 4 of a neighbouring chain (Fig. 1).
The flexible interpeptide allows a high, three-dimen-
sional cross-linking of the peptidoglycan, characteristic of
the staphylococcal cell wall. It also acts as attachment site
for various cell wall-sorted proteins, which are important
in infection and virulence of this pathogen (Perry 
 
et al
 
.,
2002; Roche 
 
et al
 
., 2003). Moreover, the interpeptide is
essential for the full expression of methicillin resistance in
methicillin-resistant 
 
S. aureus
 
 (MRSA). Shortening of the
pentaglycine chain impairs growth, leading to aberrant
septum formation and lowered methicillin resistance levels
(Maidhof 
 
et al
 
., 1991). The interpeptide is essential for 
 
S.
aureus
 
; survival with a shortened bridge reduced to only
one glycine requires as yet uncharacterized compensa-
tory mutations (Ling and Berger-Bächi, 1998).
Extensive genetic analysis and characterization of
mutant cell walls suggested that the pentaglycine inter-
peptide is synthesized in a sequential fashion by proteins
belonging to the new FemABX family of non-ribosomal
peptidyltransferases (Hegde and Shrader, 2001; Rohrer
and Berger-Bächi, 2003a). FemX, encoded by the essen-
tial gene 
 
fmhB
 
, was found to be essential for incorporation
of the first glycine to the stem peptide (Rohrer 
 
et al
 
.,
1999). The second factor, FemA, was proposed to catal-
yse the addition of the second and third glycine (Maidhof
 
et al
 
., 1991; Stranden 
 
et al
 
., 1997), whereas FemB is sup-
posed to add glycines four and five (Fig. 1) (Henze 
 
et al
 
.,
1993). The peptidyltransferases use glycyl-tRNA as donor
in a ribosome-independent reaction (Kamiryo and Matsu-
hashi, 1972).
Biochemical analysis of the staphylococcal FemABX
system has so far been hampered by the fact that the
presumed substrates for glycine addition, the lipid-bound
cell wall precursors lipid I and lipid II, could not be made
available.
Homologues of FemA, FemB and FemX have been
identified in all Gram-positive bacteria, which produce a
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branched-chain peptidoglycan with either glycine and/or
 
L
 
-amino acids in the interpeptide (Rohrer and Berger-
Bächi, 2003b). Interestingly, the pneumococcal MurMN,
FibAB respectively (Filipe 
 
et al
 
., 2000; Weber 
 
et al
 
.,
2000), were found to be associated in that species with
penicillin resistance as well. Staphylococcal strains pro-
ducing glycyl-glycine endopeptidases, such as lysos-
taphin (Thumm and Götz, 1997) or ALE1 (Sugai 
 
et al
 
.,
1997), protect their cell walls by FemABX-like immunity
factors, termed Lif or Epr, which insert serine in place of
glycine at positions 3 and 5 in the interpeptide (Ehlert
 
et al
 
., 2000). Lif was shown to be able to complement a
 
femB
 
 mutant in 
 
S. aureus
 
 (Tschierske 
 
et al
 
., 1997).
Pentapeptide modification occurs during cell wall bio-
synthesis at the inner face of the cytoplasmic membrane
before the monomeric peptidoglycan unit is translocated
across the membrane and assembled into the growing
peptidoglycan network. The soluble FemX of 
 
Lactobacillus
viridescens
 
 (Hegde and Shrader, 2001) and the 
 
Entero-
coccus faecalis
 
 BppA1 and BppA2 (Bouhss 
 
et al
 
., 2001)
have been shown to use UDP-MurNAc-pentapeptide as
substrate for the synthesis of branched peptidoglycan pre-
cursors. The inability to add the first glycine to this soluble
substrate by the staphylococcal FemX (Hegde and
Shrader, 2001) suggests that FemABX peptidyltrans-
ferases of 
 
S. aureus
 
 may, in contrast to the previous
systems, be membrane associated, and the acceptor mol-
ecule may be one of the lipid-bound cell wall precursors,
lipid I or lipid II. Lipid I (undecaprenylphosphate-MurNAc-
pentapeptide) is formed in the first lipid-linked step of cell
wall synthesis by MraY, which transfers the soluble UDP-
MurNAc-pentapeptide to the lipid carrier undecapre-
nylphosphate (C55-P). The translocase MurG subse-
quently links UDP-activated 
 
N
 
-acetyl-glucosamine (UDP-
GlucNAc) to the muramoyl moiety of lipid I, thus yielding
lipid II (undecaprenylphosphate-GlucNAc-MurNAc-pen-
tapeptide) (van Heijenoort and Gutmann, 2000).
In order to analyse the individual steps of interpeptide
formation in 
 
S. aureus
 
 and to identify the correct sub-
strates, we purified lipid I and lipid II, the essential
enzymes FemA, FemB, FemX, the glycyl-tRNA syn-
thetase and completely reconstituted 
 
in vitro
 
 the mem-
brane-bound steps of staphylococcal cell wall synthesis.
We found the Fem peptidyltransferases to be active
individually and highly substrate specific and identified
lipid II as the only substrate of the 
 
S. aureus
 
peptidyltransferases.
 
Results
 
Preparation of lipid I and lipid II – setup of the 
assays and detection system
 
Membrane preparations possess enzymatic activity (MraY
and MurG) for the formation of cell wall precursors (van
Heijenoort 
 
et al.
 
, 1978), and membranes of 
 
S. aureus
 
have been reported to contain Fem protein activities and
to synthesize glycine-labelled lipid intermediates when
complemented with soluble cellular fraction (Matsuhashi
 
et al
 
., 1967). As shown with 
 
Staphylococcus simulans
 
 22
membranes (Fig. 2), the lipid carrier molecule (C55-P)
remained unmodified in the absence of UDP-activated
precursors. Upon addition of UDP-MurNAc-PP, C55-P
was transferred into lipid I; the conversion was incomplete
because of the reversibility of the MraY-catalysed reaction
(Pless and Neuhaus, 1973). When UDP-GlcNAc was also
 
Fig. 2.
 
TLC of [U-
 
14
 
C]-glycine-labelled lipid intermediates. Undeca-
prenylphosphate (10 nmol; C55-P) was incubated 
 
in vitro
 
 with mem-
branes (360 
 
m
 
g of protein) of 
 
S. simulans
 
 22 for 60 min in the 
presence of 50 nmol of glycine lacking the UDP-activated precursors 
(lane 1). Lipid I was synthesized upon addition of UDP-MurNAc-PP 
(lane 2) and lipid II by addition of UDP-MurNAc-PP and UDP-GlcNAc 
(lane 3). Two glycine-labelled lipid intermediates migrating more 
slowly than lipid I and lipid II were separated after incubation with 
UDP-MurNAc-PP and UDP-GlcNAc and addition of supernatant I 
(330 
 
m
 
g of protein) (lane 4).
 
Fig. 1.
 
Structure of 
 
S. aureus
 
 and 
 
S. simulans
 
 22 interpeptide bridge.
e
e
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present, most of the lipid I was converted to lipid II, which
migrates somewhat more slowly. Using lipid II from a
preparative batch, its position on the chromatogram was
verified, and its molecular mass was confirmed by mass
spectroscopy (Fig. 3.1).
When radiolabelled glycine was added to the assay, no
further bands were observed (Fig. 2), and both bands
representing lipid I and lipid II did not contain radiolabel.
In contrast, when the assay mixture was supplemented
with the soluble cytosolic fraction obtained after low-speed
centrifugation (supernatant I), two additional bands
occurred with Rf-values lower than that of lipid II (Fig. 2,
lane 4). Both bands were radiolabelled, strongly suggest-
ing that they represent lipid I/lipid II intermediates with
different segments of the glycine interpeptide bridge
attached. Moreover, from the intensities of the various
bands obtained after phosphomolybdic acid (PMA) stain-
ing, it appeared that lipid II was the major substrate for
the Fem-catalysed reaction, as it was strongly reduced on
the chromatogram in favour of the two newly formed
glycine-containing intermediates.
In vitro
 
 activity of FemX, FemA and FemB
 
Although the above system, based on the use of soluble
cytosolic fractions, was sufficient to determine that all
factors necessary for interpeptide formation (i.e. the Fem
factors, glycyl-tRNA-synthetase and tRNA) were present,
 
Fig. 3.
 
 1. ES-MS spectra were obtained with an API-I single quadrupole instrument (PE-SCIEX) running in a positive mode. Peaks at 
 
m/z
 
 1878 
correspond to lipid II (A), at 
 
m/z
 
 1935 to lipid II-Gly
 
1
 
 (B), at 
 
m/z
 
 2049 to lipid II-Gly
 
3
 
 (C) and at 
 
m/z
 
 2163 to lipid II-Gly
 
5
 
 (D). Other peaks correspond 
to the non-covalent sodium or potassium ion adducts.
2. With prolonged incubation time (90 min) and elevated enzyme concentrations (molar ratio of enzyme:lipid II, 1:50), lipid II-Gly
 
2
 
 (B) at 
 
m/z
 
 1992 
and lipid II-Gly
 
4
 
 (C) at 
 
m/z
 
 2106 were detected in addition to the correct products.
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it did not allow for a detailed step-by-step analysis of
bridge formation. In particular, the presence of MurG
activity in the supernatant prevented unequivocal deter-
mination of whether lipid I or lipid II was the substrate for
FemX. High-speed ultracentrifugation (supernatant II)
clearly reduced MurG activity; however, the overall reac-
tion was strongly reduced, presumably because of simul-
taneously removing the Fem enzymes and/or glycyl-
tRNA-synthetase and tRNAs (data not shown).
We therefore His-tagged and purified FemX, FemA,
FemB and the glycyl-tRNA-synthetase of 
 
S. aureus
 
 NCTC
8325 (Fig. 4). In addition, total tRNAs were isolated from
both 
 
S. simulans
 
 22 and 
 
S. aureus
 
. Replacing the super-
natant by recombinant FemX, FemA and FemB, glycyl-
tRNA-synthetase and purified tRNAs resulted in the for-
mation of glycine-labelled lipid intermediates (Fig. 5).
Under the conditions chosen, i.e. with an excess of [
 
14
 
C]-
glycine and a defined amount of 5 nmol of lipid II in the
system, the availability of dedicated glycyl-tRNA was rate
limiting. At a concentration of 25 
 
m
 
g of total tRNA per
assay volume, the maximum amount of pentaglycine
bridge formation was obtained. There was no difference
observed using purified tRNAs from 
 
S. simulans
 
 22 or 
 
S.
aureus
 
. Assuming that all lipid II molecules were available,
 
Fig. 4. 10
 
% SDS–PAGE of recombinant proteins. His-tagged enzymes were purified on a Ni-NTA column as described in 
 
Experimental 
procedures
 
. Three 500 
 
m
 
l fractions were collected, to which an equal amount of 100% glycerol was added for preservation at 
 
-
 
20
 
∞
 
C. Gly-tRNA-
synthetase fractions (10 
 
m
 
l) and 1 
 
m
 
l of FemABX fractions were loaded on to the gel. Prestained broad-range standard marker from Bio-Rad was 
used to estimate molecular masses. Fractions 1–3 of Gly-tRNA-synthetase (A). Fractions 1–3 of FemX (B). Fractions 1–3 of FemA (C). Fractions 
1–3 of FemB (D). The following fractions were selected for further experiments: A2 (Gly-tRNA-synthetase); B2 (FemX); C1 and C2 (FemA); D1 
and D2 (FemB).
 
Fig. 5.
 
Influence of increasing tRNA concen-
trations on the FemXAB reaction. Purified lipid 
II was incubated with [U-
 
14
 
C]-glycine in the 
presence of FemXAB and recombinant tRNA 
synthetase with increasing concentrations of 
purified tRNAs. Reaction products were sepa-
rated by TLC, and incorporation of [U-
 
14
 
C]-
glycine was determined by scintillation 
counting.
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a 5:1 ratio of glycine to lipid II was expected in the final
product. As indicated in Fig. 5, the maximum amount of
glycine incorporation obtained in the 
 
in vitro
 
 system cor-
responded to an average of 4.3 mol of glycine incorpo-
rated per mol of lipid II.
 
The cell wall precursor lipid II is the only substrate of 
FemX
 
Identification of the substrates of the FemX- and subse-
quently of the FemA- and FemB-catalysed reactions was
achieved by incubation of lipid I or lipid II (Fig. 6) in the
presence of glycyl-tRNA-synthetase and tRNAs, with
FemX, FemX and FemA and FemX, FemA and FemB.
Analysis of the reaction products by thin-layer chromatog-
raphy (TLC) after incubation of lipid I with the Fem proteins
identified lipid I as a poor substrate for FemX, and no
further incorporation of glycine was detected after incuba-
tion with additional FemA and FemB (Fig. 6B).
In contrast, incubation of lipid II resulted in the formation
of glycine lipid II intermediates migrating stepwise more
slowly in the TLC system upon addition of glycine to the
pentapeptide side-chain of lipid II (Fig. 6A). The molar
ratio of radiolabelled glycine to lipid intermediate indicated
that FemX (glycine:lipid II, 1.3:1) added the first glycine to
lipid II. The glycine:lipid incorporation ratios for the FemXA
and the FemABX reactions were 2.76:1 and 4.17:1 as
expected after the formation of lipid II-Gly
 
3 and -Gly5
(Fig. 6B). Lipid II itself, i.e. without the first glycine added
by FemX, was not used by FemA and Fem B, either on
their own or combined. We only observed background Gly
incorporation levels in the range of 0.02–0.2 Gly incorpo-
rated per lipid II molecule. Although the incorporation lev-
els were somehow lower than expected theoretically,
especially for the FemABX reaction, analysis of the prod-
ucts by mass spectrometry confirmed the formation of
lipid II-Gly1 by FemX, lipid II-Gly3 by FemXA and lipid II-
Gly5 by FemXAB (Fig. 3.1). It should be noted that deter-
mination of glycine incorporation ratios required, first,
extraction of radiolabelled intermediates from the synthe-
sis assay using n-butanol/pyridine-acetate, subsequent
TLC and, finally, counting of excised bands (see Experi-
mental procedures); this procedure is likely to cause some
loss of radiolabelled products and, obviously, the extrac-
tion yields decrease with increasing bridge length of the
products.
Lipid II with intermediate glycine contents (lipid II-Gly2
and lipid II-Gly4) was not detected under these conditions
(Fig. 3.1). However, when the assay conditions were
changed (90 min incubation and a lipid II:enzymes ratio
of 50:1), such products were detectable (Fig. 3.2).
Obviously, under the experimental conditions chosen,
i.e. lipid II in micellar form and in the presence of 0.8%
Triton X-100, FemX not only accepts lipid II as a substrate
but also lipid II-Gly1. Accordingly, after 90 min of incuba-
tion, the reaction products of FemXA contained lipid II-
Fig. 6. A. TLC of glycine-labelled lipid intermediates synthesized by recombinant FemX, FemA and FemB. Purified lipid II (lanes 1–3) and lipid 
I (lanes 4–6) were incubated with [U-14C]-glycine in the presence of recombinant tRNA-synthetase and purified tRNA with FemX (lanes 1 and 
4), FemX and FemA (lanes 2 and lane 5) and FemX, FemA and FemB (lanes 3 and 6).
B. [U-14C]-glycine:lipid ratio of the analysed glycine lipid intermediates. Mean values of five experiments are given.
680 T. Schneider et al.
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Gly3 and lipid II-Gly4 (Fig. 3.2). Obviously, FemA can also
accept lipid II-Gly2 as a substrate and then incorporate
two additional glycine residues.
As reported previously, UDP-MurNAc-PP is the sub-
strate for the soluble recombinant FemX proteins of Lac-
tobacillus viridescens and Enterococcus faecalis (Hegde
and Shrader, 2001; Bouhss et al., 2002). To exclude UDP-
MurNAc-PP as a substrate for the Fem proteins of S.
aureus, 5 nmol of lipid II was incubated with FemXAB,
glycyl-tRNA-synthetase and tRNAs in the presence of 5–
100 nmol of purified UDP-MurNAc-PP isolated from S.
simulans 22. Analysis of the reaction products revealed
that the addition of glycine to lipid II was not affected even
in the presence of a 20-fold molar excess of UDP-Mur-
NAc-PP. This competition experiment demonstrates that
the FemXAB enzymes of S. aureus catalyse the addition
of glycine to the pentapeptide side-chain only after the
formation of lipid II. This result is in good agreement with
the fact that UDP-MurNAc hexapeptides were detectable
in the cytoplasm of L. viridescens (Plapp and Strominger,
1970), but not in S. aureus (Stickgold and Neuhaus, 1967)
or in the staphylococcal strains used in this study (data
not shown).
Time course of the FemXAB reactions
The formation of the Gly-containing lipid II intermediates
was followed over time (Fig. 7). Initial Gly addition by
FemX was already completed after 5 min and resulted in
a glycine:lipid II ratio of 1.22:1(see above). In contrast, the
presence of FemA in the synthesis assay decreased the
formation of lipid II-Gly1 reaction products, indicating that,
in our in vitro system, the presence of FemA interferes
with Gly addition by FemX. The maximum level of the
FemXA reaction was reached after an incubation period
of 60 min with a final glycine:lipid II ratio of 3:1. An even
stronger effect was observed upon addition of FemB. The
FemX reaction was retarded further, and glycine lipid II
intermediates were not detected before 15 min of incuba-
tion. The synthesis was not completed within 90 min of
incubation.
Analysis of the individual Fem protein reactions
As the maximum catalytic activity of FemX was observed
in the absence of FemA and FemB (Fig. 7), we purified
the unlabelled FemX and FemA reaction products to study
the FemA and FemB reactions independently (Fig. 8).
Using the standard assay, comparable amounts of
labelled Gly per lipid were added to lipid II-Gly1 by FemA
alone (1.73:1) and by FemA when FemX was present
(1.90:1). Again, the observed incorporation was some-
what lower than the theoretically expected value of two
Gly per lipid II-Gly1 incorporated, as discussed above. This
result clearly demonstrates that FemA activity in vitro does
not depend on the presence of FemX. Neither FemX nor
FemB catalysed further addition of glycine to lipid II-Gly1,
proving the preference of FemX for lipid II and of FemB
for lipid II intermediates containing at least three Gly.
The overall incorporated radioactivity by FemB and
FemAB suggested that only one more Gly residue may
have been added to the lipid II-Gly3 (Fig. 8); however,
mass spectroscopy clearly showed that only lipid II-Gly5
occurred as a product (Fig. 3.1). This further indicates that
extraction yields from the synthesis assay decrease
strongly with interpeptide chain length (see also above).
Discussion
The FemABX peptidyltransferases are interesting drug
Fig. 7. Time dependency of the FemXAB reac-
tions. Purified lipid II was incubated with [U-
14C]-glycine in the presence of recombinant 
tRNA synthetase and tRNA with addition of 
FemX (circles), FemX and FemA (squares) and 
FemX, FemA and FemB (triangles); mean val-
ues of three experiments are given.
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targets as inhibition restores susceptibility towards methi-
cillin (Labischinski, 1992; Ling and Berger-Bächi, 1998).
Therefore, we established an in vitro system using purified
bactoprenol-bound and soluble cell wall precursors as
well as His-tagged enzymes to allow detailed analysis of
single steps of glycine addition. Additionally, we included
purified staphylococcal tRNAs and Gly-tRNA-synthetase
from S. aureus in the synthesis assay as the glycine
donors for interpeptide synthesis are non-proteinogenic
Gly-tRNAs (Matsuhashi et al., 1967). Interestingly, in the
genome of S. aureus, four or five different Gly-tRNAs are
present, two proteinogenic and three non-proteinogenic
(Green and Vold, 1993), leading to the hypothesis that
each Fem factor may use dedicated Gly-tRNAs, which
remain to be attributed. In spite of the specialization at the
tRNA level, S. aureus disposes of only one Gly-tRNA-
synthetase to charge both proteinogenic and cell wall-
associated Gly-tRNAs in an ATP-dependent fashion (Niy-
omporn et al., 1968). In contrast to earlier studies
(Kamiryo and Matsuhashi, 1972), we could not observe
glycine incorporation using tRNA-synthetase and tRNAs
isolated from Escherichia coli when used in combination
with S. aureus tRNAs or tRNA-synthetase respectively
(data not shown).
In the in vitro system, neither the soluble UDP-MurNAc-
pentapeptide nor lipid I was converted to glycine-labelled
precursors by the FemABX peptidyltransferases. Only the
complete lipid II molecule could serve as substrate for
FemX and the respective Gly additives subsequently for
FemA and FemB. Therefore, we may conclude that FemX
should recognize lipid II via the sugar moiety, i.e. GlcNAc-
MurNAc. By analogy, FemA and FemB may also recog-
nize lipid II via the disaccharide unit. This could be an
explanation for the reduced reaction rate of FemX in the
presence of FemA (see also below). In addition, structural
data for FemA obtained from X-ray analysis with a reso-
lution at 2.1 Å identified a putative, L-shaped binding
groove, which could accommodate the disaccharide unit
(Benson et al., 2002b).
The single steps of glycine addition by the Fem pro-
teins were analysed by incorporation of radiolabelled
glycine to lipid II. The substrate was completely con-
verted to lipid II-Gly1 by FemX within 5 min, which corre-
sponds to a turnover rate of 19 lipid II molecules per
FemX molecule min-1. (The ratio of FemX:lipid II in the
in vitro assay was ª1:100.) Such a turnover rate is in
the same order of magnitude as that calculated recently
for Gram-negative bacteria. Mengin-Lecreux and van
Heijenoort (1985) calculated that, in E. coli K-12, 24 dis-
accharide peptide units need to be transported per min
per bactoprenol carrier (3.5 ¥ 106 disaccharide peptide
units per cell; generation time 36 min; 50% turnover per
generation; about 2000 lipid II molecules per cell). It is
not known whether the turnover of lipid II in Gram-nega-
tive and Gram-positive bacteria is similar. The amount of
peptidoglycan per dry weight differs greatly with about
10% in Gram-negative and about 30–70% in Gram-posi-
tive bacteria. However, when compared with E. coli, the
number of lipid II molecules in staphylococci is 25 times
higher than that determined for E. coli (Somner and
Reynolds, 1990), leading to the assumption that synthe-
sis of the cell wall in Gram-positive bacteria depends on
the amount of lipid II rather than on an increased syn-
thesis rate.
A rate-limiting factor for the FemABX reaction in vitro
was the availability of glycine donor tRNAs. Although
increasing concentrations of tRNAs lead to increasing
amounts of incorporated glycine, the FemABX reaction
never reached the expected values of Gly5. Similarly,
amino acid analysis of peptidoglycan synthesized in vivo
revealed submaximal values of incorporated glycine,
reflecting a minor presence of Gly3 and Gly1 interpeptide
bridges (Stranden et al., 1997; Tschierske et al., 1997;
Roos et al., 1998; Ehlert et al., 2000a). In addition, syn-
thesis of a complete lipid II-Gly5 may be favoured in the
in vivo situation with ongoing translocation of the com-
pletely modified cell wall precursor to the outside of the
cell.
As confirmed by mass spectrometry, the in vitro FemX
product is lipid II-Gly1, demonstrating that FemX indeed
adds the first Gly to the pentapeptide side-chain. When
Fig. 8. Analysis of the FemA and FemB reaction using purified lipid 
II-Gly1 (grey columns) and lipid II-Gly3 (white columns). Purified FemX 
product (grey) and FemXA product (white) were incubated with [U-
14C]-glycine in the presence of recombinant tRNA-synthetase and 
purified tRNA with FemX (columns 1 and 5), FemX and FemA (col-
umn 2), FemA only (columns 3 and 6), FemA and FemB (column 7) 
and FemB only (columns 4 and 8); mean values of two experiments 
are given.
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lipid II was incubated with FemXA, only lipid II-Gly3 was
found but no lipid II-Gly2 (Fig. 3.1). This observation
agrees with the hypothesis that FemA adds two glycine
molecules per cycle, not releasing a lipid II-Gly2 product,
whereas FemX clearly adds only one Gly per cycle to the
lipid intermediates. The molecular basis for such a differ-
ence in the catalytic mechanism has not yet been
resolved.
The FemA protein presumably contains just one Gly-
tRNA binding site, which led Benson et al. (2002) to the
hypothesis that, after the addition of the first Gly, a sub-
sequent round of Gly-tRNA binding and transfer would
account for the addition of the second glycine. However,
recently, direct interactions of FemA–FemA, FemB–FemB
and FemA–FemB were detected using the bacterial two-
hybrid system. FemX did not show any interactions with
FemA or FemB. This rather suggested that FemX acts as
a monomer while FemA and FemB may act as
homodimers (Rohrer and Berger-Bächi, 2003b). Interest-
ingly, FemA and FemB were also found to interact with the
lysostaphin immunity factor Lif of S. simulans biovar sta-
phylolyticus, which was shown to substitute serine in posi-
tions 3 and 5 of the pentaglycine interpeptide chain in S.
aureus in co-operation with FemA or FemB (Thumm and
Götz, 1997; Ehlert et al., 2000). These data imply that
FemA and FemB probably function as homodimers in
such a way that both subunits are loaded with Gly-tRNA
to ensure sequential addition of both Gly to the growing
interpeptide bridge. Furthermore, addition of Ser at the
defined positions 3 and 5 upon interaction with FemA or
FemB leads to the assumption that recognition of the lipid-
bound substrate is mediated by the Fem peptidyltrans-
ferases, whereas Lif may not possess an appropriate
binding groove.
In this study, the FemX reaction was retarded upon
addition of FemA and further impaired when FemB was
also present. As described above, inhibition by protein–
protein interactions of FemX with FemA and/or FemB
seems unlikely. Rather, the retarded conversion of lipid
II by FemX in the presence of FemAB may be caused
by competitive, non-productive binding of lipid II by
FemA and FemB. Correspondingly, the non-productive
binding by FemX and FemB could delay the formation
of lipid II-Gly3, and binding by FemX and FemA the for-
mation of lipid II-Gly5 respectively. If so, FemAB must
recognize lipid II via the disaccharide unit regardless of
the amount of Gly added. However, the appropriate
number of Gly in the interpeptide bridge is clearly
required for FemAB to be active, i.e. for FemA at least
one and for FemB at least three Gly need to be
present.
Obviously, the enzymatic activity of an individual
FemXAB peptidyltransferase does not require the pres-
ence of a second species, and the formation of a stable
Fem–multienzyme complex is not necessary to achieve a
turnover rate in vitro that is close to the in vivo situation.
However, in vivo, production of byproducts as observed
during in vitro synthesis upon increased incubation time
and elevated enzyme concentration must be prevented,
and it seems reasonable to assume that the interpeptide
bridge formation is highly co-ordinated, tightly interlinked
with the other membrane-associated steps of cell wall
biosynthesis (Fig. 9). Possibly, the Fem proteins are tran-
siently associated with each other as well as with other
cell wall biosynthesis enzymes. Moreover, further compo-
nents with as yet unidentified functions may contribute to
co-ordinating the intracellular and extracellular processes
to ensure the proper formation of the vital bacterial cell
wall.
Experimental procedures
Chemicals and materials
All chemicals were of analytical grade or better. E. coli tRNA
and E. coli tRNA-synthetase, UDP-N-acetyl-glucosamine
(UDP-GlcNAc) were purchased from Sigma.
In vitro lipid I/lipid II synthesis and purification
Synthesis and purification was performed according to the
protocol elaborated by Brötz et al. (1995)  for [14C]-lipid II
with modifications by Breukink et al. (2003). In short, lipid II
was synthesized in vitro using membrane preparations of
Micrococcus flavus DSM 1790. Membranes were isolated
from lysozyme-treated cells by centrifugation (40 000 g),
washed twice in 50 mM Tris-HCl, 10 mM MgCl2, pH 7.5,
and stored under liquid nitrogen until use. The analytical
assay was performed in a total volume of 150 ml containing
400 mg of membrane protein, 10 nmol of undecapre-
nylphosphate, 100 nmol of UDP-N-acetylmuramic acid pen-
tapeptide (UDP-MurNAc-PP), 100 nmol of UDP-GlcNAc in
60 mM Tris-HCl, 5 mM MgCl2, pH 8, and 0.5% (w/v) Triton
X-100. UDP-MurNAc-PP was purified as described previ-
ously (Kohlrausch and Höltje, 1991). For purification of mil-
ligram quantities of lipid II, the analytical procedure was
scaled up by a factor of 250. Reaction mixtures were incu-
bated for 1 h at 30∞C, and lipids were extracted with the
same volume of n-butanol/6 M pyridine-acetate, pH 4.2.
Lipid I was synthesized as described for lipid II with the
omission of UDP-GlcNAc from the synthesis reaction. Puri-
fication of lipid I/lipid II was performed on a DEAE-cellulose
column (0.9 ¥ 25 cm, DEAE SS-Typ; Serva) and eluted in a
linear gradient from chloroform–methanol–water (2:3:1) to
chloroform–methanol-300 mM ammonium bicarbonate
(2:3:1). Lipid I- and lipid II-containing fractions were identi-
fied by TLC (silica plates, 60F254; Merck) using chloro-
form–methanol–water–ammonia (88:48:10:1) as the solvent
(Rick et al., 1998). Spots were visualized by PMA staining
reagent. The concentration of purified lipids was deter-
mined as inorganic phosphate after treatment with perchlo-
ric acid (Rouser et al., 1970).
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Preparation of membranes and supernatants from 
S. aureus NCTC 8325 and S. simulans 22 for the 
synthesis of lipid–glycine intermediates
Staphylococcus aureus NCTC 8325 and S. simulans 22
cells were grown in 1.2 l of TSB medium (Merck) at 37∞C to
an OD600 of 4–5, harvested by centrifugation (10 min,
8000 g) and washed once with 50 mM Tris-HCl buffer,
10 mM MgCl2, pH 7.5. Cells were resuspended in 20 ml of
the same buffer and lysed by grinding with glass beads
(diameter 0.1 mm, B. Braun; 20 ml of beads was added to
20 ml of cell suspension). After centrifugation (30 min,
40 000 g), the membrane fraction and supernatant fraction
(supernatant  I)  were  frozen  in  liquid  nitrogen  and  stored
at  -70∞C until use. Supernatant II was obtained after high-
speed centrifugation at 100 000 g for 30 min. Protein con-
centrations were determined using the BCA assay (Pierce)
(Smith et al., 1985).
Construction of the GlyS-His6 vector
Staphylococcus aureus NCTC 8325 glycyl-tRNA-synthetase
gen glyS was amplified with specific primers containing an
NheI  (GCTAGC)  site  or  a  XhoI  (CTCGAG)  site  (glyS+:
5¢-CTAGCTAGCGCAAAAGATATGGATAC-3¢; glyS–: 5¢-
CATCTCGAGGAATTTTGTTTTTTCAGTTAAG-3¢). Poly-
merase chain reaction (PCR) products and pET24b vector
(Novagen) were digested by NheI–XhoI for ligation.
The cloning strategy resulted in Met-Ala-Ser and Leu-Glu-
(His)6 as N- and C-terminal sequences of the glycyl-tRNA-
synthetase.
Overexpression of His6-tagged proteins
Escherichia coli BL21 (DE3) cells transformed with the
recombinant plasmid were grown in Luria–Bertani medium at
30∞C. At an optical density (OD600) of 0.6, IPTG was added
to a concentration of 0.5 mM to induce expression of the
recombinant proteins. After 1.5 h, cells were harvested and
resuspended in lysis buffer (50 mM Na2HPO4, pH 7.8,
300 mM NaCl, 10 mM imidazole). Aliquots of 200 mg ml-1
lysozyme, 100 mg ml-1 DNase and 10 mg ml-1 RNase were
added; cells were incubated for 30 min on ice and sonicated.
Cell debris was spun down, and the supernatant was added
to 1 ml of Ni-NTA-agarose slurry (Qiagen). This mixture was
gently turned upside down at 4∞C for 1 h and then loaded on
to a column support. After washing with lysis buffer, weakly
bound material was removed with 50 mM Na2HPO4, pH 7.8,
300 mM NaCl and 20 mM imidazole. His-tagged proteins
were eluted with buffer containing 50 mM Na2HPO4, pH 7.8,
300 mM NaCl and 200 mM imidazole. Three fractions were
collected, which were stored in 50% glycerol at -20∞C. Pro-
Fig. 9. Cell wall biosynthesis of S. aureus. Formation of the pentaglycine interpeptide bridge does not occur before synthesis of the cell wall 
precursor lipid II is completed. When the interpeptide bridge is accomplished, the monomeric peptidoglycan unit is translocated across the 
cytoplasmic membrane to the outside and incorporated into the cell wall. UMP, uridine monophosphate; UDP, uridine diphosphate.
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tein concentrations were determined using the Bradford
method (Bradford, 1976) with BSA as a standard. Purity was
controlled by SDS-10% PAGE, and fractions containing 90%
fusion protein were used for further experiments.
Isolation of tRNA from S. aureus NCTC 8325 and S. 
simulans 22
Cells were grown in 3 l of Mueller–Hinton broth at 37∞C to an
OD600 of 0.7 and harvested. Bacteria were resuspended in
20 ml of water, added to 50 ml of boiling water and boiled for
15 min. Insoluble material was removed by centrifugation
(30 min, 40 000 g). The bacterial lysate was lyophilized and
resuspended in 10 ml of RNase-free water. Small RNA mol-
ecules were purified further using the DNA/RNA purification
kit from Qiagen according to the instructions given by the
manufacturer; purity was controlled on 0.8% agarose gels.
Purified tRNA was stored at -20∞C and heated to 65∞C for
3 min before use.
In vitro synthesis of glycine-labelled lipid intermediates
The assays for synthesis of glycine-labelled lipid intermedi-
ates were performed in a total volume of 100 ml containing
300–350 mg of protein of membranes and/or supernatant and
the substrates for lipid II synthesis [10 nmol of undecapre-
nylphosphate, 100 nmol of UDP-GlcNAc, 100 nmol of UDP-
MurNAc-PP in 100 mM Tris-HCl, 20 mM MgCl2, pH 7.5, and
0.8% Triton X-100, 2 mM ATP and 50 nmol of [U-14C]-glycine
(3.7 GBq mmol-1; Amersham Pharmacia Biotech)]. If not indi-
cated otherwise, the synthesis mixtures contained 5 nmol of
lipid I, lipid II or lipid intermediates, 300–350 mg of superna-
tant protein (or 10 mg of tRNA-synthetase and 25 mg of tRNA),
2 mM ATP and 50 nmol of [U-14C]-glycine in 100 ml of buffer
(see above). Purified Fem proteins were added at a concen-
tration of 2.7 mg per 100 ml. Reaction mixtures were incubated
for 60 min at 30∞C except for the complete ABX reaction
(17 h) or as indicated. Lipid intermediates were extracted from
the reaction mixture with the same volume of n-butanol/pyri-
dine acetate, pH 4.2, and analysed by TLC (see above).
Radiolabelled spots or lanes were visualized by iodine vapour,
excised and quantified by b-scintillation counting (1900 CA
Tri-Carb scintillation counter; Packard). Isolation of larger
quantities of non-radioactive-labelled Gly–lipid II intermedi-
ates was achieved with an upscale of the synthesis assay
applying the purification protocol described for lipid II.
Mass spectrometry
Electrospray MS spectra were recorded on an API-I single
quadrupole instrument (PE-SCIEX) working in positive mode.
Samples were infused at 100–200 ml h-1, either directly (in
methanol–chloroform, 1:1) or diluted 1:1 with 0.5% formic
acid in methanol. Sample concentrations ranged from 5 to
20 nmol per 100 ml. A needle voltage of 5600 V and an orifice
voltage of 90–120 V were used, and spectra accumulated for
at least 100 scans. Signals from the monocharged species
(m+H+) were accompanied in all cases by those from the
monosodium adduct, the monopotassium adduct and, in
some cases, the disodium adduct. In general, the magnitude
of the signal decreased with increasing glycination.
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Role of B in the Expression of Staphylococcus aureus Cell Wall
Adhesins ClfA and FnbA and Contribution to Infectivity in
a Rat Model of Experimental Endocarditis
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Isogenic Staphylococcus aureus strains with different capacities to produce B activity were analyzed for their
ability to attach to fibrinogen- or fibronectin-coated surfaces or platelet-fibrin clots and to cause endocarditis
in rats. In comparison to the B-deficient strain, BB255, which harbors an rsbU mutation, both rsbU-
complemented and B-overproducing derivatives exhibited at least five times greater attachment to fibrinogen-
and fibronectin-coated surfaces and showed increased adherence to platelet-fibrin clots. No differences in
adherence were seen between BB255 and a rsbUVWsigB isogen. Northern blotting analyses revealed that
transcription of clfA, encoding fibrinogen-binding protein clumping factor A, and fnbA, encoding fibronectin-
binding protein A, were positively influenced by B. B overproduction resulted in a statistically significant
increase in positive spleen cultures and enhanced bacterial densities in both the aortic vegetations and spleens
at 16 h postinoculation. In contrast, at 72 h postinoculation, tissues infected with the B overproducer had
lower bacterial densities than did those infected with BB255. These results suggest that although B appears
to increase the adhesion of S. aureus to various host cell-matrix proteins in vitro, it has limited effect on
pathogenesis in the rat endocarditis model. B appears to have a transient enhancing effect on bacterial
density in the early stages of infection that is lost during progression.
Staphylococcus aureus is a major human pathogen with the
capacity to cause a broad spectrum of diseases including native
and prosthetic valve endocarditis (34). Its ability to colonize
vascular tissue is thought to occur via ligand-adhesin interac-
tions between the organism’s surface determinants and host
proteins at sites of endovascular injuries and prosthetic mate-
rials (8, 11, 14, 40). S. aureus expresses a variety of distinct
surface proteins, termed MSCRAMMs (for “microbial surface
components recognizing adhesive matrix molecules”), which
allow the pathogen to bind to host extracellular matrix proteins
and establish a focus of infection (17, 21, 38, 43). Among the
MSCRAMMs are the clumping factors ClfA and ClfB (35, 36,
37, 42), which modulate bacterial adhesion to fibrinogen, and
the fibronectin-binding proteins FnbA and FnbB, which medi-
ate binding to fibronectin (15, 16, 17, 26) and to a lesser extent
fibrinogen (53). Fibrinogen is a large (340-kDa) protein found
predominantly in blood. It is also the most abundant host
protein in endothelial lesions (13), as well as the major blood
protein deposited on newly implanted biomaterials (52). Fi-
bronectin is a dimeric glycoprotein, which forms a significant
component of the conditioning layer that coats many im-
planted medical devices such as heart valves and catheters.
Both the clumping factors and the fibronectin-binding proteins
influence the pathogenicity of S. aureus in various infection
models (14, 32, 40, 44, 46, 48, 52). It has been shown previously
that B significantly influences the clumping of S. aureus in the
presence of soluble fibrinogen or fibronectin in vitro (3, 41).
In the present study, we used a series of isogenic strains to
characterize the effects of B activity on the capacity of S.
aureus to adhere to immobilized fibrinogen, fibronectin, and
platelet-fibrin clots. Additionally, we examined the effects of
B on S. aureus infectivity in a rat model of experimental
endocarditis (14, 22, 40).
MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial strains and relevant
phenotypes are listed in Table 1. Microorganisms were grown in tryptic soy broth
(Difco Laboratories, Detroit, Mich.) or Luria-Bertani medium, with aeration at
37°C and 200 rpm. For both in vitro adhesion experiments and in vivo inoculum
preparation, overnight cultures of bacteria were diluted 1:100 in fresh medium
and grown to an optical density at 600 nm of 2.0, where B was shown to be
highly active (2). Where indicated, the media were supplemented with 5 g of
erythromycin per ml or 10 g of tetracycline per ml. The presence of antibiotics
did not alter the adherence phenotype in vitro, and the mutants grew as well as
the parental strain did.
Northern blot analyses. Total RNA was isolated as described by Cheung et al.
(7). An 8-g portion of total RNA from each sample was electrophoresed
through a 1.5% agarose–0.66 M formaldehyde gel in morpholinepropanesulfonic
acid (MOPS) running buffer (20 mM MOPS, 10 mM sodium acetate, 2 mM
EDTA [pH 7]). RNA was blotted onto a positively charged nylon membrane
(Roche, Basel, Switzerland) with a vacuum blotter (Pharmacia, Uppsala, Swe-
den). The intensity of the 23S and 16S rRNA bands stained with ethidium
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Zu¨rich, Gloriastr. 32, CH-8028 Zu¨rich,
Switzerland. Phone: 41 1 634 26 70. Fax: 41 1634 49 06. E-mail:
Bischoff@immv.unizh.ch.
990
bromide was verified to be equivalent in all the samples before transfer. Labeling
and hybridization were done by using the digoxigenin labeling and detection kits
as specified by the manufacturer (Roche). The following primers were used to
generate the digoxigenin-labeled DNA probes by PCR labeling: clfA for, 5-CG
ATTGGCGTGGCTTCAGTGC-3; clfA rev; 5-CGTTGTTGAAACATTTTCC
GC-3 (nucleotides 345 to 365 and 806 to 826 of accession no. Z18852); fnbA for,
5-GGGATGGGACAAGATAAAGAAGC-3; fnbA rev., 5-ACGACACGTTG
ACCAGCATG-3; (nucleotides 174924 to 174902 and 174366 to 174347 of
accession no. AP003137.2).
Construction of plasmid pSB40NfnbAp. For pSB40NfnbAp, 250 bp of the fnbA
promoter region of BB255 was synthesized by PCR using the upstream primer
5-GCGGATCCGTTTTAAATTAGATAATGATG-3 (the BamHI linker is un-
derlined) and the downstream primer 5-CGCCTCGAGCCCTTTAAATGCAA
AATTCATT-3 (the XhoI linker is underlined). The PCR product was digested
with BamHI and XhoI and cloned into promoter probe plasmid pSB40N (29) to
obtain pSB40NfnbAp. Sequence analysis confirmed the identity of the insert.
Plasmid pSB40NfnbAp was subsequently transformed into Escherichia coli
XL1Blue containing either plasmid pAC7-sigB or pAC7 (23). The two-plasmid
testing was performed as described by Homerova et al. (23).
Functional expression of fibrinogen and fibronectin activity. Adherence of S.
aureus cells to solid-phase fibrinogen or fibronectin was measured by two meth-
ods. In the first method, flat-bottom microtiter plates (MaxiSorp; Nunc, Rosk-
ilde, Denmark) were coated with serial dilutions (in phosphate-buffered saline
PBS) of either human fibrinogen (Sigma, Buchs, Switzerland) or fibronectin
(Sigma) and blocked with 2 mg of bovine serum albumin per ml in phosphate-
buffered saline (PBS). Then 50 l of bacterial cells, corresponding to 5  108
CFU, was added to each well, and the mixtures were incubated at 37°C for 2 h.
To monitor the effects of proteases on S. aureus adherence, cells were precul-
tured and assayed in either the presence or absence of 0.4 U of the global
protease inhibitor 2-macroglobulin (Roche Diagnostics, Rotkreuz, Switzerland)
per ml. Adherent cells were fixed with warm air (60°C) for 30 min and stained
with 0.5% (wt/vol) crystal violet for 45 min. After addition of 200 l of citrate
buffer (pH 4.3) and incubation for 45 min at room temperature, the absorbances
were read in an enzyme-linked immunosorbent assay reader at 570 nm. Each
batch of assays included at least one control strain as well as blank wells.
In a second assay the fibrinogen- and fibronectin-binding capacities of the
BB255 derivatives were determined by direct binding of washed cells (104 CFU)
to solid-phase fibrinogen and fibronectin in six-well plates by using a method
previously described by Kupferwasser et al. (31).
FACS analysis. The abundance of ClfA on the cell surface was measured by
fluorescent-activated cell sorter (FACS) analysis using purified F(ab’)2 fragments
from anti-ClfA rabbit polyclonal immunoglobulin G (kindly provided by T.
Foster, Dublin, Ireland) as described previously (49). Briefly, S. aureus cells were
washed, suspended in PBS containing 10% fetal calf serum-antibody solution (10
g of antibody/ml), and incubated for 2 h at 4°C. The cells were then washed
twice with PBS–10% fetal calf serum, suspended in PBS–10% fetal calf serum-
antibody solution containing F(ab’)2 fragments of a fluorescein isothiocyanate-la-
beled swine anti-rabbit antibody (DakoCytomation, Glostrup, Denmark), incubated
for 1 h at 4°C, washed, fixed with 4% formaldehyde solution for 30 min at 4°C, and
resuspended in PBS–10% fetal calf serum before being subjected FACS analysis. S.
aureus DU5880 (35), a clfA-negative strain, was used as control.
Attachment to human platelet-fibrin clots in vitro. Platelet-fibrin clots were
produced by pouring 0.5 ml of plasma into 30-mm-diameter cell culture plates
(Corning Coster, Corning, N.Y.) in the presence of 100 l of bovine thrombin
solution (5,000 National Institute of Health units per ml) (Diagnotec AG, Li-
estal, Switzerland) and 100 l of a 0.2 mM CaCl2 solution. The clots were
dehydrated overnight at 30°C and kept at 4°C until used. Bacterial adherence was
determined by adding 2 ml of saline containing 104 CFU per ml to the wells and
agitating the plates for 3 min at 120 rpm on a rotating incubator. After gentle
decantation of the fluid, the clots were washed twice for 5 min with 2 ml of PBS
to remove nonadherent bacteria. They were then overlaid with 3 ml of Columbia
agar, which was allowed to solidify prior to incubation at 37°C. The number of
adherent bacteria that gave rise to colonies was determined after 24 h of incu-
bation and expressed as a multiple of adherent organisms relative to the original
inoculum (adherence ratio  [number of adherent bacteria/inoculum size] 
104). The statistical significance of the different attachment of the test organisms
to platelet-fibrin clots was evaluated by the one-way analysis of variance with
Bonferroni’s correction for multiple group comparisons.
Experimental endocarditis. Catheter-induced vegetations of the aortic valve
were produced in rats as previously described (22, 40). Groups of animals were
inoculated 24 h after catheterization by intravenous injection of 0.5 ml of saline
containing increasing numbers of organisms from the late exponential growth
phase. The animals were sacrificed 16 h after the bacterial challenge, and quan-
titative vegetation and spleen cultures were performed. Vegetation and spleen
tissues were serially diluted and plated onto both antibiotic-free tryptic soy agar
plates and tryptic soy agar plates containing the appropriate antibiotic, allowing
characterization of the stability of all mutants after animal passage. In a second
set of experiments, animals were sacrificed 72 h after the bacterial challenge and
vegetation and spleen cultures were processed as described above. Statistical
differences comparing the rates of aortic valve and spleen infections were eval-
uated by the 2 test with the Yates correction. Differences between median
bacterial densities in infected tissues were analyzed by the Mann-Whitney test.
Data were considered significant when P values were 	0.05 by the use of
two-tailed significance levels.
RESULTS AND DISCUSSION
Effect of B on clfA and fnbA expression. Microarray-based
analysis of the transcriptional profiles of three genetically dis-
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant genotype and phenotypea Source orreference
Strains
E. coli
XL1Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F proAB lacld Z
M15 Tn10 (Tcr)] Stratagene
S. aureus
BB255 rsbU; low B activity 1
IK181 BB255 
rsbUVWsigB; Emr 30
GP268 BB255 rsbU; Tcr 19
MB138 BB255 rsbW7 (Am); Emr (high level of B activity) 2
DU5880 8325-4 clfA1::Tn917; Emr 35
Plasmids
pAC7 Cmr, expression plasmid containing the PBAD promoter and the araC gene 45
pAC7-sigB Cmr, 767-bp PCR fragment of the sigB ORF from strain COL into pAC7 23
pSB40N Apr, promoter probe plasmid 29
pSB40NclfAp Apr, 500-bp chromosomal fragment covering the clfA promoter region of COL into pSB40N 23
pSB40NfnbAp Apr, 250-bp PCR fragment covering the fnbA promoter region of BB255 into pSB40N This study
a Abbreviations: Apr, ampicillin resistant; Cmr, chloramphenicol resistant; Emr, erythromycin resistant; Mcr, methicillin resistant; Tcr, tetracycline resistant; ORF,
open reading frame.
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tinct S. aureus strains indicated that clfA and fnbA were posi-
tively influenced by B activity (4). In those studies, clfA tran-
scription appeared to be strongly up-regulated by B during
later growth stages whereas no significant differences in clfA
expression were observable during early growth. We confirmed
these findings by Northern blot analyses. As shown in Fig. 1,
the clfA transcript was produced in a B-dependent manner. A
2.9-knt transcript was strongly produced in the rsbU-comple-
mented strain, GP268, but was very weak in the isogenic

rsbUVWsigB mutant, IK181 (Fig. 1A). In addition to the
B-dependent transcript, a larger clfA-encoding transcript (4.5
knt) was observed during early growth in both GP268 and
IK181, suggesting that basal transcription of clfA is governed in
S. aureus by a B-independent process during early growth
stages. The finding that clfA expression increased with growth
is striking and contradicts the common paradigm that
MSCRAMM-encoding genes are expressed predominantly
during the early growth stages.
In contrast to clfA, microarray analysis (4) indicated that the
presence of a functional sigB operon promotes fnbA transcrip-
tion mainly during the early growth stages but not in later
stages. Northern blot analysis identified two distinct fnbA-en-
coding transcripts (Fig. 1B), with the shorter transcript (3.1
knt) being B dependent and the larger transcript (3.7 knt)
being independent of B activity. The shorter transcript was
observed only in GP268 during early growth, while the larger
transcript was detectable in both BB255 derivatives analyzed
until mid-log phase, corroborating the microarray results (4).
Two-plasmid testing of the clfA and fnbA promoter regions.
We used a two-plasmid system, which has proved useful in
identifying promoters recognized by RNA polymerase contain-
ing S. aureus B (23), to test whether the fnbA promoter region
that gives rise to the 3.1-knt transcript is recognized by B. The
clfA promoter, which was already identified to be B depen-
dent by this method, was used as positive control (23). E. coli
strains harboring plasmids pAC7sigB and pSB40NclfAp yielded
dark blue colonies upon selection on LBACX-ARA plates,
confirming that there is a physical interaction between the S.
aureus B-E. coli RNA polymerase holoenzyme hybrid and the
clfA promoter region. However, no such interaction was ob-
servable for the E. coli transformant harboring plasmids
pAC7sigB and pSB40NfnbAp, suggesting that B does not di-
rectly mediate fnbA transcription. Interestingly, E. coli cells
harboring pSB40NfnbAp and the control plasmid, pAC7,
yielded light blue colonies on LBACX- ARA plates, indicating
that the fnbA promoter was recognized by the A-containing E.
coli RNA polymerase holoenzyme. These findings, together
with the transcriptional profile of fnbA during in vitro growth
(4) and the lack of a significant B consensus promoter se-
quence (23) in the upstream region of the fnbA open reading
frame, strongly suggest that the positive effect of B on fnbA
transcription is most probably indirect and occurs by an as yet
unidentified mechanism. It is known that fnbA transcription is
enhanced by SarA (12,54, 55) and down-regulated by agr (47,
55). It has been suggested that B activity has a positive effect
on the expression of the sarA locus (3, 4, 18), as well as a
negative effect on the expression of the agr locus (3, 4, 24).
Thus, the two global regulators may, at least in part, account
for the up-regulatory effect of B activity on fnbA transcription.
However, the mechanisms by which B modulates SarA pro-
duction are not completely understood (3, 4, 9, 10, 18, 24).
B dependence of surface-bound ClfA. To determine
whether the B-dependent increase in clfA expression corre-
lates with an increase in the amount of surface-bound ClfA, we
used FACS analysis to determine the ClfA abundance on the
surfaces of a series of BB255 derivatives with differing abilities
to produce B activity. As indicated in Fig. 2, FACS shifts were
clearly observed for the rsbU-complemented strain, GP268
(Fig. 2C), and the BB255 derivative, MB138 (Fig. 2D), with
high B activity due to an amber mutation within the gene
encoding the anti-B factor RsbW (2). In contrast, BB255 (Fig.
2A) and its 
rsbUVWsigB mutant, IK181 (Fig. 2B) demon-
strated very slight FACS shifts. A clfA-negative S. aureus strain,
DU5880, was negative by FACS analysis (data not shown),
indicating that the shifts observed for the BB255 derivatives
were ClfA specific.
Functional expression of fibrinogen and fibronectin activity.
The findings that clfA and fnbA expression are positively influ-
enced by B raises the question whether and how B affects S.
aureus adherence to the host cell matrix proteins fibrinogen
and fibronectin. The BB255 derivatives were therefore ana-
lyzed for their abilities to attach to fibrinogen- or fibronectin-
coated surfaces in vitro (Fig. 3). GP268 and MB138 exhibited
at least five times greater attachment to either fibrinogen-
coated (Fig. 3A) or fibronectin-coated (Fig. 3B) surfaces than
BB255 did. Moreover, the binding capacities correlated with
B activity; the greatest binding was observed with the B
overproducer, MB138, and the lowest binding was observed
with the 
rsbUVWsigB mutant IK181. No obvious differences
in adherence were detectable between BB255 and IK181, cor-
roborating previous findings suggesting that BB255, although
producing a significant amount of B, is unable to activate this
alternative transcription factor due to its inability to generate
the positive regulator of B activity, RsbU (3, 19).
Similar results were observed when bacterial binding to solid
fibrinogen and fibronectin was determined by a method de-
scribed by Kupferwasser et al. (31). The numbers of CFU
FIG. 1. Northern blot analyses of clfA and fnbA. Total RNAs of
strains GP268 (BB255 rsbU) and IK181 (BB255 
rsbUVWsigB) grown
in LB medium and harvested at the time points indicated were probed
with clfA (A) and fnbA (B), respectively. Relevant transcripts and their
sizes are indicated.
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bound to solid fibrinogen and fibronectin were again signifi-
cantly increased (P 	 0.05) in both GP268 and MB138 com-
pared to those in BB255 and IK181 (Fig. 4). Both experimental
outcomes are consistent with previous findings showing a pos-
itive effect of B on the attachment of S. aureus to either
soluble fibrinogen (41) or soluble fibronectin (3).
Effect of the universal protease inhibitor 2-macroglobulin
on the adherence phenotype of the BB255 derivatives. Karlsson
et al. (27) reported that in sarA mutant cells, which produced
large amounts of the four major extracellular proteases of S.
aureus, the levels of cell-bound fibronectin-binding proteins A
and B were low in comparison to those in wild-type cells. This
was found to occur independently of fnbA or fnbB transcrip-
tion. More recently, the same authors showed that extracellu-
lar protease production among clinical isolates of S. aureus
varied mainly due to differences in sarA expression. They fur-
ther indicated that the level of B-dependent expression of
sarA determined the level of protease production; there was an
inverse correlation between B activity and protease activity
(28). Because synthesis of extracellular proteases is activated
by agr (5, 25, 33) and because agr expression is negatively
regulated by B activity (3, 4, 24), it is reasonable that B
activity down-regulates extracellular protease production in an
indirect manner. This B-mediated decrease in extracellular
protease levels is likely to increase the amount of wall-an-
chored fibronectin-binding protein and thus may be, at least
for fibronectin, the primary reason for the observed increase in
the adherence of sigB strains. To determine whether B-
SarA-mediated differences in protease activity might account
for the adherence differences observed between sigB and sigB
mutant strains, we repeated the adherence experiments in the
presence of the universal protease inhibitor 2-macroglobulin.
The fibrinogen and fibronectin adherence profiles obtained in
presence of 2-macroglobulin were almost identical to those
shown in Fig. 3. This finding does not agree with the recent
findings by Xiong et al. (55), who observed a 30% increase in
fibronectin-binding activity for strains grown in the presence of
2-macroglobulin compared to strains grown in its absence.
However, Xiong et al. noted that the predominant mechanism
dictating phenotypic fibronectin binding seems to occur at the
level of fnbA transcription. Our findings support this hypoth-
esis and indicate that the differences in adherence observed
between sigB and sigB mutant strains were not likely to be
due to B-SarA-mediated alterations in the protease activity of
the respective strains but were caused by the increased B-
dependent expression of clfA and fnbA. Furthermore, fibrino-
gen- and fibronectin-binding protein homologues, such as ClfB
and FnbB, whose expression is not considered to be affected by
B activity, were apparently not able to mask the strong de-
crease in adherence to fibrinogen and fibronectin observed for
FIG. 2. Histograms of ClfA expression on the surface of S. aureus cells. FACS analysis was performed with both irrelevant antibodies (gray
areas) and purified anti-ClfA F(ab)2 fragments (white areas). (A) BB255 (rsbU); (B) IK181 (BB255 
rsbUVWsigB); (C) GP268 (BB255 rsbU
);
(D) MB138 [BB255 rsbW7(Am)].
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the B-activity-defective strains, illustrating the importance of
ClfA and FnbA for the capacity of S. aureus to adhere to these
host cell matrix proteins.
Adherence of S. aureus to platelet-fibrin clots. Since cardiac
vegetations contain numerous proteins and platelet factors,
which were not present in the in vitro ligand assay described
above, the adherence experiments were repeated with platelet-
fibrin clots, which more closely mimic cardiac vegetations of
recovering damaged valves (39). Adherence of the B-activity-
producing strain GP268 to platelet-fibrin clots was higher than
that of BB255 and its 
rsbUVWsigB mutant, IK181, and was
further increased in the B overproducer MB138 (P 	 0.05),
indicating a positive correlation of B activity with the capacity
of S. aureus to adhere to platelet-fibrin clots (Fig. 5).
Experimental endocarditis. Binding of S. aureus to platelets
has been considered crucial for the development of infective
endocarditis by affecting vegetation formation and septic em-
bolization (50, 51). Additionally, several in vivo studies have
implicated ClfA, ClfB, and FnbA as pathogenic factors in ex-
perimental S. aureus infection (14, 40, 44, 52). Thus, the B-
activity-associated increase in binding of S. aureus to immobi-
lized fibrinogen, fibronectin, and platelet-fibrin clots suggests
that B activity is likely to facilitate the development of infec-
tive endocarditis as well. This hypothesis was tested in a rat
catheter-induced aortic vegetation model of infection. As in
previous experiments (14, 40), the rate of infection 16 h posti-
noculation was inoculum dependent (Fig. 6). The BB255 de-
rivatives caused endocarditis in 20 to 40% and 90 to 100% of
rats at low and high inocula, respectively. No statistically sig-
nificant difference in infectivity could be observed among any
of the strains analyzed (P 0.05), even though the B-activity-
FIG. 3. Bacterial adherence of BB255 and its derivatives to increas-
ing concentrations of immobilized fibrinogen (A) and immobilized
fibronectin (B). Strains used were BB255 (squares), IK181 (BB255

rsbUVWsigB, circles), GP268 (BB255 rsbU, triangles), and MB138
[BB255 rsbW7(Am), diamonds].
FIG. 4. Bacterial adherence of BB255 and its derivatives to immo-
bilized fibrinogen (50 g/ml) (A) or immobilized fibronectin (10 g/
ml) (B). Adherence was expressed as the percentage of bacteria bound
to the immobilized host cell matrix proteins from an initial inocolum of
104 CFU.
FIG. 5. In vitro adherence of S. aureus organisms to platelet-fibrin
clots. The adherence ratio was expressed as a function of the original
inoculum (see Materials and Methods). The results represent the
means and standard deviations for 12 independent determinations.
Asterisk, P 	 0.05 versus all the other groups.
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producing strains tended to cause slightly more endocarditis
than did BB255 or its 
rsbUVWsigB mutant (Fig. 6).
The bacterially challenged animals were also analyzed for
positive spleen cultures (Fig. 6). In general, spleen cultures
were positive more often than aortic cultures were. This dem-
onstrated that the animals had been appropriately inoculated
and suggested that spleen colonization was not necessarily
dependent on valve infection. Importantly, in contrast to aortic
vegetations, the frequency of positive spleen cultures corre-
lated with increased B activity (Fig. 6) and was most pro-
nounced in rats challenged with the B overproducer MB138
(P	 0.05). All spleen cultures became positive as the inoculum
size was increased 10-fold (Fig. 6B). Although spleen coloni-
zation at 16 h after inoculation is primarily indicative of inoc-
ulation and does not necessarily indicate a spleen infection, it
might become relevant in terms of the in vivo survival capacity
of the bacteria, in combination with the respective bacterial
density that is reached in this organ (see below).
Analysis of the bacterial densities obtained after 16 h re-
vealed that all animals had comparable bacterial densities in
FIG. 6. Infectivity titer determination for the various test organisms in the rat model of experimental endocarditis 16 h postinoculation. The
figure shows a compilation of results from six separate experiments. (A) An inoculum size of 103 CFU was used to obtain results in four
experiments. Pooled results are shown. In two experiments, the rats were challenged with bacterial inocula of 2  103 to 3  103 CFU/ml. In the
two other experiments, the rats were challenged with 4  103 6  to 103 CFU/ml. The results were similar with both inocula. (B) An inoculum
size of 104 CFU was used to obtain results in two experiments. The columns indicate the percentage of positive vegetations and spleen cultures.
The number of animals per group (n) and the S. aureus strain are indicated at the bottom of the columns. Statistical differences were evaluated
by the 2 test with the Yates correction. , P 	 0.05 compared with BB255 and IK181.
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their aortic vegetations at low inocula (P  0.05). However, at
high inocula, the rats inoculated with the B overproducer
MB138 had significantly higher vegetation bacterial densities
(P 	 0.05) than did those in all other groups (Table 2). Addi-
tionally, the bacterial densities of MB138 within colonized
spleens were significantly higher (P 	 0.05) than those of
BB255 and IK181 when the animals were challenged with a low
inoculum (Table 2). Since all strains analyzed displayed similar
abilities to grow under in vitro conditions, the higher vegeta-
tion bacterial densities observed for MB138 after 16 h was
unlikely to be due to an increase in growth rate and thus may
reflect an abated clearance of the B-overproducing strain by
host defense mechanisms at this site. Spleens are known to
display a massive recruitment of polymorphonuclear neutro-
phils (PMNs), which are considered to fulfill major functions in
the host defense system (13). Several laboratories have shown
that B activity significantly reduces the sensitivity of S. aureus
to oxygen radicals and hydrogen peroxide (19, 24, 30), which
are released by PMNs to challenge the pathogenic bacteria.
Interestingly, SarA influences the capacity of S. aureus to be
internalized by PMNs and to survive inside of PMNs (20). The
findings that challenging rats with MB138 resulted in statisti-
cally significantly larger numbers of positive spleen cultures
and higher bacterial densities 16 h postinoculation than did
challenging them with BB255 or IK181, combined with the
observation that B-activity-possessing strains produce larger
quantities of sarA-containing transcripts, suggest that B activ-
ity may indeed contribute to the survival capacity of S. aureus
under in vivo conditions during the early stages of infection,
especially at sites with a high PMN content.
To monitor the evolution of the infection with time, rats
were challenged with high inocula and were sacrificed 72 h
after bacterial inoculation. By 72 h postinoculation (Fig. 7), the
rates of aortic infection slightly decreased relative to the rates
at 16 h but remained similar between groups (P  0.05). The
number of CFU recovered in infected vegetations of rats in-
oculated with either BB255, IK181, or GP268 strains increased
relative to the number recovered at 16 h and were larger
(although not statistically significantly larger) than the number
of CFU recovered from vegetations of rats inoculated with
MB138, which decreased relative to the number observed by
16 h.
By 72 h postinoculation, the rates of spleen infection of rats
inoculated with either BB255, IK181, or GP268 slightly de-
creased relative to the rates observed at 16 h (Fig. 6). In
contrast, the frequency of positive spleen cultures remained
unchanged (100%) in animals that were challenged with
MB138. However, the difference in spleen infection frequency
between MB138 and the other derivatives tested was not sta-
tistically significant. Surprisingly, while the number of CFU
obtained from spleens of rats inoculated with either BB255,
IK181, or GP268 increased relative to the number obtained
16 h, the same was not observable for MB138 (Table 3). The
number of CFU obtained from the spleens of MB138-inocu-
lated animals after 72 h remained more or less unchanged
relative to the number obtained after 16 h and was significantly
smaller than the number of CFU recovered from the spleens of
BB255, IK181, or GP268-infected animals (P 	 0.05). The
observed decrease in bacterial densities in both vegetations
and spleens by 72 h suggests that high B activity negatively
FIG. 7. Infectivity titer determination in the rat model of experi-
mental endocarditis 72 h after inoculation with an inoculum size of 104
CFU. The figure shows a compilation of results of separate experi-
ments. Details are as in Fig. 6.
TABLE 2. Bacterial densities in vegetations and spleens of rats that developed experimental endocarditis 16 h after bacterial challenge
Bacterial strain
Median bacterial densitya (CFU/g) (range) with inoculum of:
103 CFU 104 CFU
Vegetations Spleens Vegetations Spleens
BB255 5.63 (4.51–6.22) 1.74 (1.57–2.47) 5.80 (3.67–8.57) 2.99 (2.35–4.29)
IK181 5.61 (3.52–7.88) 1.80 (1.05–2.36) 5.78 (3.01–7.36) 2.73 (2.33–3.53)
GP268 6.09 (2.40–7.20) 2.05 (1.53–2.86) 5.53 (3.98–8.87) 2.98 (2.50–4.59)
MB138 6.18 (4.28–7.93) 2.10 (1.60–3.30)† 7.85 (5.93–8.41)‡ 3.28 (3.05–3.51)*
a †, P 	 0.05 versus BB255 and IK181; ‡, P 	 0.05 versus all the other groups; *, P 	 0.05 versus IK181.
TABLE 3. Bacterial densities in infected vegetations and spleens of
rats 72 h after bacterial challenge with an inoculum of 104 CFU
Bacterial
strain
Median bacterial densitya (CFU/g) (range) in:
Vegetations Spleens
BB255 8.75 (6.30–9.84) 5.44 (4.49–5.60)†
IK181 8.32 (3.37–9.35) 5.17 (1.78–5.60)†
GP268 9.19 (5.75–9.57) 5.15 (3.05–5.64)†
MB138 6.03 (3.11–9.48) 3.43 (1.96–5.56)
a †, P 	 0.05 versus MB138.
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influences the ability of S. aureus to develop high cell densities
at the infection site during later stages of infection.
The in vivo data presented here demonstrate that B activity
has little to no effect on the development of infective endocar-
ditis, irrespective of its ability to positively influence the ex-
pression of clfA and fnbA, somehow contradicting previous
publications showing that inactivation of clfA or fnbA had small
but significant impacts on the infectivity of S. aureus (40, 52). It
is worth noticing that Xiong at al. (55), who investigated the
impacts of sar and agr mutations on fnbA expression and on the
fibronectin adherence capacity under in vitro and in vivo con-
ditions, found that mutations of sarA and/or agr resulted in a
marked effect on fnbA expression but had no statistically sig-
nificant impact on infectivity in an experimental rabbit endo-
carditis model. It becomes clear from the transcription and
adhesion data shown here that S. aureus is still able to produce
significant amounts of fibrinogen- and fibronectin-binding pro-
teins even in the absence of B activity. The amounts of clf- and
fnb-encoding transcripts produced by the sigB mutant strains
seem to be sufficient to allow the pathogen to bind to the host
cell matrix proteins in vivo, giving a simple explanation of why
mutations of clfA or fnbA decrease the infectivity of S. aureus
but sigB does not. Moreover, our in vivo findings are in agree-
ment with previous findings demonstrating that mutations in
sigB had no significant effect on the virulence of S. aureus in
four different animal models (6, 24, 41).
Considering that B-dependent promoters are present in the
upstream regulatory regions of many virulence-associated loci,
it is nevertheless surprising that any attempt to demonstrate an
influence of B on the virulence of S. aureus in an animal
model has failed to date. Based on the findings that the ex-
pression of various virulence-associated factors is influenced by
B activity (3, 4, 18, 19, 24, 30, 42) but that no influence on
infectivity has been demonstrated so far, we have to conclude
that B is more likely to be a modulator of virulence gene
expression and not a virulence determinant by itself. Thus, one
possible function of B on S. aureus-host interactions might be
the global regulation of factors associated with virulence in a
way (i) promoting adhesion of the pathogen to host cells, i.e.,
by upregulation of MSCRAMMS, and (ii) allowing the organ-
ism to persist at the attachment site without harming the host
tissue, i.e., by down-regulation of exoprotein production,
thereby reducing the inflammatory response caused by the host
defense system. Such a function of B would fit with our ob-
servations that B had a positive impact on the ability of S.
aureus to reach high cell densities during the early stages of
infection while having a negative influence on the capacity of
the pathogen to develop high cell densities during later stages
of infection. Further support is given by the recent findings by
Bischoff et al. (4), who showed that B had a negative influence
on the expression of various excreted virulence factors, such as
proteases, lipases, and hemolysins, which all are supposed to
be important for the ability of S. aureus to evade the site of
infection, once the infection has been established. While pro-
moting adhesion during early stages, B activity may decrease
the ability of the pathogen to evade the primary site of infec-
tion during later growth stages, thus decreasing its capacity to
damage the host cell tissue, and to establish new sites of in-
fection.
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